

UNIVERSITY OF OKLAHOMA
COLLEGE OF MEDICINE

CURRICULUM VITAE

Joan L Walker, MD

Professor, Department of Obstetrics & Gynecology
Section of Gynecologic Oncology
Louise and Clay Bennett Chair in Cancer
George Lynn Cross Research Professor
Peggy and Charles Stephenson Cancer Center 5050
800 NE 10th Street
Oklahoma City, OK 73104
Phone: (405) 271-8707
Fax: (405) 271-1006
Email: joan-walker@ouhsc.edu

Appointment Type: Tenured

EDUCATION AND TRAINING

Postgraduate Education and Training

2018	Training in Dissemination and Implementation Research for Cancer (TIDRIC) 2018, Cancer D&I Research, National Cancer Institute, Rockville, MD, MD, USA Mentor: Heather Brandt
2012	Palliative Care - Board Certified, M. D. Anderson Cancer Center, Houston, TX
1988 - 1990	Clinical Fellow, Gynecologic Oncology, University of California - Irvine, Orange, CA
1986 - 1988	Research Fellow, Gynecologic Oncology, University of California - Irvine, Orange, CA
1982 - 1986	Resident, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA

Education

1990	Masters of Epidemiology - Incomplete College of Health, University of Oklahoma, Oklahoma City, OK
1978 - 1982	Doctor of Medicine University of California, Los Angeles, CA
1974 - 1978	Bachelor of Science, Biochemistry University of California, Davis, CA
1970 - 1974	High School Diploma Pasadena High School, Pasadena, CA

PROFESSIONAL EXPERIENCE

Academic

- 2002 - Present Professor, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Oklahoma, Oklahoma City, OK
- 2017 - 2022 Full Graduate Faculty Appointment, Graduate College, University of Oklahoma, Oklahoma City, OK
- 1996 - 2002 Associate Professor, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, University of Oklahoma, Oklahoma City, OK
- 1990 - 1996 Assistant Professor, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK
- 1986 - 1990 Clinical Instructor, Department of Obstetrics and Gynecology, University of California, Irvine, CA

Administrative

- 2021 - Present Gynecologic Oncology Clinic Medical Director, Gynecologic Oncology, Stephenson Cancer Center, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- 2016 - Present Section Chief, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, University of Oklahoma, Oklahoma City, OK
- 1997 - 2006 Chief, Section of Gynecologic Oncology, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 1997 - 2006 Fellowship Director, Gynecologic Oncology Fellowship Program, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, University of Oklahoma, Oklahoma City, OK
- 2004 - 2006 Chief, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, University of Oklahoma, Oklahoma City, OK
- 2002 - 2004 Program Director, Gynecologic Oncology Fellowship Program, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 1997 - 2004 Program Director, Gynecologic Oncology Fellowship Program, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 1997 - 2002 Chief, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, University of Oklahoma, Oklahoma City, OK
- 1997 - 2002 Program Director, Gynecologic Oncology Fellowship Program, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, University of Oklahoma, Oklahoma City, OK

HONORS AND AWARDS

Louise and Clay Bennett Chair in Cancer, University of Oklahoma (Received), 2016 - Present

George Lynn Cross Research Professor, University of Oklahoma (Received), 2009 - Present

Council Member, Society of Gynecologic Oncologists (Received), 2008 - Present

Faculty Teaching Award, University of Oklahoma Department of Obstetrics and Gynecology (Received), 2020 - 2021

Western Association of Gynecologic Oncology- Joan Walker Poster Award, Joan Walker Poster Award / Western Association of Gynecologic Oncology, Western Association of Gynecologic Oncology, June 16, 2021

Faculty Teaching Award, University of Oklahoma Department of Obstetrics and Gynecology (Received), 2019 - 2020

Innovation Award SGO 2020, Society of Gynecologic Oncology (Received), March 2020 - June 2020

Society of Gynecology Oncology (SGO) 2020 Innovation Award, Innovation Award in Oncology, Society of Gynecologic Oncology SGO 2020 (Received), January 1, 2020 - June 1, 2020

Top Doctors, 405 Magazine (Received), February 2020

2017 Top Doctors, Oklahoma Magazine (Received), May 22, 2017

The James A. Merrill Chair in Obstetrics and Gynecology, University of Oklahoma (Received), August 1, 2007 - March 6, 2016

Faculty Teaching Award for Excellence in Teaching Medical Students, University of Oklahoma Department of Obstetrics and Gynecology (Received), 2014 - 2015

Brian and Sandra O'Brien Presidential Professorship, The University of Oklahoma (Received), May 2002 - 2014

James F. Nolan Award, Western Association of Gynecologic Oncology (WAGO) (Received), 2005

James F. Nolan Award for Paper, Western Association of Gynecologic Oncology (Received), 2005

Faculty Award for Excellence in Resident Education, Council on Resident Education of Obstetrics and Gynecology Faculty (Received), 1999

The Best Doctors in America, Woodward/White, Inc. (Received), 1999

Presidential Professorship, University of Oklahoma (Received), April 1998

401 Best Doctors for Women, Good Housekeeping (Received), August 1997

Resident Teaching Award, University of California-Gynecologic Oncology (Received), 1990

Resident Teaching Award, University of California--Gynecologic Oncology (Received), 1987

BOARD AND PRACTICE CERTIFICATION

- 2012 - Present Hospice and Palliative Care, American Board of Obstetrics and Gynecology, Maintenance of Certification
- 2009 - Present Robotic Surgery Certification, Robotic Surgery
- 1996 - Present Certification to perform laparoscopic surgeries, Gynecologic Oncology Group, National Cancer Institute
- 1992 - Present Board Certification, Gynecologic Oncology, The American Board of Obstetrics and Gynecology, Maintenance of Certification
- 1988 - Present Board Certification, Gynecologic Oncology, The American Board of Obstetrics and Gynecology, Maintenance of Certification
- 1988 - Present Diplomate, Obstetrics and Gynecology, The American Board of Obstetrics and Gynecology, Active

LICENSURE

- 1990 - Present Medical License, Medicine, Oklahoma State Board of Medical Licensure & Supervision, Active
- 1985 - Present Medical License, Medicine, Medical Board of California, Active
- 1984 - 2004 Medical License, Medicine, Pennsylvania Department of State, Inactive

SCHOLARSHIP

Contracts, Grants, and Sponsored Research

* indicates mentee

Current

Clinical Trial Agreements

Walker, J. L. (Principal Investigator), Moxley, K. M. (Principal Investigator), "A Lead Academic Participating Site in Oklahoma for the Design and Conduct of," Sponsored by National Institutes of Health, Federal

Grant/Contract Number: 1UG1CA233193-01

Current Funding (Total Cost per Year): \$1,672,081.00

March 7, 2019 - Present

Walker, J. L. (Principal Investigator), Moore, K. (Co-Principal Investigator), "A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects with Stage IIIb-IV Ovarian Cancer in Clinical Complete Response following Surgery and Primary Chemotherapy (VITAL)," Ovarian Cancer Research

Grant/Contract Number: Gradalis-CL-PTL-119

Additional Information: Active/Closed to Enrollment

June 23, 2017 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A phase II evaluation of copanlisib (BAY 80-6946) (IND #130822), a selective inhibitor of P13KCA, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations,"

Sponsored by NRG, Federal
Grant/Contract Number: NRG GY008
September 2016 - Present

Moore, K. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A multicenter, multinational, double-blind, 2-arm, randomized, phase 2/3, study of physician's choice chemotherapy ([PCC] weekly paclitaxel or pegylated liposomal doxorubicin [PLD]) plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo for subjects with platinum-resistant, recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer," Sponsored by OXiGENE, Private
Grant/Contract Number: OX4325 FOCUS Oxigene
June 2016 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A phase I/II study of ruxolitinib with front-line neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer," Sponsored by NRG, Federal
Grant/Contract Number: NRG GY007
May 2016 - Present

Moxley, K. M. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A phase 2, randomized study of MNL0128 (a dual TORC1/2 inhibitor), MLN0128+MLN1117 (a P13Ka inhibitor), weekly paclitaxel, or the combination of weekly paclitaxel and MLN0128 in women with advanced, recurrent, or persistent endometrial cancer," Sponsored by Millennium Pharmaceuticals, Private
Grant/Contract Number: Millennium C31004
March 28, 2016 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A randomized phase II/III study of the combination of cediranib and olaparib compared to cediranib or olaparib alone, or standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS) (IND 124225)," Sponsored by NRG, Federal
Grant/Contract Number: NRG GY005
February 2016 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, Stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer," Sponsored by NRG, Federal
Grant/Contract Number: NRG GY006
January 2016 - Present

Jackson, C. C. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A phase 3, multicenter, randomized, open-label study of avelumab (MSB0010718C) alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer," Sponsored by Pfizer, Private
Grant/Contract Number: Pfizer B9991009 Javelin
December 23, 2015 - Present

Holman, L. L. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A phase 3, randomized, double-blind, placebo-controlled, multicenter study of niraparib maintenance treatment in patients with HRD-positive advanced ovarian cancer following response on front-line platinum-based chemotherapy," Sponsored by Tesaro, Private
Grant/Contract Number: Tesaro PR-30-5017-C GOG 3012
December 8, 2015 - Present

Moore, K. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A phase 2 proof-of-concept study of ACP-196 alone and in combination with pembrolizumab in subjects with recurrent ovarian cancer," Sponsored by Acerta Pharma BV, Private
Grant/Contract Number: ACE-ST-208
November 2015 - Present

Moore, K. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "Molecular analysis for therapy choice (MATCH)," Sponsored by ECOG-ACRIN, Federal
Grant/Contract Number: PM ECOG-ACRIN EAY131
August 2015 - Present

Slomovitz, B. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer," Sponsored by Gynecologic Oncology Group
Grant/Contract Number: NCT02228681
Additional Information: 74 patients currently enrolled. Ongoing. Active. Not recruiting new patients
February 2015 - Present

Walker, J. L. (Principal Investigator), "Compassionate use Veliparib (ABT-888) for BRCA1 or BRCA2+ recurrent ovarian cancer"
Additional Information: The purpose of this study is to provide the patient with access to the investigational drug, Veliparib (ABT-888), to see if it works in treating their type of cancer.
September 24, 2014 - Present

Walker, J. L. (Co-Investigator), Mannel, R. S. (Co-Investigator), "Clinical Proteomic Technology Assessment for Cancer (CPTAC)"
Additional Information: The goal of this project is to prospectively collect and process breast, colon, and ovarian cancer biospecimens and normal tissue as part of the CPTAC (Clinical Proteomic Tumor Analysis Consortium) phase II project for proteomic and genomic analysis in order to improve the diagnosis, treatment, and prevention of cancer. More specifically, these biospecimens will be obtained in a manner designed to optimize conditions for proteomic analysis.
July 3, 2014 - Present

Moore, K. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "The MILO study (MEK inhibitor in low-grade serious ovarian cancer): A multinational, randomized, open-label phase 3 study of MEK162 vs. physician's choice of chemotherapy in patients with recurrent or persistent low-grade serious carcinoma of the ovary, fallopian tube or primary peritoneum," Sponsored by MILO Array, Private
Grant/Contract Number: MILO Array-162-311
June 2013 - Present

Walker, J. L. (Principal Investigator), "Amendment - Biopsy number needed to detect CIN 3," Sponsored by National Institutes of Health - NCI (DHHS) SUCCEED, Federal
Additional Information: No cost extension until January 2011
January 2011 - Present

Walker, J. L. (Site PI), "Laparoscopic Approach to Cervical Cancer (LACC)," Sponsored by Queensland Centre for Gynaecological Cancer, Outside Facility
Grant/Contract Number: NCT0014211
Additional Information: Randomized trial of radical hysterectomy and lymphadenectomy either robotic/laparoscopic vs laparotomy
January 31, 2008 - Present

Moore, K. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A phase 2, open-label, single-arm study to evaluate the safety and efficacy of niraparib in women with advanced, relapsed, high-grade serious epithelial ovarian, fallopian tube, or primary peritoneal cancer who have

received at least three previous chemotherapy regimen," Sponsored by Tesaro, Private
Grant/Contract Number: Tesaro PR 30 5020 C
2000 - Present

Moore, K. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A phase 3 placebo-controlled study of carboplatin/paclitaxel with or without concurrent and continuation maintenance veliparib (PARP inhibitor) in subjects with previously untreated stages III or IV high-grade serious epithelial ovarian, fallopian tube, or primary peritoneal cancer," Sponsored by Abbvie, Private
Grant/Contract Number: Abbvie GOG3005 M13-694
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A phase II trial evaluating cisplatin (NSC #119875) and gemcitabine (NSC #613327) concurrent with intensity-modulated radiation therapy (IMRT) in the treatment of locally advanced squamous cell carcinoma of the vulva," Sponsored by NRG-GOG, Federal
Grant/Contract Number: NRG-GOG-0279
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab (NSC #704865, IND #7921) followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer," Sponsored by National Cancer Institute, Federal
Grant/Contract Number: NRG-GOG-0213
Additional Information: NCI-supplied agents: Bevacizumab NSC #704865, IND #7921
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer," Sponsored by NRG, Federal
Grant/Contract Number: NRG GY004
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A phase III trial of adjuvant chemotherapy as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the Outback trial (ANZGOG 092/GOG-274/RTOG 1174)," Sponsored by NRG-GOG, Federal
Grant/Contract Number: ANZGOG 092/GOG-274/RTOG 1174
Additional Information: NRG-GOG-0274
2000 - Present

Moore, K. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A randomized open label phase II study of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of patients with persistent or relapsed epithelial ovarian, fallopian tube or primary peritoneal carcinoma," Sponsored by GlaxoSmithKline, Private
Grant/Contract Number: GSK OVA-7 UnivVA
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A randomized phase II trial of paclitaxel and carboplatin vs. bleomycin, etoposide and cisplatin for newly diagnosed advanced stage and recurrent chemo-naïve stage sex cord-stromal tumors of the ovary," Sponsored by NRG-GOG, Federal
Grant/Contract Number: NRG-GOG 0264
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A randomized phase II/III study of paclitaxel/carboplatin/metformin (NSC #91485) versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, Stage IVB or recurrent endometrial cancer," Sponsored by NRG-GOG, Federal
Grant/Contract Number: NRG-GOG-0268B
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A randomized phase II/III study to assess the efficacy of trametinib (GSK 120212) in patients with recurrent or progressive low-grade serious ovarian cancer or peritoneal cancer," Sponsored by NRG-GOG, Federal
Grant/Contract Number: NRG-GOG-0281
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus," Sponsored by NRG-GOG, Federal
Grant/Contract Number: NRG-GOG-0238
2000 - Present

Moore, K. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A randomized, double-blind, placebo controlled, phase 2 study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer," Sponsored by Morphotek, Private
Grant/Contract Number: Morphotek MORAb-003-011
2000 - Present

Moore, K. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "A randomized, open label phase II study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus investigator's choice of chemotherapy in adults with folate receptor alpha positive advanced epithelial ovarian cancer, primary peritoneal cancer or primary fallopian tube cancer," Sponsored by ImmunoGen, Private
Grant/Contract Number: ImmunoGen IMGN853-0403 GOG301
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "Can diet and physical activity modulate ovarian, fallopian tube, and primary peritoneal cancer progression-free survival?," Sponsored by NRG-GOG, Federal
Grant/Contract Number: NRG-GOG-0225
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "Comparative analysis of CA-IX, p16, proliferative markers and human papilloma virus (HPV) in the diagnosis of significant cervical lesions in patients with a cytologic diagnosis of atypical glandular cell (AGC)," Sponsored by NRG-GOG, Federal
Grant/Contract Number: NG-GOG-0237
2000 - Present

Walker, J. L. (Principal Investigator), "Double-blind, placebo controlled phase III trial of maintenance FANG (bi-shRNA and GMCSF augmented autologous tumor cell immunotherapy) for high risk stage III/IV ovarian cancer," Sponsored by Tesaro, Private
Grant/Contract Number: Gradalis CL-PTL-119
2000 - Present

Mannel, R. S., **Walker, J. L.** (Co-Principal Investigator), "Evaluation of physical function and quality of life (QOL) before and after non-radical surgical therapy (extra fascial hysterectomy or cone biopsy with pelvic lymphadenectomy) for stage IA1 (LVSI+) and IA2-IB1 (<2cm) cervical cancer," Sponsored by NRG-GOG, Federal
Grant/Contract Number: NRG-GOG--0278
2000 - Present

Moore, K. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "Feasibility IB trial of paclitaxel/carboplatin + galunisertib (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary," Sponsored by Lilly, Private
Grant/Contract Number: Lilly-Galunisertib
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "Pazopanib neoadjuvant trial on non-rhabdomyosarcoma soft tissue sarcomas (PAZNTIS): A phase II/III randomized trial of preoperative chemoradiation or preoperative radiation plus or minus pazopanib (NSC# 737754, IND# 118613)," Sponsored by NRG-GOG, Federal
Grant/Contract Number: NRG-GOG-ARST1321
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "Perfusion CT imaging to determine outcomes in patients participating in GOG00262: A randomized phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel in combination with carboplatin with or without bevacizumab (NSC #704865, IND #721) in the treatment of primary stage II, III or IV epithelial ovarian, peritoneal or fallopian tube," Sponsored by ACRIN, Federal
Grant/Contract Number: ACRIN 6695
2000 - Present

Benbrook, D. M. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "Pharmacodynamic assay validation for a phase 0 trial," Sponsored by University of Oklahoma, The University of Oklahoma (Institutional)
Grant/Contract Number: OU201305DB Phase-0
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "Phase II randomized trial of nivolumab with or without ipilimumab in patients with persistent or recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer," Sponsored by NRG, Federal
Grant/Contract Number: NRG-GY003
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "Randomized Phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy," Sponsored by NRG-GOG, Federal
Grant/Contract Number: NRG-GOG 0263
2000 - Present

Mannel, R. S. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "Responders pilot study: Molecular profiling of tumors from cancer patients who are exceptional responders," Sponsored by National Cancer Institute, Federal
Grant/Contract Number: PM NCI 9671
2000 - Present

Walker, J. L. (Co-Principal Investigator), Mannel, R. S. (Principal Investigator), "Lead academic participating site for the development and conduct of NCTN trials," Sponsored by NIH-NCI National

Clinical Trials Network (NCTN), Federal
Grant/Contract Number: U10CA180798
Total Direct Costs: \$1,221,450.00
April 14, 2014 - March 31, 2019

Cooperative Agreements

Walker, J. L. (Principal Investigator), "Gynecologic knowledge of physicians in Oklahoma: A ten-year follow-up survey of primary care physicians," Sponsored by OUHSC Department of OB/GYN
Additional Information: 2009JW Gyn Knowledge
2000 - Present

Grants

Walker, J. L., Bui, T. C. (Co-Investigator), "Relational Agent to provide Cervical Cancer Education," Cervical Cancer Research, Sponsored by NRG Oncology, Foundation
Grant/Contract Number: NCORP Pilot grant
Current Funding (Total Cost per Year): \$50,000.00
Additional Information: Collaboration with Karmanos Cancer Center in Detroit Radika Gogoi, MD
January 30, 2021 - Present

Benbrook, D. M. (Principal Investigator), **Walker, J. L.** (Co-Principal Investigator), "Ovarian cancer chemoprevention," Ovarian Cancer Research, Sponsored by NIH-National Cancer Institute (NCI), Federal
Grant/Contract Number: R01CA196200
Current Funding (Total Cost per Year): \$126,139.00
Total Direct Costs: \$340,535.00
August 14, 2014 - July 31, 2025

Walker, J. L. (Principal Investigator), "NRG Oncology NCORP Research Base," Gynecologic Oncology Research, Sponsored by NIH-NCI NRG Oncology Foundation, Inc., Foundation
Grant/Contract Number: UG1CA189867
Current Funding (Total Cost per Year): \$126,139.00
August 1, 2014 - July 31, 2025

Castellano, T. (Site PI), 5% Effort*, "Pilot study to describe current opioid prescribing, dispensing and usage patterns in post-operative and outpatient gynecologic oncology patients.," Decrease Opioid Dosing in Post operative cancer patients, Sponsored by OSTCR, State
Grant/Contract Number: U54GM104938 NIH/NIGMS
Current Funding (Total Cost per Year): \$50,000.00
Total Direct Costs: \$50,000.00
Additional Information: Larger multiinstitutional Grant application sent to NIH Heal Initiative
July 20, 2018 - June 20, 2019

Research Agreements

Walker, J. L., 5% Effort, "NCI SBIR Topic 423 - Software to Address Social Determinants of Health in Oncology Practices," SBIR NCI grant to implement social determinants of health screening and interventions in Stephenson Cancer Center, Sponsored by NCI, Federal
Grant/Contract Number: NCI- SBIR- 2021 topic 423
Current Funding (Total Cost per Year): \$300,000.00
Additional Information: Pilot grant for the first year and then eligible for the three year funding program
September 1, 2021 - July 30, 2022

Completed

Clinical Trial Agreements

Walker, J. L. (Co-Investigator), Wenzel, L. (Co-Investigator), "Patient IPAD shared decision tool for IP chemotherapy"

Grant/Contract Number: PCORI

Additional Information: Patient and oncologist discuss toxicity and benefits of IP chemotherapy for the treatment of ovarian cancer

September 1, 2013 - August 31, 2016

Walker, J. L. (Principal Investigator), "A non-interventional prospective study of the accuracy of the Precision Therapeutics, Inc. chemoresponse assay in patients with recurrent epithelial ovarian, peritoneal, or fallopian tube cancer"

Grant/Contract Number: PT-301 V.2

Additional Information: Major goals of this project are: To determine the relationship between the results of the PTI ChemoResponse Assay and progression free survival of patients with persistent, refractory and recurrent ovarian cancer; to determine the accuracy of the PTI ChemoResponse assay in predicting clinical tumor response; and to assess possible correlation between assay results and overall survival in the population.

December 17, 2004 - February 28, 2014

Walker, J. L. (Co-Principal Investigator), Mannel, R. S. (Co-Investigator), "For the establishment of clinical cancer trials program at the University of Oklahoma College of Medicine," Sponsored by College of Medicine, The University of Oklahoma (Institutional)

Grant/Contract Number: C10CA27469 (GOG27469-083)

Additional Information: To support the gynecologic oncology phase I through Phase III clinical trials including the regulatory, nursing, and data collection associated with these studies at the University of Oklahoma Health Sciences Center College of Medicine. Co-investigator on several projects

July 1, 1989 - February 28, 2014

Walker, J. L. (Principal Investigator), "Biomarkers in women's cancer"

Additional Information: This project is a collaborative program of clinical and translational scientists working on pilot studies using the latest biomarker technology for cervical, endometrial, and ovarian cancer.

October 1, 2010 - September 30, 2012

Walker, J. L. (Principal Investigator), "Amendment - Biopsy number needed to detect CIN 3,"

Sponsored by National Institutes of Health - NCI (DHHS) SUCCEED, Federal

Total Direct Costs: \$60,000.00

June 2011

Walker, J. L. (Principal Investigator), "A single-arm, open-label, phase II study to assess the safety and efficacy of the trifunctional antibody catumaxomab (Anti-EpCAM x anti-CD-3) administered intraperitoneally in ovarian cancer patients with recurrent symptomatic malignant ascites,"

Sponsored by Fresenius Biotech North America, Inc., Private

Total Direct Costs: \$165,350.00

March 28, 2006 - December 30, 2009

Walker, J. L. (Principal Investigator), "Amendment - Biopsy number needed to detect CIN 3,"

Sponsored by National Institutes of Health - NCI (DHHS) SUCCEED, Federal

Total Direct Costs: \$450,000.00

October 1, 2008 - September 30, 2009

Walker, J. L. (Principal Investigator), "Biopsy number needed to detect CIN 3," Sponsored by National Institutes of Health - NCI (DHHS) SUCCEED - Amendment, Federal
Total Direct Costs: \$450,000.00
October 1, 2008 - September 30, 2009

Walker, J. L. (Principal Investigator), "A study to understand cervical cancer early endpoints and determinants," Sponsored by National Institutes of Health (DHHS) SUCCEED, Federal
Total Direct Costs: \$1,979,839.00
August 13, 2003 - July 31, 2009

Walker, J. L. (Principal Investigator), "Clinical evaluation of the APTIMA® HPV assay on the TIGRIS® DTS system in women with ASC-US PAP test results and in women 30 years of age or older with negative PAP test results using ThinPrep test specimens," Sponsored by Gen-Probe, Inc., Private
Total Direct Costs: \$976,376.00
April 29, 2008 - February 28, 2009

Walker, J. L. (Principal Investigator), "A prospective, non-randomized, clinical trial of DNP-modified autologous tumor vaccine in epithelial ovarian cancer patients with persistent or recurrent disease," Sponsored by AVAX Technologies, Inc., Private
Total Direct Costs: \$70,000.00
July 1, 2000 - June 30, 2005

Walker, J. L. (Principal Investigator), "Cancer prevention and control committee co-chair," Sponsored by American College of Obstetrics and Gynecologists/Gynecologic Oncology Group, Federal
Total Direct Costs: \$7,333.00
August 1, 1999 - March 31, 2004

Walker, J. L. (Co-Principal Investigator), "A phase 2, multi-center, double-blind, placebo-controlled, dose-finding study of ZYC101a in the treatment of high-grade squamous intra-epithelial lesions of the uterine cervix (#00-01)," Sponsored by Zycos, Inc., Private
Total Direct Costs: \$34,800.00
January 1, 2001 - December 31, 2003

Walker, J. L. (Co-Principal Investigator), "Phase 2 nonrandomized study of LY35381 HCl in patients with recurrent or advanced endometrial cancer," Sponsored by Lilly Research Laboratories, Private
Total Direct Costs: \$25,914.00
February 10, 1999 - December 31, 2003

Walker, J. L. (Co-Principal Investigator), "A phase II/III trial of chemotherapy alone versus chemotherapy plus SCH 58500 in newly diagnosed state III ovarian and primary peritoneal cancer patient with >0.5 cm and <2 cm residual disease following surgery," Sponsored by Schering-Plough Research Institute, Foundation
Total Direct Costs: \$65,680.00
March 24, 1999 - June 30, 2003

Walker, J. L. (Co-Principal Investigator), "A one-year extension study to evaluate the long-term safety of ZYC101a in subjects previously enrolled in Zycos Protocol 00-01," Sponsored by Zycos, Inc., Private
2001 - 2002

Walker, J. L. (Co-Principal Investigator), "Continuation of treatment and monitoring of safety in patients treated with LY383381 for advanced cancer," Sponsored by Eli Lilly & Co., Private

Total Direct Costs: \$5,000.00
January 1, 2001 - December 31, 2002

Walker, J. L. (Co-Principal Investigator), "A randomized, open-label study of darbepoetin alfa (Novel Erythropoiesis Stimulating Protein, NESP) using fixed and weight-based dosing for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy," Sponsored by Amgen, Inc., Private
Total Direct Costs: \$81,000.00
December 1, 2001 - November 30, 2002

Walker, J. L. (Principal Investigator), "A double-blind placebo controlled trial of intravenous OvaRex Mab-B43 as post chemotherapy consolidation for ovarian, tubal and peritoneal carcinoma," Sponsored by AltaRex Corp, Private
Total Direct Costs: \$20,646.00
October 1, 1998 - October 31, 2002

Walker, J. L. (Principal Investigator), "SIP08-01: Health care-seeking behaviors among women experiencing symptoms potentially suggestive of ovarian cancer," Sponsored by CDC, Federal
Total Direct Costs: \$194,081.00
September 1, 2001 - September 29, 2002

Walker, J. L. (Co-Principal Investigator), "A phase II/III, double-blind, placebo controlled, randomized, dose finding and efficacy confirmation multicenter study of topical treatment with MX6 (Adapalene Gel) vs. placebo in patients with cervical intraepithelial neoplasia (CIN) Level I (MX6-14)," Sponsored by Maxia Pharmaceuticals, Private
May 1, 2001 - December 31, 2001

Walker, J. L. (Co-Principal Investigator), "Multi-center pilot study I of the MediSpectra optical detection system for detection of cervical cancer and its precursors," Sponsored by MediSpectra, Private
Total Direct Costs: \$108,360.00
January 1, 2001 - December 31, 2001

Walker, J. L. (Principal Investigator), "Biomarkers in women's cancers," Sponsored by OU Cancer Institute - Cancer Research Program Awards, The University of Oklahoma (Institutional)
Total Direct Costs: \$125,000.00
2000 - 2001

Walker, J. L. (Co-Principal Investigator), "The cost of cancer treatment study," Sponsored by RAND, Private
Total Direct Costs: \$15,250.00
December 1, 2000 - November 30, 2001

Walker, J. L. (Co-Principal Investigator), "A phase I study of adjuvant whole pelvic radiation therapy with concomitant weekly cisplatin & topotecan every three weeks following radical hysterectomy in patients with carcinoma of the cervix (Stages IA, IB, and IIA)," Sponsored by SmithKline Beecham Pharmaceuticals, Private
Total Direct Costs: \$30,000.00
December 1, 2000 - May 30, 2001

Walker, J. L. (Principal Investigator), "Cancer prevention and control committee co-chair," Sponsored by American College of Obstetrics and Gynecologists/Gynecologic Oncology Group, Federal
Total Direct Costs: \$11,000.00
April 1, 2000 - March 31, 2001

Walker, J. L. (Co-Principal Investigator), "Long-term follow-up evaluation of subjects participating in phase III clinical studies of MX6 (Adapalene Gel/Collagen Sponge) in subjects with cervical intraepithelial neoplasia level II, III, or carcinoma In Situ (CIN II, III, or CIS)," Private
Total Direct Costs: \$3,750.00
June 3, 1998 - December 31, 2000

Walker, J. L. (Principal Investigator), "A phase II open, randomized, multicenter trial to assess the activity and tolerability of IV ZD9331 or topotecan given as second-line therapy to patients with ovarian cancer progressing between 6 and 12 months after receiving platinum and taxol given in combination," Sponsored by AstraZeneca, Private
Total Direct Costs: \$2,200,000.00
December 1, 1999 - December 15, 2000

Walker, J. L. (Principal Investigator), "Initial dose escalation study of Biotope," Sponsored by Zycos, Inc., Private
Total Direct Costs: \$43,950.00
September 1, 1999 - September 1, 2000

Walker, J. L. (Principal Investigator), "Phase II dose-ranging study of MC6 in subjects with cervical intraepithelial neoplasia level I (CIN I), (MX08)," Sponsored by Maxia Pharmaceuticals, Private
Total Direct Costs: \$50,000.00
September 1, 1999 - September 1, 2000

Walker, J. L. (Principal Investigator), "A phase I/II open, multicenter trial to determine the efficacy and tolerability of IV ZD9331 in patients with recurrent or refractory ovarian cancer following treatment with topotecan," Sponsored by Zeneca Pharmaceuticals, Private
Total Direct Costs: \$55,000.00
August 4, 1999 - June 15, 2000

Walker, J. L. (Principal Investigator), "Cancer prevention and control committee co-chair," Sponsored by American College of Obstetrics and Gynecologists/Gynecologic Oncology Group, Federal
Total Direct Costs: \$3,000.00
May 31, 1999 - May 29, 2000

Walker, J. L. (Principal Investigator), "A phase II/III open, multicenter trial to determine the efficacy and tolerability of IV ZD9331 ('Vamydex') in patients with ovarian carcinoma, refractory or resistant to platinum and taxol and resistant or intolerant to topotecan as the most recent therapy," Sponsored by Zeneca Pharmaceuticals, Private
Total Direct Costs: \$55,000.00
January 1, 1999 - January 1, 2000

Walker, J. L. (Co-Principal Investigator), "Phase III clinical study of MX6 (Adapalene Gel/Collagen Sponge) vs. placebo in subjects with cervical intraepithelial neoplasia level II, III, or carcinoma In Situ (CIN II, III, or CIS) (USA)," Sponsored by Maxia Pharmaceuticals, Private
Total Direct Costs: \$30,000.00
June 3, 1998 - December 31, 1999

Walker, J. L. (Co-Principal Investigator), "Study of pharmacokinetics/update of MX6 (Adapalene Gel/Collagen Sponge) in subjects with cervical intraepithelial neoplasia level II, III, or carcinoma In Situ (CIN II, III, or CIS)," Sponsored by Maxia Pharmaceuticals, Private
Total Direct Costs: \$35,000.00
June 3, 1998 - December 31, 1999

Walker, J. L. (Principal Investigator), "Cancer prevention and control committee co-chair," Sponsored by American College of Obstetrics and Gynecologists/Gynecologic Oncology Group, Federal
Total Direct Costs: \$1,122.00
April 1, 1999 - July 31, 1999

Walker, J. L. (Principal Investigator), "Cancer prevention and control committee co-chair," Sponsored by American College of Obstetrics and Gynecologists/Gynecologic Oncology Group, Federal
Total Direct Costs: \$3,366.00
April 1, 1998 - March 31, 1999

Grants

Walker, J. L. (Co-Investigator), Benbrook, D. M. (Principal Investigator), "Ovarian cancer chemoprevention," Ovarian Cancer Research, Sponsored by NIH-National Cancer Institute (NCI), Federal
Grant/Contract Number: R01CA196200
Total Direct Costs: \$340,535.00
July 7, 2015 - June 30, 2020

Walker, J. L. (Principal Investigator), "Cancer prevention and control committee co-chair"
Grant/Contract Number: 2U10CA101165
Additional Information: Dr. Walker served as Co-Chair of a major committee of the Grantor. The Co-Chair conducted a meeting of the committee at the Grantor's semiannual meetings. The committee Co-Chair is responsible for the development of the scientific plans for his/her committee and for reporting the progress of the scientific plans to the Grantor's president and to its members at its quarterly and semiannual meetings.
June 1, 2012 - 2016

Walker, J. L. (Principal Investigator), "A phase 3 study of PSC833 in combination with paclitaxel and carboplatin (PC-PDC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum," Sponsored by Novartis Pharmaceuticals, Federal
Total Direct Costs: \$150,000.00
October 15, 1997 - April 15, 2002

Walker, J. L. (Principal Investigator), For the Establishment of Clinical Cancer Trials Program at the University of Oklahoma, Sponsored by National Institute of Health/Gynecologic Oncology Group, Federal
Current Funding (Total Cost per Year): \$120,000.00
Total Direct Costs: \$720,000.00
July 1, 1989 - March 31, 2002

Walker, J. L. (Principal Investigator), "Randomized trial on the clinical management of ASCUS and LSIL of the uterine cervix-clinical centers," Sponsored by National Cancer Institute, Federal
Total Direct Costs: \$3,334,521.00
Additional Information: No cost extension for analysis of data and manuscript production approved by NCI
September 30, 1995 - September 29, 2001

Walker, J. L. (Principal Investigator), "Consultant services for chronic disease service and cervical cancer detection and control program," Sponsored by Oklahoma State Department of Health/Chronic Disease Services, State
Total Direct Costs: \$185,200.00
November 1, 1993 - June 30, 2001

Walker, J. L. (Principal Investigator), "A Randomized Double-Blind Placebo Controlled Phase IIB Study of the Safety and Efficacy of OvaRex Mab-B43-13 in Ovarian Cancer Patients with an Elevated Serum CA 125 but Without Evidence of Disease," Sponsored by AltaRex Corp, Federal
Total Direct Costs: \$20,646.00
May 12, 1999 - May 11, 2001

Walker, J. L., "A Phase I/II Open Multicenter Trial to Determine the Efficacy and Tolerability of IV ZD9331 in Patients with Recurrent or Refractory Ovarian Cancer Following Treatment with Topotecan," Sponsored by Zeneca Pharmaceuticals, Federal
Total Direct Costs: \$55,000.00
August 4, 1999 - June 15, 2000

Walker, J. L. (Principal Investigator), "A double-blind, multicenter, parallel study comparing the efficacy and safety of Kytril tablets with placebo in the prevention of nausea and vomiting during the days following administration of IV Cyclophosphamide-based or Carboplatin-based chemotherapy in patients with malignant disease," Sponsored by SmithKline Beecham Pharmaceuticals, Private
Total Direct Costs: \$19,200.00
May 26, 1999 - April 21, 2000

Walker, J. L. (Principal Investigator), "Phase II study of amifostine combined with topotecan," Sponsored by SmithKline Beecham Pharmaceuticals, Federal
Total Direct Costs: \$66,000.00
May 1, 1997 - May 1, 1999

Walker, J. L. (Principal Investigator), "Outpatient implantation of the Port-a-Cath venous access system positioned with the Cath-finder catheter tracking device in gynecologic oncology patients," Sponsored by Deltec
Total Direct Costs: \$50,000.00
September 1, 1995 - September 1, 1996

Walker, J. L. (Principal Investigator), "Health Research Scientist Recruitment Award," Genital Tract Malignancies, HPV and Associated Oncogenes, Sponsored by Oklahoma Center for the Advancement of Science and Technology (OCAST), State
Total Direct Costs: \$150,000.00
June 1, 1992 - May 30, 1993

Walker, J. L. (Principal Investigator), A Phase III randomized study of Cyclophosphamide and Cisplatin with or without pre-treatment with WR-2721 in patients with Stage III or Stage IV Epithelial Ovarian Carcinoma, Sponsored by U.S. Bioscience, Federal
Total Direct Costs: \$30,000.00
April 15, 1992 - April 15, 1993

Walker, J. L. (Principal Investigator), "Cervical Neoplasia Associated with Human Papillomavirus Infection," Sponsored by Presbyterian Health Foundation, Foundation
Total Direct Costs: \$69,080.00
January 1, 1991 - December 31, 1991

Non-Funded Research

Walker, J. L. (Principal Investigator), "Evaluation of retrievable inferior vena cava filters a registry," Sponsored by OUHSC Department of OB/GYN, The University of Oklahoma (Institutional)
September 15, 2008 - September 15, 2009

Walker, J. L. (Principal Investigator), "Outcomes in gynecologic cancer," Sponsored by OUHSC Department of OB/GYN, The University of Oklahoma (Institutional)
September 4, 2002 - June 30, 2009

Walker, J. L. (Principal Investigator), "Prospective cohort study of women with evidence of early invasive cancer of the cervix and a desire to preserve their reproductive ability with radical trachelectomy"
June 26, 2002 - June 30, 2009

Walker, J. L. (Principal Investigator), "Phase II trial of intraperitoneal chemotherapy in stage IA, IB, IC, II, III and IV and recurrent platinum sensitive ovarian, fallopian tube, and primary peritoneal carcinoma and stage III and IV uterine cancer," Sponsored by OUHSC Department of OB/GYN, The University of Oklahoma (Institutional)
January 13, 2006 - May 31, 2009

Walker, J. L. (Principal Investigator), "Adenocarcinoma of the uterus with cervical extension and adenocarcinoma of the cervix: Are the clinical presentations truly different?," Sponsored by OUHSC Department of OB/GYN, The University of Oklahoma (Institutional)
May 15, 2000 - April 30, 2009

Walker, J. L. (Principal Investigator), "A retrospective review of clostridium difficile in the Ob/Gyn patient," Sponsored by OUHSC Department of OB/GYN, The University of Oklahoma (Institutional)
April 8, 2007 - January 31, 2009

Walker, J. L. (Principal Investigator), "LEEP complications, fertility, and pregnancy outcomes," Sponsored by National Institutes of Health, Federal
January 1, 2001 - December 31, 2007

Walker, J. L. (Principal Investigator), "Retrospective chart review of treatment-related complications and toxicities in patients receiving intraperitoneal chemotherapy at University of Oklahoma," Sponsored by OUHSC Department of OB/GYN, The University of Oklahoma (Institutional)
August 2, 2006 - August 16, 2007

Walker, J. L. (Principal Investigator), "Women's geriatric ovarian cancer study," Sponsored by National Institutes of Health, Federal
September 1, 2001 - August 30, 2002

Professional Service Agreements

Walker, J. L. (Co-Principal Investigator), Mannel, R. S. (Co-Principal Investigator), "The Cancer Genome Atlas (TCGA)"
Grant/Contract Number: 12XS514
Additional Information: The overall goal of this project is to collect, store, and ship tissue specimens to the sponsor per their guidelines. This project will be a contract agreement with multiple, specific task orders. The TCGA is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing.
October 12, 2012 - October 11, 2013

Walker, J. L. (Expert Physician/Consultant), "For health policy in gynecology," Sponsored by Aetna Life Insurance Company, Private
Current Funding (Total Cost per Year): \$5,000.00
1992 - 1993

Publications - Peer-Reviewed/Refereed

* indicates Mentee

+ indicates Co-First Author

indicates Contributing Author/Corresponding Author

Scientific/Scholarly Journals

1. **Walker, J. L.**# (in press). Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. *Elsevier*(YGYNO-978653; No. of pages: 8; 4C:), 8.
2. Wenzel, L., Huang, H. Q., Cella, D., McKinney, C. O., Zevon, M. A., LaChance, J. A., **Walker, J. L.**, Salani, R., Modesitt, S. C., Morris, R. T., Bradley, W. H., Boente, M. P., von Gruenigen, V. E. (2021). Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. *Gynecologic oncology*. PMID: 34548162. DOI: 10.1016/j.ygyno.2021.08.028
3. Duska, L. R., Filiaci, V. L., **Walker, J. L.**, Holman, L. L., Hill, E. K., Moore, R. G., Ring, K. L., Pearl, M. L., Muller, C. Y., Kushnir, C. L., Lankes, H. A., Samuelson, M. I., Carrick, K. S., Rajan, A., Rodgers, W. H., Kohn, E. C., Piekarz, R., Leslie, K. K. (2021). A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. *Clinical cancer research : an official journal of the American Association for Cancer Research*. PMID: 33766814. DOI: 10.1158/1078-0432.CCR-20-4618
4. Gillen, J., Miller, A., Bell-McGuinn, K. M., Schilder, R. J., **Walker, J. L.**, Mathews, C. A., Duska, L. R., Guntupalli, S. R., O'Ceirbhail, R., Hays, J., Hagemann, A. R., Gray, H. J., Gordon, S. W., Armstrong, D. K., Chen, A., Fracasso, P. M., Aghajanian, C., Moore, K. (2021). Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. *Gynecologic oncology*. PMID: 33610319. DOI: 10.1016/j.ygyno.2021.01.037
5. Russo, S., **Walker, J. L.**, Carlson, J. W., **Walker, J. L.**, Ward, L. C., Covens, A., Tanner, 3rd, E. J., Armer, J. M., Ridner, S., Hayes, S., Taghian, A. G., Brunelle, C., Lopez-Acevedo, M., Davidson, B. A., Schaverien, M. V., Ghamande, S. A., Bernas, M., Chevillat, A. L., Yost, K. J., Schmitz, K., Coyle, B., Zucker, J., Enserro, D., Pugh, S., Paskett, E. D., Ford, L., McCaskill-Stevens, W. (2021). Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers. *Gynecologic oncology*, 160(2), 625-632. PMID: 33158510. DOI: 10.1016/j.ygyno.2020.10.026
6. **Walker, J. L.**, **Walker, J. L.**, Lin, E., Romisher, A., Bouchie, M. P., Bleaken, B., Menko, A. S., Kukuruzinska, M. A. (2021). Specification of the patterning of a ductal tree during branching morphogenesis of the submandibular gland. *Scientific reports*, 11(1), 330. PMID: 33432003. DOI: 10.1038/s41598-020-79650-y
7. **Walker, J. L.**, Huang, H. Q., Armer, J., Carlson, J. W., Lockwood, S., Nolte, S., Kauderer, J., Hutson, A., **Walker, J. L.**, Fleury, A. C., Bonebrake, A., Soper, J. T., Mathews, C., Zivanovic, O., Richards, W. E., Tan, A., Alberts, D. S., Barakat, R. R., Wenzel, L. B. (2021). GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function. *Gynecologic oncology*, 160(1), 244-251. PMID: 33109392. DOI: 10.1016/j.ygyno.2020.10.023
8. Ellison, M. A., **Walker, J. L.**, Ropp, P. J., Durrant, J. D., Arndt, K. M. (2020). MutantHuntWGS: A Pipeline for Identifying *Saccharomyces cerevisiae* Mutations. *G3 (Bethesda, Md.)*, 10(9), 3009-3014. PMID: 32605926. DOI: 10.1534/g3.120.401396
9. Mullany, S., Miller, D. S., Robison, K., Levinson, K., Lee, Y. C., Yamada, S. D., **Walker, J. L.**,

- Markman, M., Marin, A., Mast, P., diZerega, G. (2020). Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery. *Gynecologic oncology reports*, 34, 100627. PMID: 32953961. DOI: 10.1016/j.gore.2020.100627
10. Ellison, M. A., **Walker, J. L.**, Ropp, P. J., Durrant, J. D., Arndt, K. M. (2020). Accuracy and Efficiency of Deep-Learning-Based Automation of Dual Stain Cytology in Cervical Cancer Screening. *Journal of the National Cancer Inst*, 113(1), 1-7. PMID: 32605926. DOI: doi:10.1093/jnci/djaa066
 11. Pinheiro, M., Gage, J. C., Clifford, G. M., Demarco, M., Cheung, Li C., Chen, Z., Yeager, M., Cullen, M., Boland, J. F., Chen, X., Raine-Bennett, T., Steinberg, M., Bass, S., Befano, B., Xiao, Y., Tenet, V., **Walker, J. L.**, Zuna, R. E., Poitras, N. E., Gold, M. A., Dunn, T., Yu, K., Zhu, B., Burdett, L., Turan, S., Lorey, T., Castle, P. E., Wentzensen, N., Burk, R. D., Schiffman, M., Mirabello, L. (2020). Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral-host interaction with implications for disease intervention. *International Journal of Cancer*, n/a(n/a). DOI: 10.1002/ijc.33033
 12. Moore, K., Miller, A. N., Bell-McGuinn, K. M., Schilder, R. J., **Walker, J. L.**, O'Ceirbhail, R. E., Guntupalli, S. R., Armstrong, D. K., Hagemann, A. R., Gray, H. J., Duska, L. R., Mathews, C. A., Chen, A. J., O'Malley, D., Gordon, S., Fracasso, P. M., Aghajanian, C. (2020). A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. *Gynecologic oncology*, 156(1), 13-22. PMID: 31708167. DOI: 10.1016/j.ygyno.2019.10.012
 13. Mai, P. L., Huang, H. Q., Wenzel, L. B., Han, P. K., Moser, R. P., Rodriguez, G. C., Boggess, J., Rutherford, T. J., Cohn, D. E., Kauff, N. D., Phillips, K. A., Wilkinson, K., Wenham, R. M., Hamilton, C., Powell, M. A., **Walker, J. L.**, Greene, M. H., Hensley, M. L. (2020). Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. *Gynecologic oncology*, 156(1), 131-139. PMID: 31759774. DOI: 10.1016/j.ygyno.2019.10.026
 14. Carter, J., Huang, H. Q., Armer, J., Carlson, J. W., Lockwood, S., Nolte, S., Stewart, B. R., Kauderer, J., Hutson, A., **Walker, J. L.**, Fleury, A. C., Bonebrake, A., Soper, J. T., Mathews, C., Zivanovic, O., Richards, W. E., Tan, A., Alberts, D. S., Barakat, R. R., Wenzel, L. (2019). GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE). *Gynecologic oncology*, 155(3), 452-460. PMID: 31679787. DOI: 10.1016/j.ygyno.2019.09.027
 15. **Walker, J. L.**[#], Mannel, R. S.[#] (2019). Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. *New England Journal of Medicine*, 381(20), 1929-1939. PMID: 31722153. DOI: 10.1056/NEJMoa1902626
 16. **Walker, J. L.**, Brady, M. F., Wenzel, L., Fleming, G. F., Huang, H. Q., DiSilvestro, P. A., Fujiwara, K., Alberts, D. S., Zheng, W., Tewari, K. S., Cohn, D. E., Powell, M. A., Van Le, L., Davidson, S. A., Gray, H. J., Rose, P. G., Aghajanian, C., Myers, T., Alvarez Secord, A., Rubin, S. C., Mannel, R. S. (2019). Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 37(16), 1380-1390. PMID: 31002578. DOI: 10.1200/JCO.18.01568
 17. Wagner, S., Roberson, D., Boland, J., Yeager, M., Cullen, M., Mirabello, L., Dunn, S. T., **Walker, J. L.**, Zuna, R. E., Schiffman, M., Wentzensen, N. (2019). Development of the TypeSeq Assay for Detection of 51 HPV Genotypes by Next Generation Sequencing. *Journal of clinical microbiology*. PMID: 30814267. DOI: 10.1128/JCM.01794-18

18. Clifford, G. M., Tenet, V., Georges, D., Alemany, L., Pavón, M. A., Chen, Z., Yeager, M., Cullen, M., Boland, J. F., Bass, S., Steinberg, M., Raine-Bennett, T., Lorey, T., Wentzensen, N., **Walker, J. L.**, Zuna, R. E., Schiffman, M., Mirabello, L. (2019). Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women. *Papillomavirus research (Amsterdam, Netherlands)*, 7, 67-74. PMID: 30738204. DOI: 10.1016/j.pvr.2019.02.001
19. Hoover, D., **Walker, J. L.**# (in press). Smoking cessation treatment needs of low SES cervical cancer survivors. *American Journal of Health Behavior Submission*.
20. Conrad, R. D., Liu, A. H., Wentzensen, N., Zhang, R. R., Dunn, S. T., Wang, S., Schiffman, M., Gold, M. A., **Walker, J. L.**, Zuna, R. E. (2018). Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis. *Cancer cytopathology*, 126(11), 950-958. PMID: 30351473. DOI: 10.1002/cncy.22055
21. Tew, W. P., Sill, M. W., **Walker, J. L.**, Secord, A. A., Bonebrake, A. J., Schilder, J. M., Stuckey, A., Rice, L., Tewari, K. S., Aghajanian, C. A. (2018). Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. *Gynecologic oncology*, 151(2), 257-263. PMID: 30177462. DOI: 10.1016/j.ygyno.2018.08.027
22. Felix, A. S., Cohn, D. E., Brasky, T. M., Zaino, R., Park, K., Mutch, D. G., Creasman, W. T., Thaker, P. H., **Walker, J. L.**, Moore, R. G., Lele, S. B., Guntupalli, S. R., Downs, L. S., Nagel, C. I., Boggess, J. F., Pearl, M. L., Ioffe, O. B., Randall, M. E., Brinton, L. A. (2018). Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study. *American journal of obstetrics and gynecology*, 219(5), 459.e1-459.e11. PMID: 30096321. DOI: 10.1016/j.ajog.2018.08.002
23. Wang, Y., Xu, X., Maglic, D., Dill, M. T., Mojumdar, K., Ng, P. K., Jeong, K. J., Tsang, Y. H., Moreno, D., Bhavana, V. H., Peng, X., Ge, Z., Chen, H., Li, J., Chen, Z., Zhang, H., Han, L., Du, D., Creighton, C. J., Mills, G. B., **Cancer Genome Atlas Research Network**, Camargo, F., Liang, H. (2018). Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. *Cell reports*, 25(5), 1304-1317.e5. PMID: 30380420. DOI: 10.1016/j.celrep.2018.10.001
24. Chan, J. K., Brady, W., Monk, B. J., Brown, J. R., Shahin, M. S., Rose, P. G., Kim, J. H., Secord, A. A., **Walker, J. L.**, Gershenson, D. M. (2018). A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). *Gynecologic oncology*, 150(2), 247-252. PMID: 29921512. DOI: 10.1016/j.ygyno.2018.05.029
25. von Gruenigen, V. E., Huang, H. Q., Cella, D., Zevon, M., LaChance, J. A., **Walker, J. L.**, Salani, R., Modesitt, S. C., Morris, R. T., Bradley, W. H., Boente, M. P., Wenzel, L. (2018). Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. *Gynecologic oncology*. PMID: 29778506. DOI: 10.1016/j.ygyno.2018.05.017
26. Traylor, M., **Walker, J. L.**, Corrigan, A. A., Hernandez, M. A., Newhouse, S. J., Folarin, A. A., Patel, H., Ross, P. J., Sanderson, J. D., Spicer, J., Prescott, N. J., Mathew, C. G., Marinaki, A. M., Lewis, C. M. (2018). Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer. *PloS one*, 13(5), e0188911. PMID: 29715290. DOI: 10.1371/journal.pone.0188911
27. Huang, H. Q., Wenzel, L. B., Han, P. K., Moser, R. P., Rodriguez, G. C., J. B., Rutherford, T. J., Cohn, D. E., Kauff, N. D., Phillips, K.-A., Wilkinson, K., Wenham, R. W., Hamilton, C. A., Powell,

- M. A., **Walker, J. L.**, Greene, M. H., Hensley, M. L. (in press). Prospective Follow-up of Quality of Life for Participants Undergoing Risk-Reducing Salpingo-Oophorectomy or Ovarian Cancer Screening in GOG-0199: An NRG Oncology/GOG Study Corresponding Author: Phuong Mai. *Journal of Gynecologic Oncology*.
28. Kunos, C. A., Massett, H. A., Galassi, A., **Walker, J. L.**, Good, M. J., Díaz, L. B., McCaskill-Stevens, W. (2018). Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Patient Accrual in Puerto Rico. *Frontiers in oncology*, 8, 102. PMID: 29692980. DOI: 10.3389/fonc.2018.00102
 29. **Walker, J. L.** (2018). GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study. *Gynecologic oncology*, 149, 2.
 30. Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., **Walker, J. L.**, Kim, B. G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., Davidson, S. A., Rubin, S. C., DiSilvestro, P., Basen-Engquist, K., Chan, J. K., Spirtos, N. M., Ashfaq, R., Mannel, R. S. (2017). A randomized controlled clinical trial of bevacizumab and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: An NRG Oncology/Gynecology Group Study. *Lancet Oncology*.
 31. Felix, A. S., Brasky, T. M., Cohn, D. E., Mutch, D. G., Creasman, W. T., Thaker, P. H., **Walker, J. L.**, Moore, R. G., Lele, S. B., Guntupalli, S. R., Downs, L. S., Nagel, C., Boggess, J. F., Pearl, M. L., Ioffe, O. B., Deng, W., Miller, D. S., Brinton, L. A. (2017). Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. *International journal of cancer*. PMID: 29063589. DOI: 10.1002/ijc.31127
 32. Bishop, E. A., Java, J. J., Moore, K., Spirtos, N. M., Pearl, M. L., Zivanovic, O., Kushner, D. M., Backes, F., Hamilton, C. A., Geller, M. A., Hurteau, J., Mathews, C., Wenham, R. M., Ramirez, P. T., Zweizig, S., **Walker, J. L.** (2017). Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. *American journal of obstetrics and gynecology*. PMID: 29037481. DOI: 10.1016/j.ajog.2017.09.026
 33. Cohn, D. E., Sill, M. W., **Walker, J. L.**, O'Malley, D., Nagel, C. I., Rutledge, T. L., Bradley, W., Richardson, D. L., Moxley, K. M., Aghajanian, C. (2017). Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. *Gynecologic oncology*, 146(3), 477-483. PMID: 28756871. DOI: 10.1016/j.ygyno.2017.07.135
 34. Clarke, M. A., Luhn, P., Gage, J. C., Bodelon, C., Dunn, S. T., **Walker, J. L.**, Zuna, R. E., Hewitt, S., Killian, J. K., Yan, L. L., Miller, A. N., Schiffman, M., Wentzensen, N. (2017). Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. *International journal of cancer*, 141(4), 701-710. PMID: 28500655. DOI: 10.1002/ijc.30781
 35. Grabosch, S., Tseng, G., Edwards, R. P., Lankes, H. A., Moore, K., Odunsi, K., Vlad, A., Ma, T., Strange, M., Brozick, J., Lugade, A., Omilian, A., Bshara, W., Stuckey, A. R., **Walker, J. L.**, Birrer, M. (2017). Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. *Gynecologic Oncology*, 146(1), 134-145. PMID: 28483269. DOI: 10.1016/j.ygyno.2017.04.008
 36. Wenzel, L., Mukamel, D., Osann, K., Havrilesky, L., Sparks, L., Lipscomb, J., Wright, A. A., **Walker, J. L.**, Alvarez, R., Van Le, L., Robison, K., Bristow, R., Morgan, R., Rimel, B. J., Ladd, H., Hsieh, S., Wahi, A., Cohn, D. (2017). Rationale and Study Protocol for the Patient-Centered Outcome Aid (PCOA) Randomized Controlled Trial: A Personalized Decision Tool for Newly Diagnosed Ovarian Cancer Patients. *Contemporary Clinical Trials*, 57(June 2017), 29-36. PMID:

28330753. DOI: 10.1016/j.cct.2017.03.006

37. Wenzel, L. B., Mukamel, D. B., Osann, K., Sparks, L., Havrilesky, L. J., Wright, A. A., **Walker, J. L.** (2017). Shared decision-making in ovarian cancer. *JCO*, 35(15 Suppl May 2017), 5549-5549. DOI: 10.1200/JCO.2017.35.15_supl.5549
38. Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., **Walker, J. L.**, Kim, B. G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., Davidson, S. A. (2017). Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. *The Lancet Oncology*, 18(6), 779-791. PMID: 28438473. DOI: 10.1016/S1470-2045(17)30279-6
39. Bishop, E. A., Java, J. J., Moore, K., **Walker, J. L.** (2017). Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. PMID: 28399028. DOI: 10.1097/IGC.0000000000000947
40. Mai, P. L., Piedmonte, M., Han, P. K., Moser, R. P., **Walker, J. L.**, Rodriguez, G., Boggess, J., Rutherford, T. J., Zivanovic, O., Cohn, D. E., Thigpen, J. T., Wenham, R. M., Friedlander, M. L., Hamilton, C. A., Bakkum-Gamez, J., Olawaiye, A. B., Hensley, M. L., Greene, M. H., Huang, H. Q., Wenzel, L. (2017). Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. *Gynecologic oncology*, 145(1), 122-129. PMID: 28190649. DOI: 10.1016/j.ygyno.2017.02.008
41. Jandial, D. A., Brady, W. E., Howell, S. B., Lankes, H. A., Schilder, R. J., Beumer, J. H., Christner, S. M., Strychor, S., Powell, M. A., Hagemann, A. R., Moore, K., **Walker, J. L.**, DiSilvestro, P. A., Duska, L. R., Fracasso, P. M., Dizon, D. S. (2017). A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. *Gynecologic oncology*. PMID: 28341300. DOI: 10.1016/j.ygyno.2017.03.013
42. **Cancer Genome Atlas Research Network** (2017). Integrated genomic and molecular characterization of cervical cancer. *Nature*, 543(7645), 378-384. PMID: 28112728. DOI: 10.1038/nature21386
43. Brasky, T. M., Felix, A. S., Cohn, D. E., McMeekin, S., Mutch, D. G., Creasman, W. T., Thaker, P. H., **Walker, J. L.**, Moore, R. G., Lele, S. B., Guntupalli, S. R., Downs, L. S., Nagel, C. I., Boggess, J. F., Pearl, M. L., Ioffe, O. B., Park, K. J., Ali, S., Brinton, L. A. (2017). Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. *Journal of the National Cancer Institute*, 109(3), 1-10. PMID: 28376204. DOI: 10.1093/jnci/djw251
44. Mai, P. L., Piedmonte, M., Han, P. K., Moser, R. P., **Walker, J. L.**, Rodriguez, G., Boggess, J., Rutherford, T. J., Zivanovic, O., Cohn, D. E., Thigpen, J. T., Wenham, R. M., Friedlander, M. L., Hamilton, C. A., Bakkum-Gamez, J., Olawaiye, A. B., Hensley, M. L., Greene, M. H., Huang, H. Q., Wenzel, L. (2017). Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. *Gynecologic oncology*. PMID: 28190649. DOI: 10.1016/j.ygyno.2017.02.008
45. Ng, C., Zhang, Z., Lee, S. I., Marques, H. S., Burgers, K., Su, F., Bauza, J., Mannel, R. S., **Walker, J. L.**, Huh, W. K., Rubin, S. C., DiSilvestro, P., Martin, L. P., Chan, J. K., Bookman, M. A., Coleman, R. L., Lee, T. Y. (2017). CT perfusion as an early biomarker of treatment efficacy in

advanced ovarian cancer: an ACRIN and GOG study. *Clinical cancer research : an official journal of the American Association for Cancer Research*. PMID: 28174234. DOI: 10.1158/1078-0432.CCR-16-1859

46. Schiffman, M., Yu, K., Zuna, R. E., Terence Dunn, S., Zhang, H., **Walker, J. L.**, Gold, M. A., Hyun, N., Rydzak, G., Katki, H. A., Wentzensen, N. (2017). Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have \geq CIN2. *International journal of cancer*, 140(3), 718-725. PMID: 27696414. DOI: 10.1002/ijc.30456
47. Skates, S. J., Greene, M. H., Buys, S. S., Mai, P. L., Brown, P. H., Piedmonte, M., Rodriguez, G. C., Schorge, J. O., Sherman, M., Daly, M. B., Rutherford, T. J., Brewster, W. R., O'Malley, D. M., Partridge, E. E., Boggess, J., Drescher, C. W., Isaacs, C., Berchuck, A., Domchek, S. M., Davidson, S. A., Edwards, R. P., Elg, S. A., Wakeley, K., Phillips, K. A., Armstrong, D. K., Horowitz, I. R., Fabian, C. J., **Walker, J. L.**, Sluss, P. M., Welch, W. R., Minasian, L., Horick, N., Kasten, C. H., Nayfield, S., Alberts, D. S., Finkelstein, D. M., Lu, K. (2017). Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. *Clinical cancer research : an official journal of the American Association for Cancer Research*. PMID: 28143870. DOI: 10.1158/1078-0432.CCR-15-2750
48. Conrad, R. D., Wentzensen, N., Zhang, R. R., Wang, S., Schiffman, M., Gold, M. A., **Walker, J. L.**, Zuna, R. E. (2017). Distribution of cell types differs in Papanicolaou tests of squamous cells carcinomas and adenocarcinomas. *Journal of the American Society of Cytopathology*, 6(1), 10-15. DOI: 10.1016/j.jasc.2016.08.003
49. Thomas, E. D., Nugent, E. K., MacAllister, M. C., Moxley, K. M., Landrum, L. M., **Walker, J. L.**, McMeekin, S., Mannel, R. S., McGwin, G., Moore, K. (2017). Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial. *Gynecologic Oncology*, 144(1), 193-199. PMID: 27836205. DOI: 10.1016/j.ygyno.2016.11.008
50. Brasky, T. M., Felix, A. S., Cohn, D. E., McMeekin, S., Mutch, D. G., Creasman, W. T., Thaker, P. H., **Walker, J. L.**, Moore, R. G., Lele, S. B., Guntupalli, S. R., Downs, L. S., Nagel, C. I., Boggess, J. F., Pearl, M. L., Ioffe, O. B., Park, K. J., Ali, S., Brinton, L. A. (2016). Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. *Journal of the National Cancer Institute*, 109(3). PMID: 27986878. DOI: 10.1093/jnci/djw251
51. Garcia-Soto, A. E., Java, J. J., Nieves Neira, W., Pearson, J. M., Cohn, D. E., Lele, S. B., Tewari, K. S., **Walker, J. L.**, Alvarez Secord, A., Armstrong, D. K., Copeland, L. J. (2016). Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. *Gynecologic oncology*, 143(3), 484-489. PMID: 27726923. DOI: 10.1016/j.ygyno.2016.10.003
52. Fader, A. N., Java, J., Tenney, M., Ricci, S., Jackson, C. C., Temkin, S. M., Spirtos, N., Kushnir, C. L., Pearl, M. L., Zivanovic, O., Tewari, K. S., O'Malley, D., Hartenbach, E. M., Hamilton, C. A., Gould, N. S., Mannel, R. S., Rodgers, W., **Walker, J. L.** (2016). Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. *Gynecologic oncology*, 143(3), 460-465. PMID: 27743738. DOI: 10.1016/j.ygyno.2016.10.016
53. Monk, B. J., Facciabene, A., Brady, W. E., Aghajanian, C. A., Fracasso, P. M., **Walker, J. L.**, Lankes, H. A., Manjarrez, K. L., Danet-Desnoyers, G. H., Bell-McGuinn, K. M., McCourt, C. K., Malykhin, A., Hershberg, R. M., Coukos, G. (2016). Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. *Clinical cancer research : an official journal of the*

American Association for Cancer Research. PMID: 27702821. DOI: 10.1158/1078-0432.CCR-16-1453

54. Sherman, M. E., Drapkin, R. I., Horowitz, N. S., Crum, C. P., Friedman, S., Kwon, J. S., Levine, D. A., Shih, L., Shoupe, D., Swisher, E. M., **Walker, J. L.**, Trabert, B., Greene, M. H., Samimi, G., Temkin, S. M., Minasian, L. M. (2016). Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. *Cancer prevention research (Philadelphia, Pa.)*, 9(9), 713-20. PMID: 27221539. DOI: 10.1158/1940-6207.CAPR-15-0384
55. Monk, B. J., Sill, M. W., **Walker, J. L.**, Darus, C. J., Sutton, G., Tewari, K. S., Martin, L. P., Schilder, J. M., Coleman, R. L., Balkissoon, J., Aghajanian, C. (2016). Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, 34(19), 2279-86. PMID: 27217446. DOI: 10.1200/JCO.2015.65.8153
56. **Walker, J. L.**, Wenzel, L., Huang, H., Brady, M. F. (2016). Patient-reported outcomes in GOG 252: NRG Oncology Study of IV vs IP chemotherapy for ovarian, fallopian, or peritoneal carcinoma. *Gynecologic Oncology*, 141(Suppl 1), Page 208. DOI: 10.1016/j.ygyno.2016.04.536
57. Coleman, R. L., Brady, M. F., Herzog, T. J., Armstrong, D. K., Sabbatini, P., **Walker, J. L.**, Kim, B., Fujiwara, K., Tewari, K. S., O'Malley, D. M. (2016). Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213. *JCO*, 34(15_suppl), 5523. DOI: 10.1200/JCO.2016.34.15_suppl.5523
58. Liu, A. H., Gold, M. A., Schiffman, M., Smith, K. M., Zuna, R. E., Dunn, S. T., Gage, J. C., **Walker, J. L.**, Wentzensen, N. (2016). Comparison of Colposcopic Impression Based on Live Colposcopy and Evaluation of Static Digital Images. *Journal of lower genital tract disease*, 20(2), 154-61. PMID: 27015261. DOI: 10.1097/LGT.0000000000000194
59. Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., **Walker, J. L.**, DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., Huh, W. K., O'Malley, D. M., Boente, M. P., Michael, H., Monk, B. J. (2016). Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. *The New England journal of medicine*, 374(8), 738-48. PMID: 26933849. DOI: 10.1056/NEJMoa1505067
60. Bodelon, C., Vinokurova, S., Sampson, J. N., den Boon, J. A., **Walker, J. L.**, Horswill, M. A., Korthauer, K., Schiffman, M., Sherman, M. E., Zuna, R. E., Mitchell, J., Zhang, X., Boland, J. F., Chaturvedi, A. K., Dunn, S. T., Newton, M. A., Ahlquist, P., Wang, S., Wentzensen, N. (2016). Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. *Carcinogenesis*, 37(2), 188-96. PMID: 26660085. DOI: 10.1093/carcin/bgv171
61. Eskander, R. N., Ali, S., Dellinger, T., Lankes, H. A., Randall, L. M., Ramirez, N. C., Monk, B. J., **Walker, J. L.**, Eisenhauer, E., Hoang, B. H. (2016). Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*, 26(1), 125-32. PMID: 26397159. DOI: 10.1097/IGC.0000000000000563
62. Gourley, C., **Walker, J. L.**, Mackay, H. J. (2016). Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer. *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting*, 35, 143-51. PMID: 27249695. DOI: 10.14694/EDBK_158927

63. Castro, F. A., Koshiol, J., Quint, W., Wheeler, C. M., Gillison, M. L., Vaughan, L. M., Kleter, B., van Doorn, L. J., Chaturvedi, A. K., Hildesheim, A., Schiffman, M., Wang, S., Zuna, R. E., **Walker, J. L.**, Dunn, S. T., Wentzensen, N. (2015). Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. *BMC infectious diseases*, 15, 544. PMID: 26607224. DOI: 10.1186/s12879-015-1281-5
64. Ruskin, R., Rowland, M. R., Moore, K., Lefkowitz, C., Walter, A., Slaughter, K., Landrum, L. M., **Walker, J. L.**, Matzo, M. (2015). How do palliative care needs vary across the disease trajectory in patients with gynecologic cancer? *JCO*, 33(29_suppl), 106. PMID: 28148074. DOI: 10.1200/jco.2015.33.29_suppl.106
65. Ruskin, R., Rowland, M. R., Moore, K., Slaughter, K., Walter, A., Landrum, L. M., **Walker, J. L.**, Matzo, M. (2015). Predictors of referral to outpatient specialty palliative care (SPC) in gynecologic cancer (GC) patients. *JCO*, 33(29_suppl), 159. PMID: 28148032. DOI: 10.1200/jco.2015.33.29_suppl.159
66. Ferriss, J. S., Java, J. J., Bookman, M. A., Fleming, G. F., Monk, B. J., **Walker, J. L.**, Homesley, H. D., Fowler, J., Greer, B. E., Boente, M. P., Burger, R. A. (2015). Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. *Gynecologic oncology*, 139(1), 17-22. PMID: 26216729. DOI: 10.1016/j.ygyno.2015.07.103
67. Felix, A. S., McMeekin, S., Mutch, D., **Walker, J. L.**, Creasman, W. T., Cohn, D. E., Ali, S., Moore, R. G., Downs, L. S., Ioffe, O. B., Park, K. J., Sherman, M. E., Brinton, L. A. (2015). Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial. *Gynecologic oncology*, 139(1), 70-6. PMID: 26341710. DOI: 10.1016/j.ygyno.2015.08.022
68. Cohn, D. E., Havrilesky, L. J., Osann, K., Lipscomb, J., Hsieh, S., **Walker, J. L.**, Wright, A. A., Alvarez, R. D., Karlan, B. Y., Bristow, R. E., DiSilvestro, P. A., Wakabayashi, M. T., Morgan, R., Mukamel, D. B., Wenzel, L. (2015). Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice. *Gynecologic oncology*, 138(3), 712-6. PMID: 26177553. DOI: 10.1016/j.ygyno.2015.07.014
69. McMeekin, D. S., Sill, M. W., **Walker, J. L.**, Moore, K., Waggoner, S. E., Thaker, P. H., Rizack, T., Hoffman, J. S., Fracasso, P. M. (2015). A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. *Gynecologic oncology*, 138(1), 36-40. PMID: 25958319. DOI: 10.1016/j.ygyno.2015.04.038
70. Brooks, S. E., Carter, R. L., Plaxe, S. C., Basen-Engquist, K. M., Rodriguez, M., Kauderer, J., **Walker, J. L.**, Myers, T. K., Drake, J. G., Havrilesky, L. J., Van Le, L., Landrum, L. M., Brown, C. L. (2015). Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study. *Gynecologic oncology*, 138(1), 101-8. PMID: 25937529. DOI: 10.1016/j.ygyno.2015.04.033
71. **Walker, J. L.**, Powell, C. B., Chen, L. M., Carter, J. B., Bae Jump, V. L., Parker, L. P., Borowsky, M. E., Gibb, R. K. (2015). Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. *Cancer*, 121(13), 2108-20. PMID: 25820366. DOI: 10.1002/cncr.29321
72. den Boon, J. A., Pyeon, D., Wang, S., Horswill, M., Schiffman, M., Sherman, M., Zuna, R. E., Wang, Z., Hewitt, S. M., Pearson, R., Schott, M., Chung, L., He, Q., Lambert, P., **Walker, J. L.**, Newton, M. A., Wentzensen, N., Ahlquist, P. (2015). Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling.

Proceedings of the National Academy of Sciences of the United States of America, 112(25), E3255-64. PMID: 26056290. DOI: 10.1073/pnas.1509322112

73. Felix, A. S., Brinton, L. A., McMeekin, D. S., Creasman, W. T., Mutch, D., Cohn, D. E., **Walker, J. L.**, Moore, R. G., Downs, L. S., Soslow, R. A., Zaino, R., Sherman, M. E. (2015). Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial. *Journal of the National Cancer Institute*, 107(9). PMID: 26089540. DOI: 10.1093/jnci/djv158
74. Dizon, D. S., Brady, W. E., Lankes, H. A., Jandial, D. A., Howell, S. B., Schilder, R. J., Beumer, H. G., Christner, S. M., Strychor, S., Powell, M. A., Hagemann, A. R., Moore, K., **Walker, J. L.**, DiSilvestro, P., Fracasso, P. M. (2015). *JCO*, 33(15_suppl), 5515. DOI: 10.1200/jco.2015.33.15_suppl.5515
75. Bell-McGuinn, K. M., Brady, W. E., Schilder, R. J., Fracasso, P. M., Moore, K., **Walker, J. L.**, Duska, L. R., Mathews, C. A., Chen, A., Shepherd, S. P., Giranda, V. L., Aghajanian, C. (2015). A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. *JCO*, 33(15_suppl), 5507. DOI: 10.1200/jco.2015.33.15_suppl.5507
76. Basen-Engquist, K., Huang, H. Q., Herzog, T. J., Armstrong, D. K., Sabbatini, P., **Walker, J. L.**, Kim, B. G., Fujiwara, K., Tewari, J. S., O'Malley, D. M., Coleman, R. L. (2015). Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG study - Analysis of patient reported outcomes (PRO) on chemotherapy randomization. *JCO*, 33(15_suppl), 5525. DOI: 10.1200/jco.2015.33.15_suppl.5525
77. Wentzensen, N., **Walker, J. L.**, Gold, M. A., Smith, K. M., Zuna, R. E., Mathews, C., Dunn, S. T., Zhang, R. R., Moxley, K. M., Bishop, E., Tenney, M., Nugent, E., Graubard, B. I., Wacholder, S., Schiffman, M. (2015). Multiple biopsies and detection of cervical cancer precursors at colposcopy. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 33(1), 83-9. PMID: 25422481. DOI: 10.1200/JCO.2014.55.9948
78. Berek, J. S., Edwards, R. P., Parker, L. P., DeMars, L. R., Herzog, T. J., Lentz, S. S., Morris, R. T., Akerley, W. L., Holloway, R. W., Method, M. W., Plaxe, S. C., **Walker, J. L.**, Friccius-Quecke, H., Krasner, C. N. (2014). Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*, 24(9), 1583-9. PMID: 25254563. DOI: 10.1097/IGC.0000000000000286
79. Zaino, R. J., Brady, W. E., Todd, W., Leslie, K., Fischer, E. G., Horowitz, N. S., Mannel, R. S., **Walker, J. L.**, Ivanovic, M., Duska, L. R. (2014). Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists*, 33(6), 543-53. PMID: 25272292. DOI: 10.1097/PGP.0000000000000177
80. Sherman, M. E., Piedmonte, M., Mai, P. L., Ioffe, O. B., Ronnett, B. M., Van Le, L., Ivanov, I., Bell, M. C., Blank, S. V., DiSilvestro, P., Hamilton, C. A., Tewari, K. S., Wakeley, K., Kauff, N. D., Yamada, S. D., Rodriguez, G., Skates, S. J., Alberts, D. S., **Walker, J. L.**, Minasian, L., Lu, K., Greene, M. H. (2014). Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 32(29), 3275-83. PMID: 25199754. DOI: 10.1200/JCO.2013.54.1987

81. Zhao, L., Wentzensen, N., Zhang, R. R., Dunn, S. T., Gold, M. A., Wang, S., Schiffman, M., **Walker, J. L.**, Zuna, R. E. (2014). Factors associated with reduced accuracy in Papanicolaou tests for patients with invasive cervical cancer. *Cancer cytopathology*, 122(9), 694-701. PMID: 24888458. DOI: 10.1002/cncy.21443
82. Sahasrabudde, V. V., Gravitt, P. E., Dunn, S. T., Robbins, D., Brown, D., Allen, R. A., Eby, Y. J., Smith, K. M., Zuna, R. E., Zhang, R. R., Gold, M. A., Schiffman, M., **Walker, J. L.**, Castle, P. E., Wentzensen, N. (2014). Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*, 60(4), 414-7. PMID: 24881489. DOI: 10.1016/j.jcv.2014.04.016
83. Bishop, E. A., Java, J., Moore, K., **Walker, J. L.** (2014). Operative outcomes among a geriatric population of endometrial cancer patients: An ancillary data analysis of Gynecologic Oncology Group study LAP2. *Gynecologic Oncology*, 133(Suppl 1), 7. DOI: 10.1016/j.ygyno.2014.03.032
84. Burger, R. A., Brady, M. F., Bookman, M. A., Monk, B. J., **Walker, J. L.**, Homesley, H. D., Fowler, J., Greer, B. E., Boente, M., Fleming, G. F., Lim, P. C., Rubin, S. C., Katsumata, N., Liang, S. X. (2014). Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 32(12), 1210-7. PMID: 24637999. DOI: 10.1200/JCO.2013.53.6524
85. Jackson, C. C., Java, J., Moore, K., **Walker, J. L.** (2014). The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study. *Gynecologic oncology*, 133(1), 23-7. PMID: 24680587. DOI: 10.1016/j.ygyno.2014.01.041
86. Fleming, G. F., Filiaci, V. L., Marzullo, B., Zaino, R. J., Davidson, S. A., Pearl, M., Makker, V., Burke, 2nd, J. J., Zweig, S. L., Van Le, L., Hanjani, P., Downey, G., **Walker, J. L.**, Reyes, H. D., Leslie, K. K. (2014). Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a Gynecologic Oncology Group study. *Gynecologic oncology*, 132(3), 585-92. PMID: 24456823. DOI: 10.1016/j.ygyno.2014.01.015
87. Koshiol, J., Sklavos, M., Wentzensen, N., Kemp, T., Schiffman, M., Dunn, S. T., Wang, S., **Walker, J. L.**, Safaeian, M., Zuna, R. E., Hildesheim, A., Pfeiffer, R. M., Pinto, L. A. (2014). Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study. *International journal of cancer*, 134(2), 411-25. PMID: 23824624. DOI: 10.1002/ijc.28354
88. Sahasrabudde, V. V., Gravitt, P. E., Dunn, S. T., Brown, D., Allen, R. A., Eby, Y. J., Smith, K. M., Zuna, R. E., Zhang, R. R., Gold, M. A., Schiffman, M., **Walker, J. L.**, Castle, P. E., Wentzensen, N. (2014). Comparison of human papillomavirus detections in urine, vulvar, and cervical samples from women attending a colposcopy clinic. *Journal of clinical microbiology*, 52(1), 187-92. PMID: 24197879. DOI: 10.1128/JCM.01623-13
89. Landrum, L. M., Nugent, E. K., Zuna, R. E., Syzek, E., Mannel, R. S., Moore, K., **Walker, J. L.**, McMeekin, D. S. (2014). Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. *Gynecologic oncology*, 132(1), 50-4. PMID: 24219982. DOI: 10.1016/j.ygyno.2013.11.005
90. **Walker, J. L.** (2013). Intraperitoneal chemotherapy requires expertise and should be the standard of care for optimally surgically resected epithelial ovarian cancer patients. *Annals of oncology : official journal of the European Society for Medical Oncology*, 24 Suppl 10, x41-45. PMID: 24265403. DOI: 10.1093/annonc/mdt469

91. Luhn, P., Houldsworth, J., Cahill, L., Schiffman, M., Castle, P. E., Zuna, R. E., Dunn, S. T., Gold, M. A., **Walker, J. L.**, Wentzensen, N. (2013). Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results. *Gynecologic Oncology*, 130(3), 595-600. PMID: 23769811. DOI: 10.1016/j.ygyno.2013.06.005
92. Smith, J. S., Brewer, N. T., Saslow, D., Alexander, K., Chernofsky, M. R., Crosby, R., Derting, L., Devlin, L., Dunton, C. J., Engle, J., Fernandez, M., Fouad, M., Huh, W., Kinney, W., Pierce, J., Rios, E., Rothholz, M. C., Shlay, J. C., Shedd-Steele, R., Vernon, S. W., **Walker, J. L.**, Wynn, T., Zimet, G. D., Casey, B. R. (2013). Recommendations for a national agenda to substantially reduce cervical cancer. *Cancer causes & control : CCC*, 24(8), 1583-93. PMID: 23828553. DOI: 10.1007/s10552-013-0235-8
93. Landrum, L. M., Java, J., Mathews, C. A., Lanneau, Jr, G. S., Copeland, L. J., Armstrong, D. K., **Walker, J. L.** (2013). Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. *Gynecologic oncology*, 130(1), 12-8. PMID: 23578540. DOI: 10.1016/j.ygyno.2013.04.001
94. Brinton, L. A., Felix, A. S., McMeekin, D. S., Creasman, W. T., Sherman, M. E., Mutch, D., Cohn, D. E., **Walker, J. L.**, Moore, R. G., Downs, L. S., Soslow, R. A., Zaino, R. (2013). Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. *Gynecologic oncology*, 129(2), 277-84. PMID: 23485770. DOI: 10.1016/j.ygyno.2013.02.023
95. Alvarez, E. A., Brady, W. E., **Walker, J. L.**, Rotmensch, J., Zhou, X. C., Kendrick, J. E., Yamada, S. D., Schilder, J. M., Cohn, D. E., Harrison, C. R., Moore, K., Aghajanian, C. (2013). Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecologic oncology*, 129(1), 22-7. PMID: 23262204. DOI: 10.1016/j.ygyno.2012.12.022
96. Liao, S. Y., Rodgers, W., Kauderer, J., Darcy, K. M., Carter, R., Susumu, N., Nagao, S., **Walker, J. L.**, Hatae, M., Stanbridge, E. J. (2013). Endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia is HPV-independent and correlates with carbonic anhydrase-IX expression: a Gynaecological Oncology Group Study. *British journal of cancer*, 108(3), 613-20. PMID: 23299542. DOI: 10.1038/bjc.2012.578
97. Koshiol, J., Dunn, S. T., **Walker, J. L.**, Zuna, R. E., Schiffman, M., Sherman, M. E., Gold, M. A., Allen, R. A., Zhang, R. R., Wang, S., Wentzensen, N. (2013). Reproducibility of linear array for human papillomavirus genotyping. *Journal of clinical microbiology*, 51(2), 625-8. PMID: 23196360. DOI: 10.1128/JCM.03036-12
98. Luhn, P., **Walker, J. L.**, Schiffman, M., Zuna, R. E., Dunn, S. T., Gold, M. A., Smith, K. M., Mathews, C., Allen, R. A., Zhang, R. R., Wang, S., Wentzensen, N. (2013). The role of co-factors in the progression from human papillomavirus infection to. *Gynecologic Oncology*, 128(2), 267-270. PMID: 23146688. DOI: 10.1016/j.ygyno.2012.11.003
99. Wentzensen, N., **Walker, J. L.**, Schiffman, M., Yang, H. P., Zuna, R. E., Dunn, S. T., Allen, R. A., Zhang, R. R., Sherman, M., Gold, M. A., Wang, S. (2013). Heterogeneity of high-grade cervical intraepithelial neoplasia related to HPV16: implications for natural history and management. *International journal of cancer*, 132(1), 148-54. PMID: 22488167. DOI: 10.1002/ijc.27577
100. Gould, N., Sill, M. W., Mannel, R. S., Thaker, P. H., DiSilvestro, P. A., Waggoner, S. E., Yamada, S. D., Armstrong, D. K., Fracasso, P. M., Wenzel, L., Huang, H., **Walker, J. L.** (2012). A phase I study with an expanded cohort to assess feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study. *Gynecologic oncology*, 125,

54-58. PMID: 22155262. DOI: 10.1016/j.ygyno.2011.12.417

101. Carter, R. L., Kang, L., Darcy, K. M., Kauderer, J., Liao, S. Y., Rodgers, W., **Walker, J. L.**, Lankes, H. A., Dunn, S. T., Stanbridge, E. J. (2012). A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study. *Cancer causes & control : CCC*, 23(12), 2013-21. PMID: 23073789. DOI: 10.1007/s10552-012-0081-0
102. Gould, N., Sill, M. W., Mannel, R. S., Thaker, P. H., DiSilvestro, P. A., Waggoner, S. E., Yamada, S. D., Armstrong, D. K., Fracasso, P. M., **Walker, J. L.** (2012). A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. *Gynecologic oncology*, 127(3), 506-10. PMID: 22943879. DOI: 10.1016/j.ygyno.2012.08.037
103. Leslie, K. K., Sill, M. W., Lankes, H. A., Fischer, E. G., Godwin, A. K., Gray, H., Schilder, R. J., **Walker, J. L.**, Tewari, K., Hanjani, P., Abulafia, O., Rose, P. G. (2012). Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. *Gynecologic oncology*, 127(2), 345-50. PMID: 22885469. DOI: 10.1016/j.ygyno.2012.07.127
104. Carter, J. B., Huang, H., Chase, D. M., **Walker, J. L.**, Cella, D., Wenzel, L. (2012). Sexual function of patients with endometrial cancer enrolled in the Gynecologic Oncology Group LAP2 Study. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*, 22(9), 1624-33. PMID: 23095778. DOI: 10.1097/IGC.0b013e31827277fa
105. Mathews, C. A., Stoner, J. A., Wentzensen, N., Moxley, K. M., Tenney, M. E., Tuller, E. R., Myers, T., Landrum, L. M., Lanneau, G., Zuna, R. E., Gold, M. A., Wang, S., **Walker, J. L.** (2012). Tubal ligation frequency in Oklahoma women with cervical cancer. *Gynecologic oncology*, 127(2), 278-82. PMID: 22858904. DOI: 10.1016/j.ygyno.2012.07.119
106. van der Marel, J., Quint, W. G., Schiffman, M., van de Sandt, M. M., Zuna, R. E., Dunn, S. T., Smith, K. M., Mathews, C. A., Gold, M. A., **Walker, J. L.**, Wentzensen, N. (2012). Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16. *International journal of cancer*, 131(6), E946-53. PMID: 22419273. DOI: 10.1002/ijc.27532
107. Wentzensen, N., Schwartz, L., Zuna, R. E., Smith, K. M., Mathews, C., Gold, M. A., Allen, R. A., Zhang, R. R., Dunn, S. T., **Walker, J. L.**, Schiffman, M. (2012). Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 18(15), 4154-62. PMID: 22675168. DOI: 10.1158/1078-0432.CCR-12-0270
108. Dizon, D. S., Blessing, J. A., Penson, R. T., Drake, R. D., **Walker, J. L.**, Johnston, C. M., DiSilvestro, P. A., Fader, A. N. (2012). A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. *Gynecologic oncology*, 125(2), 367-71. PMID: 22366594. DOI: 10.1016/j.ygyno.2012.02.019
109. Wentzensen, N., Gravitt, P. E., Long, R., Schiffman, M., Dunn, S. T., Carreon, J. D., Allen, R. A., Gunja, M., Zuna, R. E., Sherman, M. E., Gold, M. A., **Walker, J. L.**, Wang, S. (2012). Human papillomavirus load measured by Linear Array correlates with quantitative PCR in cervical cytology specimens. *Journal of clinical microbiology*, 50(5), 1564-70. PMID: 22337992. DOI: 10.1128/JCM.06240-11
110. Gould, N., Sill, M. W., Mannel, R. S., Thaker, P. H., DiSilvestro, P., Waggoner, S., Yamada, S. D.,

- Armstrong, D. K., Wenzel, L., Huang, H., Fracasso, P. M., **Walker, J. L.** (2012). A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. *Gynecologic oncology*, 125(1), 54-8. PMID: 22155262. DOI: 10.1016/j.ygyno.2011.12.417
111. Nugent, E. K., Bishop, E. A., Mathews, C. A., Moxley, K. M., Tenney, M., Mannel, R. S., **Walker, J. L.**, Moore, K., Landrum, L. M., McMeekin, D. S. (2012). Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? *Gynecologic oncology*, 125(1), 94-8. PMID: 22155415. DOI: 10.1016/j.ygyno.2011.11.049
112. Perry, L., Lanneau, G., Curiel, J., Mathews, C., Moxley, K. M., Landrum, L. M., Moore, K., **Walker, J. L.**, Mannel, R. S., McMeekin, S. (2012). Phase II study of intravenous bevacizumab (bev) and paclitaxel (pac), and intraperitoneal (ip) cisplatin (c), followed by bevacizumab (bev) maintenance, for advanced ovarian cancer: A report on progression free survival (PFS) and toxicity. *Journal of Clinical Oncology*, 125(Suppl 1), S22. DOI: 10.1016/j.ygyno.2011.12.052
113. Moore, D. H., Ali, S., Koh, W. J., Michael, H., Barnes, M. N., McCourt, C. K., Homesley, H. D., **Walker, J. L.** (2012). A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study. *Gynecologic oncology*, 124(3), 529-33. PMID: 22079361. DOI: 10.1016/j.ygyno.2011.11.003
114. **Walker, J. L.**, Piedmonte, M. R., Spirtos, N. M., Eisenkop, S. M., Schlaerth, J. B., Mannel, R. S., Barakat, R., Pearl, M. L., Sharma, S. K. (2012). Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 30(7), 695-700. PMID: 22291074. DOI: 10.1200/JCO.2011.38.8645
115. Milam, M. R., Java, J., **Walker, J. L.**, Metzinger, D. S., Parker, L. P., Coleman, R. L. (2012). Nodal metastasis risk in endometrioid endometrial cancer. *Obstetrics and gynecology*, 119(2 Pt 1), 286-92. PMID: 22270280. DOI: 10.1097/AOG.0b013e318240de51
116. Hocker, J. R., Bishop, E. A., Lightfoot, S. A., Lerner, M. R., Peyton, M. D., Brackett, D. J., Hanas, R. J., McMeekin, D. S., **Walker, J. L.**, Hanas, J. S. (2012). Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals. *Cancer investigation*, 30(2), 189-97. PMID: 22149058. DOI: 10.3109/07357907.2011.636115
117. Yang, H. P., Zuna, R. E., Schiffman, M., **Walker, J. L.**, Sherman, M. E., Landrum, L. M., Moxley, K. M., Gold, M. A., Dunn, S. T., Allen, R. A., Zhang, R. R., Long, R., Wang, S., Wentzensen, N. (2012). Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3. *PLoS one*, 7(1), e29051. PMID: 22253702. DOI: 10.1371/journal.pone.0029051
118. Zuna, R. E., Tuller, E., Wentzensen, N., Mathews, C., Allen, R. A., Shanesmith, R., Dunn, S. T., Gold, M. A., Wang, S., **Walker, J. L.**, Schiffman, M. (2011). HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer. *Infectious agents and cancer*, 6, 19. PMID: 22035468. DOI: 10.1186/1750-9378-6-19
119. Landrum, L. M., Hyde, Jr, J., Mannel, R. S., McMeekin, D. S., Moore, K., **Walker, J. L.** (2011). Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. *Gynecologic oncology*, 122(3), 527-31. PMID: 21664657. DOI: 10.1016/j.ygyno.2011.05.022
120. Morgan, M. A., Sill, M. W., Fujiwara, K., Greer, B., Rubin, S., DeGeest, K., Yamada, S. D.,

- Waggoner, S., Coleman, R. L., **Walker, J. L.**, Mannel, R. S. (2011). A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. *Gynecologic Oncology*, 121(2), 264-8. PMID: 21277623. DOI: 10.1016/j.ygyno.2010.12.358
121. Morgan, M. A., Sill, M. W., Fujiwara, K., Greer, B., Rubin, S. C., DeGeest, K., Yamada, S. D., Waggoner, S., Coleman, R. L., **Walker, J. L.**, Mannel, R. S. (2011). A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. *Gynecologic oncology*, 121(2), 264-8. PMID: 21277623. DOI: 10.1016/j.ygyno.2010.12.358
122. Farley, J., Sill, M. W., Birrer, M., **Walker, J. L.**, Schilder, R. J., Thigpen, J. T., Coleman, R. L., Miller, B. E., Rose, P. G., Lankes, H. A. (2011). Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. *Gynecologic oncology*, 121(2), 303-8. PMID: 21329967. DOI: 10.1016/j.ygyno.2011.01.030
123. Szarewski, A., Cadman, L., Mesher, D., Austin, J., Ashdown-Barr, L., Edwards, R. K., Lyons, D., **Walker, J. L.**, Christison, J., Frater, A., Waller, J. (2011). HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. *British journal of cancer*, 104(6), 915-20. PMID: 21343937. DOI: 10.1038/bjc.2011.48
124. Herzog, T. J., Sill, M. W., **Walker, J. L.**, O'Malley, D., Shahin, M., DeGeest, K., Weiner, S. A., Mutch, D., DeBernardo, R. L., Lentz, S. S. (2011). A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). *Gynecologic oncology*, 120(3), 454-8. PMID: 21168198. DOI: 10.1016/j.ygyno.2010.11.008
125. Monk, B. J., Sill, M. W., Hanjani, P., Edwards, R. K., Rotmensch, J., DeGeest, K., Bonebrake, A. J., **Walker, J. L.** (2011). Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. *Gynecologic oncology*, 120(3), 459-63. PMID: 21144560. DOI: 10.1016/j.ygyno.2010.11.012
126. **Walker, J. L.** (2011). Lose dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group. *Gynecol Oncol*, 120(2), 224-8. PMID: 21075438. DOI: 10.1016/j.ygyno.2010.10.018
127. Kunos, C. A., Sill, M. W., Buekers, T. E., **Walker, J. L.**, Schilder, J. M., Yamada, S. D., Waggoner, S. E., Mohiuddin, M., Fracasso, P. M. (2011). Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. *Gynecologic oncology*, 120(2), 224-8. PMID: 21075438. DOI: 10.1016/j.ygyno.2010.10.018
128. Liao, S. Y., Rodgers, W., Kauderer, J., Bonfiglio, T. A., Darcy, K. M., Carter, R., Levine, L., Spirtos, N. M., Susumu, N., Fujiwara, K., **Walker, J. L.**, Hatae, M., Stanbridge, E. J. (2011). Carbonic anhydrase IX (CA-IX) and high-risk human papillomavirus (H-HPV) as diagnostic biomarkers of cervical dysplasia/neoplasia in Japanese women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) Study. *British journal of cancer*, 104(2), 353-60. PMID: 21157448. DOI: 10.1038/sj.bjc.6606049
129. Liao, S. Y., Rogers, W. H., Kauderer, J., Darcy, K. M., Carter, R., Levine, L., Spirtos, N. M., Susumu, N., Fujiwara, K., **Walker, J. L.**, Hatae, M., Stanbridge, E. J. (2010). Carbonic anhydrase

- IX and human papillomavirus infection in endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia: A Gynecologic Oncology Group (GOG) study. *Modern Pathol*, 23(1S), 232A-270A.
130. Burger, R. A., Brady, M. F., Bookman, M. A., **Walker, J. L.**, Homesley, H. D., Fowler, J., Monk, B. J., Greer, B. E., Boente, M., Liang, S. X. (2010). Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. *Journal of Clinical Oncology*, 28(18 suppl). PMID: 27937479. DOI: 10.1200/jco.2010.28.18_suppl.lba1
131. **Walker, J. L.**, Piedmonte, M. R., Spirtos, N. M., Eisenkop, S. M., Schlaerth, J. B., Mannel, R. S., Barakat, R., Pearl, M. L., Sharma, S. K. (2010). Recurrence and survival after randomization to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. *Gynecologic Oncology*, 117, 393. PMID: 22291074. DOI: 10.1200/JCO.2011.38.8645
132. Burger, R. A., Brady, M. F., Monk, B. J., **Walker, J. L.**, Homesley, H. D., Fowler, J., Greer, B. E., Boente, M., Liang, S. X. (2010). Safety and subgroup efficacy analyses in GOG 218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): A gynecologic Oncology Group study. *Annals Oncol*, 21(Suppl 8).
133. Wentzensen, N., Zuna, R. E., Sherman, M. E., Gold, M. A., Schiffman, M., Dunn, S. T., Jeronimo, J., Zhang, R. R., **Walker, J. L.**, Wang, S. (2009). Accuracy of cervical specimens obtained for biomarker studies in women with CIN3. *Gynecologic oncology*, 115(3), 493-6. PMID: 19773045. DOI: 10.1016/j.ygyno.2009.09.001
134. Liao, S. Y., Rodgers, W., Kauderer, J., Bonfiglio, T. A., **Walker, J. L.**, Darcy, K. M., Carter, R., Hatae, M., Levine, L., Spirtos, N. M., Stanbridge, E. J. (2009). Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. *International journal of cancer*, 125(10), 2434-40. PMID: 19670419. DOI: 10.1002/ijc.24615
135. **Walker, J. L.**, Piedmonte, M. R., Spirtos, N. M., Eisenkop, S. M., Schlaerth, J. B., Mannel, R. S., Spiegel, G., Barakat, R., Pearl, M. L., Sharma, S. K. (2009). Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 27(32), 5331-6. PMID: 19805679. DOI: 10.1200/JCO.2009.22.3248
136. Kornblith, A. B., Huang, H. Q., **Walker, J. L.**, Spirtos, N. M., Rotmensch, J., Cella, D. (2009). Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 27(32), 5337-42. PMID: 19805678. DOI: 10.1200/JCO.2009.22.3529
137. Wentzensen, N., Schiffman, M., Dunn, T., Zuna, R. E., Gold, M. A., Allen, R. A., Zhang, R. R., Sherman, M. E., Wacholder, S., **Walker, J. L.**, Wang, S. (2009). Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. *International journal of cancer*, 125(9), 2151-8. PMID: 19585494. DOI: 10.1002/ijc.24528
138. Tenney, M., **Walker, J. L.** (2009). Role of laparoscopic surgery in the management of endometrial cancer. *Journal of the National Comprehensive Cancer Network : JNCCN*, 7(5), 559-67. PMID: 19460281.

139. Moore, K., Frank, S. G., Alward, E. K., Landrum, L. M., Myers, T. K., **Walker, J. L.**, Gold, M. A., McMeekin, D. S., Vesely, S. K., Mannel, R. S. (2009). Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? *Cancer*, 115(7), 1472-80. PMID: 19235786. DOI: 10.1002/cncr.24190
140. Shen-Gunther, J., Mannel, R. S., **Walker, J. L.**, Johnson, G. A. (2009). Construction of the ileocolonic continent urinary reservoir: Operative technique at University of Oklahoma. *J Gynecologic Surgery*, 13(2), 83-88. DOI: 10.1089/gyn.1997.13.83
141. Wentzensen, N., Schiffman, M., Dunn, S. T., Zuna, R. E., **Walker, J. L.**, Allen, R. A., Zhang, R. R., Sherman, M. E., Wacholder, S., Jeronimo, J., Gold, M. A., Wang, S. (2009). Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. *International journal of cancer*, 124(4), 964-9. PMID: 19030188. DOI: 10.1002/ijc.23969
142. Landrum, L. M., Moore, K., Myers, T. K., Lanneau, Jr, G. S., McMeekin, D. S., **Walker, J. L.**, Gold, M. A. (2009). Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. *Gynecologic oncology*, 112(2), 337-41. PMID: 19041126. DOI: 10.1016/j.ygyno.2008.10.009
143. **Walker, J. L.**, Morrison, A., DiSilvestro, P., von Gruenigen, V. E. (2009). A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study. *Gynecologic oncology*, 112(1), 78-84. PMID: 19010522. DOI: 10.1016/j.ygyno.2008.09.035
144. Wang, S., Zuna, R. E., Wentzensen, N., Dunn, S. T., Sherman, M. E., Gold, M. A., Schiffman, M., Wacholder, S., Allen, R. A., Block, I., Downing, K., Jeronimo, J., Carreon, J. D., Safaeian, M., Brown, D., **Walker, J. L.** (2009). Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 18(1), 113-20. PMID: 19124488. DOI: 10.1158/1055-9965.EPI-08-0591
145. McMeekin, D. S., **Walker, J. L.**, Hartenbach, E. M., Bookman, M. A., Koh, W. J. (2009). Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study. *Gynecologic oncology*, 112(1), 134-41. PMID: 18962846. DOI: 10.1016/j.ygyno.2008.09.015
146. Moore, K., Bannon, R. J., Lanneau, G. S., Zuna, R. E., **Walker, J. L.**, Gold, M. A. (2008). Cervical dysplasia among women over 35 years of age. *American journal of obstetrics and gynecology*, 199(5), 471.e1-5. PMID: 18486088. DOI: 10.1016/j.ajog.2008.03.048
147. Jeronimo, J., Wentzensen, N., Long, R., Schiffman, M., Dunn, S. T., Allen, R. A., **Walker, J. L.**, Gold, M. A., Zuna, R. E., Sherman, M. E., Wacholder, S., Wang, S. (2008). Evaluation of linear array human papillomavirus genotyping using automatic optical imaging software. *Journal of clinical microbiology*, 46(8), 2759-65. PMID: 18550741. DOI: 10.1128/JCM.00188-08
148. Moore, K., Reid, M., Fong, D. N., Myers, T. K., Landrum, L. M., Moxley, K. M., **Walker, J. L.**, McMeekin, D. S., Mannel, R. S. (2008). Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? *Gynecologic oncology*, 110(2), 133-9. PMID: 18495221. DOI: 10.1016/j.ygyno.2008.03.008
149. Wenzel, L., Huang, H. Q., Cella, D., **Walker, J. L.**, Armstrong, D. K., Gynecologic Oncology Group (2008). Validation of the FACT/GOG-AD subscale for ovarian cancer-related abdominal

- discomfort: A Gynecologic Oncology Group study. *Gynecologic Oncology*, 110(1), 60-64. PMID: 18430468. DOI: 10.1016/j.ygyno.2008.02.011
150. Carlson, J. W., Kauderer, J., **Walker, J. L.**, Gold, M. A., O'Malley, D., Tuller, E., Clarke-Pearson, D. L. (2008). A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. *Gynecologic oncology*, 110(1), 76-82. PMID: 18482765. DOI: 10.1016/j.ygyno.2008.03.005
 151. Wenzel, L., Huang, H. Q., Cella, D., **Walker, J. L.**, Armstrong, D. K. (2008). Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study. *Gynecologic oncology*, 110(1), 60-4. PMID: 18430468. DOI: 10.1016/j.ygyno.2008.02.011
 152. Lhomme, C., Joly, F., **Walker, J. L.**, Lissoni, A. A., Nicoletto, M. O., Manikhas, G. M., Baekelandt, M. M.O., Gordon, A. N., Fracasso, P. M., Mietlowski, W. L., Jones, G. J., Dugan, M. H. (2008). Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. *JCO*, 26(16), 2674-2682. PMID: 18509179. DOI: 10.1200/JCO.2007.14.9807
 153. Lhommé, C., Joly, F., **Walker, J. L.**, Lissoni, A. A., Nicoletto, M. O., Manikhas, G. M., Baekelandt, M. M., Gordon, A. N., Fracasso, P. M., Mietlowski, W. L., Jones, G. J., Dugan, M. H. (2008). Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 26(16), 2674-82. PMID: 18509179. DOI: 10.1200/JCO.2007.14.9807
 154. Landrum, L. M., Skaggs, V., Gould, N., **Walker, J. L.**, McMeekin, D. S. (2008). Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation. *Gynecologic oncology*, 108(3), 584-90. PMID: 18155755. DOI: 10.1016/j.ygyno.2007.11.010
 155. Moore, K., Gold, M. A., McMeekin, D. S., **Walker, J. L.**, Rutledge, T., Zorn, K. K. (2008). Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes. *Gynecologic oncology*, 108(3), 466-71. PMID: 18191994. DOI: 10.1016/j.ygyno.2007.11.043
 156. Landrum, L. M., Gold, M. A., Moore, K., Myers, T. K., McMeekin, D. S., **Walker, J. L.** (2008). Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. *Gynecologic oncology*, 108(2), 342-7. PMID: 17988721. DOI: 10.1016/j.ygyno.2007.10.004
 157. Liao, S. Y., Rogers, W. H., Bonfiglio, T., Kauderer, J., **Walker, J. L.**, Darcy, K. M., Carter, R., Hatae, M., Hannigan, E. V., Stanbridge, E. J. (2007). Carbonic anhydrase IX (CAIX) and human papillomavirus (HPV) as potential diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells of undetermined significance (AGS): A Gynecologic Oncology Group (GOG) study. *Modern Path*, 20(74A), (USCAP#321).
 158. **Walker, J. L.**, Markman, M. (2007). Management of intraperitoneal chemotherapy for treatment of ovarian cancer. *UpToDate Online*, 15(2).
 159. Stehman, F. B., Ali, S., Keys, H. M., Muderspach, L. I., Chafe, W. E., Gallup, D. G., **Walker, J. L.**, Gersell, D. (2007). Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. *American journal of obstetrics and*

- gynecology*, 197(5), 503.e1-6. PMID: 17980189. DOI: 10.1016/j.ajog.2007.08.003
160. Chen, W., Li, F., Mead, L., White, H., **Walker, J. L.**, Ingram, D. A., Roman, A. (2007). Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. *Virology*, 367(1), 168-74. PMID: 17602722. DOI: 10.1016/j.virol.2007.05.030
 161. Landrum, L. M., Lanneau, G. S., Skaggs, V. J., Gould, N., **Walker, J. L.**, McMeekin, D. S., Gold, M. A. (2007). Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era. *Gynecologic oncology*, 106(3), 521-5. PMID: 17540438. DOI: 10.1016/j.ygyno.2007.04.029
 162. Moore, K., Lanneau, G. S., Smith, C. M., Lanneau, M., **Walker, J. L.**, Gold, M. A., McMeekin, S. (2007). Pathologic findings and outcomes for octogenarians presenting with uterine malignancy. *Gynecologic oncology*, 106(3), 572-8. PMID: 17618678. DOI: 10.1016/j.ygyno.2007.05.028
 163. Moore, K., Cofer, A., Elliot, L., Lanneau, G., **Walker, J. L.**, Gold, M. A. (2007). Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. *American journal of obstetrics and gynecology*, 197(2), 141.e1-6. PMID: 17689626. DOI: 10.1016/j.ajog.2007.03.029
 164. Dunn, S. T., Allen, R. A., Wang, S., **Walker, J. L.**, Schiffman, M. (2007). DNA extraction: an understudied and important aspect of HPV genotyping using PCR-based methods. *Journal of virological methods*, 143(1), 45-54. PMID: 17399803. DOI: 10.1016/j.jviromet.2007.02.006
 165. Chan, J. K., Urban, R., Cheung, M. K., Shin, J. Y., Husain, A., Teng, N. N., Berek, J. S., **Walker, J. L.**, Kapp, D. S., Osann, K. (2007). Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. *Cancer*, 109(12), 2454-60. PMID: 17503431. DOI: 10.1002/cncr.22727
 166. Marth, C., **Walker, J. L.**, Barakat, R. R., Casado, A., Gadducci, A., Miller, B., Odicino, F., Pujade-Lauraine, E., Sehouli, J., Tropé, C., Wenzel, L., Zeimet, A. G. (2007). Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. *Cancer*, 109(4), 645-9. PMID: 17238177. DOI: 10.1002/cncr.22467
 167. Wenzel, L. B., Huang, H. Q., Armstrong, D. K., **Walker, J. L.**, Cella, D. (2007). Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 25(4), 437-43. PMID: 17264340. DOI: 10.1200/JCO.2006.07.3494
 168. **Walker, J. L.**, Armstrong, D. K., Huang, H. Q., Fowler, J., Webster, K., Burger, R. A., Clarke-Pearson, D. (2006). Phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study. *Gynecologic Oncology*, 100(1), 27-30. PMID: 16368440.
 169. DiSilvestro, P. A., **Walker, J. L.**, Morrison, A., Rose, P. G., Homesley, H., Warshal, D. (2006). Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group. *Gynecologic oncology*, 103(3), 1038-42. PMID: 16889823. DOI: 10.1016/j.ygyno.2006.06.017
 170. Bell, J., Brady, M. F., Young, R. C., Lage, J., **Walker, J. L.**, Look, K. Y., Rose, G. S., Spirtos, N. M. (2006). Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. *Gynecologic oncology*, 102(3), 432-9. PMID: 16860852. DOI: 10.1016/j.ygyno.2006.06.013
 171. **Walker, J. L.**, Wang, S., Schiffman, M., Solomon, D. (2006). Predicting absolute risk of CIN3

- during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). *American journal of obstetrics and gynecology*, 195(2), 341-8. PMID: 16890545. DOI: 10.1016/j.ajog.2006.02.047
172. Bell, J., Brady, M. F., Young, R. C., Lage, J., **Walker, J. L.**, Look, K. Y., Rose, G. S., Spirtos, N. M. (2006). Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage ovarian carcinoma: a Gynecologic Oncology Group study. *Gynecologic Oncology*, 102(3), 432-39. PMID: 16860852. DOI: 10.1016/j.ygyno.2006.06.013
 173. Wenzel, L. B., Huang, H. Q., Armstrong, D. K., **Walker, J. L.**, Cella, D. (2006). Baseline quality of life (QOL) as a predictor of tolerance to intraperitoneal (IP) chemotherapy for advanced epithelial ovarian cancer (EOC): A Gynecologic Oncology Group study. *Journal of Clinical Oncology*, 24(18 suppl). PMID: 27952184. DOI: 10.1200/jco.2006.24.18_suppl.5007
 174. Moore, K., **Walker, J. L.** (2006). The abnormal pap test: Evaluation, treatment and monitoring. *Journal of Clinical Outcomes Management*, 13(4), 217-221.
 175. Markman, M., **Walker, J. L.** (2006). Intraperitoneal chemotherapy of Ovarian Cancer: A review, with a focus on practical aspects of treatment. *Journal of Clinical Oncology*, 24(6), 1-7. PMID: 16461779. DOI: 10.1200/JCO.2005.05.2456
 176. Markman, M., **Walker, J. L.** (2006). Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 24(6), 988-94. PMID: 16461779. DOI: 10.1200/JCO.2005.05.2456
 177. Tillmanns, T. D., Falkner, C. A., Engle, D. B., Wan, J. Y., Mannel, R. S., **Walker, J. L.**, Johnson, G. A., McMeekin, D. S., Zuna, R. E., Gold, M. A. (2006). Preoperative predictors of positive margins after loop electrosurgical excisional procedure-Cone. *Gynecologic oncology*, 100(2), 379-84. PMID: 16321430. DOI: 10.1016/j.ygyno.2005.09.015
 178. Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., **Walker, J. L.**, Burger, R. A. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *The New England journal of medicine*, 354(1), 34-43. PMID: 16394300. DOI: 10.1056/NEJMoa052985
 179. Rutledge, T. L., Gold, M. A., McMeekin, D. S., Huh, W. K., Powell, M. A., Lewin, S. N., Mutch, D. G., Johnson, G. A., **Walker, J. L.**, Mannel, R. S. (2006). Carcinosarcoma of the ovary-a case series. *Gynecologic oncology*, 100(1), 128-32. PMID: 16213011. DOI: 10.1016/j.ygyno.2005.07.119
 180. **Walker, J. L.**, Armstrong, D. K., Huang, H. Q., Fowler, J., Webster, K., Burger, R. A., Clarke-Pearson, D. (2006). Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. *Gynecologic oncology*, 100(1), 27-32. PMID: 16368440. DOI: 10.1016/j.ygyno.2005.11.013
 181. Castle, P. E., **Walker, J. L.**, Schiffman, M., Wheeler, C. M. (2005). Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. *International journal of cancer*, 117(6), 1007-12. PMID: 15986443. DOI: 10.1002/ijc.21279
 182. Wang, S., **Walker, J. L.**, Schiffman, M., Solomon, D. (2005). Evaluating the risk of cervical precancer with a combination of cytologic, virologic, and visual methods. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 14(11 Pt 1), 2665-8. PMID:

16284394. DOI: 10.1158/1055-9965.EPI-05-0151

183. Wang, S., Dasgupta, A., Sherman, M. E., **Walker, J. L.**, Gold, M. A., Zuna, R. E., Sakoda, L., Wacholder, S., Schiffman, M., Baker, C. C. (2005). Towards improved biomarker studies of cervical neoplasia: effects of precolposcopic procedures on gene expression patterns. *Diagnostic molecular pathology : the American journal of surgical pathology, part B*, 14(2), 59-64. PMID: 15905687.
184. Wenzel, L., Huang, H., Armstrong, D., **Walker, J. L.**, Cella, D. (2004). Quality of life (QOL) results of a randomized study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial. *Journal of Clinical Oncology*, 22(14), 454. DOI: 10.1200/jco.2004.22.14_suppl.5026
185. Moore, K., **Walker, J. L.** (2004). Can frequency and severity of symptoms predict the presence of ovarian cancer? *Nature clinical practice. Oncology*, 1(2), 72-3. PMID: 16264821. DOI: 10.1038/ncponc0040
186. Moore, K., **Walker, J. L.** (2004). High risk human papillomavirus testing: guidelines for use in screening, triage, and follow-up for the prevention and early detection of cervical cancer. *Journal of the National Comprehensive Cancer Network : JNCCN*, 2(6), 589-96. PMID: 19780302.
187. Rutledge, T. L., Kamelle, S. A., Tillmanns, T. D., Gould, N. S., Wright, J. D., Cohn, D. E., Herzog, T. J., Rader, J. S., Gold, M. A., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., McMeekin, D. S. (2004). A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? *Gynecologic oncology*, 95(1), 70-6. PMID: 15385112. DOI: 10.1016/j.ygyno.2004.07.027
188. McMeekin, S., Tillmanns, T., Chaudry, T., Gold, M. A., Johnson, G., **Walker, J. L.**, Mannel, R. S. (2004). Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. *Gynecologic oncology*, 95(1), 157-64. PMID: 15385126. DOI: 10.1016/j.ygyno.2004.07.008
189. Kamelle, S. A., Rutledge, T. L., Tillmanns, T. D., Gould, N. S., Cohn, D. E., Wright, J., Herzog, T. J., Rader, J. S., Gold, M. A., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., McMeekin, D. S. (2004). Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? *Gynecologic oncology*, 94(2), 249-55. PMID: 15297159. DOI: 10.1016/j.ygyno.2004.05.038
190. Eitan, R., Abu-Rustum, N. R., **Walker, J. L.**, Barakat, R. R. (2004). Endometrial cancer metastatic to infrarenal aortic lymph nodes unrecognized during laparoscopic inframesenteric aortic lymph node dissection. *Gynecologic oncology*, 93(1), 260-2. PMID: 15047248. DOI: 10.1016/j.ygyno.2004.01.003
191. Follen, M., Meyskens, Jr, F. L., Alvarez, R. D., **Walker, J. L.**, Bell, M. C., Storthz, K. A., Sastry, J., Roy, K., Richards-Kortum, R., Cornelison, T. L. (2003). Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers. *Cancer*, 98(9 Suppl), 2044-51. PMID: 14603541. DOI: 10.1002/cncr.11674
192. Eitan, R., Abu-Rustum, N. R., **Walker, J. L.**, Barakat, R. R. (2003). Ligation of an anatomic variant of renal vasculature during laparoscopic periaortic lymph node dissection: a cause of postoperative renal infarction. *Gynecologic oncology*, 91(2), 416-20. PMID: 14599875.
193. Shen-Gunther, J., Mannel, R. S., **Walker, J. L.**, Gold, M. A., Johnson, G. A. (2003). Outpatient implantation of a central venous access system in gynecologic oncology patients. *The Journal of*

reproductive medicine, 48(11), 875-81. PMID: 14686020.

194. Falkner, C. A., **Walker, J. L.** (2003). Management of atypical and low-grade cervical cytology. *Cancer journal (Sudbury, Mass.)*, 9(5), 377-81. PMID: 14690312.
195. Gold, M. A., **Walker, J. L.**, Berek, J. S., Hallum, 3rd, A. V., Garcia, D. J., Alberts, D. S. (2003). Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. *Gynecologic oncology*, 90(2), 325-30. PMID: 12893194.
196. (2003). A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. *American journal of obstetrics and gynecology*, 188(6), 1393-400. PMID: 12824968.
197. Mannel, R. S., **Walker, J. L.**, Gould, N., Scribner, Jr, D. R., Kamelle, S., Tillmanns, T., McMeekin, D. S., Gold, M. A. (2003). Impact of individual physicians on enrollment of patients into clinical trials. *American journal of clinical oncology*, 26(2), 171-3. PMID: 12714890. DOI: 10.1097/01.COC.0000017798.43288.7C
198. Rose, P., Rodriguez, M., **Walker, J. L.**, Greer, B., Fusco, N., McGuire, W. (2002). Phase I study of liposomal doxorubicin (Doxil) and prolonged etoposide as second-line therapy in recurrent or persistent ovarian, tubal and peritoneal carcinoma: A Gynecologic Oncology Group study. *Gynecologic Oncology*, 85(1), 136-9. DOI: 10.1006/gyno.2002.6584
199. Rose, P. G., Rodriguez, M., **Walker, J. L.**, Greer, B., Fusco, N., McGuire, W. (2002). A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study. *Gynecologic oncology*, 85(1), 136-9. PMID: 11925133. DOI: 10.1006/gyno.2002.6584
200. Scribner, Jr, D. R., **Walker, J. L.**, Johnson, G. A., McMeekin, D. S., Gold, M. A., Mannel, R. S. (2002). Laparoscopic pelvic and paraaortic lymph node dissection in the obese. *Gynecologic oncology*, 84(3), 426-30. PMID: 11855882. DOI: 10.1006/gyno.2001.6548
201. Sherman, M. E., Schiffman, M., Cox, J. T., **ALTS Group** (2002). Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). *Journal of the National Cancer Institute*, 94(2), 102-7. PMID: 11792748.
202. Castle, P. E., Hildesheim, A., Bowman, F. P., Strickler, H. D., **Walker, J. L.**, Pustilnik, T., Edwards, R. P., Crowley-Nowick, P. A. (2002). Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. *Journal of clinical immunology*, 22(1), 23-7. PMID: 11958590.
203. Mayr, N. A., Taoka, T., Yuh, W. T., Denning, L. M., Zhen, W. K., Paulino, A. C., Gaston, R. C., Sorosky, J. I., Meeks, S. L., **Walker, J. L.**, Mannel, R. S., Buatti, J. M. (2002). Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. *International journal of radiation oncology, biology, physics*, 52(1), 14-22. PMID: 11777618.
204. Scribner, Jr, D. R., **Walker, J. L.**, Johnson, G. A., McMeekin, S., Gold, M. A., Mannel, R. S. (2001). Surgical management of early-stage endometrial cancer in the elderly: is laparoscopy feasible? *Gynecologic oncology*, 83(3), 563-8. PMID: 11733973. DOI: 10.1006/gyno.2001.6463
205. Goldstein, R. B., Bree, R. L., Benson, C. B., Benacerraf, B. R., Bloss, J. D., Carlos, R., Fleischer, A. C., Goldstein, S. R., Hunt, R. B., Kurman, R. J., Kurtz, A. B., Laing, F. C., Parsons, A. K., Smith-Bindman, R., **Walker, J. L.** (2001). Evaluation of the woman with postmenopausal bleeding:

- Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement. *Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine*, 20(10), 1025-36. PMID: 11587008.
206. Scribner, Jr, D. R., **Walker, J. L.**, Johnson, G. A., McMeekin, S., Gold, M. A., Mannel, R. S. (2001). Laparoscopic pelvic and paraaortic lymph node dissection: analysis of the first 100 cases. *Gynecologic oncology*, 82(3), 498-503. PMID: 11520146. DOI: 10.1006/gyno.2001.6314
 207. Sherman, M. E., Solomon, D., Schiffman, M., **Walker, J. L.** (2001). Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. *American journal of clinical pathology*, 116(3), 386-94. PMID: 11554167. DOI: 10.1309/JM3V-U4HP-W8HJ-68XV
 208. Gould, N., Kamelle, S., Tillmanns, T., Scribner, D., Gold, M. A., **Walker, J. L.**, Mannel, R. S. (2001). Predictors of complications after inguinal lymphadenectomy. *Gynecologic oncology*, 82(2), 329-32. PMID: 11531288. DOI: 10.1006/gyno.2001.6266
 209. Fracasso, P. M., Brady, M. F., Moore, D. H., **Walker, J. L.**, Rose, P. G., Letvak, L., Grogan, T. M., McGuire, W. P. (2001). Phase II study of paclitaxel and valsopodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 19(12), 2975-82. PMID: 11408492.
 210. McMeekin, D. S., Lashbrook, D., Gold, M. A., Johnson, G., **Walker, J. L.**, Mannel, R. S. (2001). Analysis of FIGO Stage IIIc endometrial cancer patients. *Gynecologic oncology*, 81(2), 273-8. PMID: 11330962. DOI: 10.1006/gyno.2001.6157
 211. Stoler, M. H., Schiffman, M., **ALTS Group** (2001). Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. *JAMA*, 285(11), 1500-5. PMID: 11255427.
 212. Solomon, D., Schiffman, M., Tarone, R., **ALTS Group** (2001). Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. *Journal of the National Cancer Institute*, 93(4), 293-9. PMID: 11181776.
 213. Rose, P. G., Brunetto, V. L., VanLe, L., Bell, J., **Walker, J. L.**, Lee, R. B. (2000). A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecologic oncology*, 78(2), 212-6. PMID: 10926805. DOI: 10.1006/gyno.2000.5865
 214. **Walker, J. L.** (2000). Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. *Journal of the National Cancer Institute*, 92(5), 397-402. PMID: 10700419.
 215. Scribner, Jr, D. R., Mannel, R. S., **Walker, J. L.**, Johnson, G. A. (1999). Cost analysis of laparoscopy versus laparotomy for early endometrial cancer. *Gynecologic oncology*, 75(3), 460-3. PMID: 10600307. DOI: 10.1006/gyno.1999.5606
 216. Keys, H. M., Bundy, B. N., Stehman, F. B., Muderspach, L. I., Chafe, W. E., Suggs, 3rd, C. L., **Walker, J. L.**, Gersell, D. (1999). Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. *The New England journal of medicine*, 340(15), 1154-61. PMID: 10202166. DOI: 10.1056/NEJM199904153401503
 217. Scribner, Jr, D. R., **Walker, J. L.** (1998). Low-grade endometrial stromal sarcoma preoperative

- treatment with Depo-Lupron and Megace. *Gynecologic oncology*, 71(3), 458-60. PMID: 9887250. DOI: 10.1006/gyno.1998.5174
218. Asbury, R., Blessing, J. A., Buller, R., Malfetano, J. H., **Walker, J. L.**, Sevin, B. U. (1998). A phase II trial of amonafide in patients with leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. *Am J Clin Oncol*, 21(2), 145-6. PMID: 9537200.
 219. Asbury, R., Blessing, J. A., Buller, R., Malfetano, J. H., **Walker, J. L.**, Sevin, B. U. (1998). Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study. *American journal of clinical oncology*, 21(2), 145-6. PMID: 9537200.
 220. Shen-Gunther, J., Mannel, R. S., **Walker, J. L.**, Johnson, G. A., Sienko, A. E. (1998). Laparoscopic paraaortic lymphadenectomy using laparoscopic coagulating shears. *The Journal of the American Association of Gynecologic Laparoscopists*, 5(1), 47-50. PMID: 9454876.
 221. Podnos, Y. D., Gamboa, G., Kurosaki, T., Buller, R., **Walker, J. L.**, Manetta, A. (1997). Ovarian vein vs peripheral blood CA125 serum levels: a comparative study. *Gynecologic oncology*, 66(1), 71-4. PMID: 9234924. DOI: 10.1006/gyno.1997.4712
 222. Johnson, G. A., Mannel, R. S., Khalifa, M., **Walker, J. L.**, Wren, M., Min, K. W., Benbrook, D. M. (1997). Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. *Gynecologic oncology*, 65(3), 425-9. PMID: 9190969. DOI: 10.1006/gyno.1997.4660
 223. Khalifa, M. A., Lacher, D. A., Lage, J. M., Mannel, R. S., **Walker, J. L.**, Angros, L. H., Min, K. W. (1997). Immunohistochemical assessment of proliferation markers and altered gene expression in archival specimens of ovarian epithelial tumors. *Cancer detection and prevention*, 21(6), 532-9. PMID: 9398993.
 224. Khalifa, M. A., Abdoh, A. A., Mannel, R. S., **Walker, J. L.**, Angros, L. H., Min, K. W. (1997). P-glycoprotein as a prognostic indicator in pre- and postchemotherapy ovarian adenocarcinoma. *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists*, 16(1), 69-75. PMID: 8986535.
 225. Shen-Gunther, J., **Walker, J. L.**, Johnson, G. A., Mannel, R. S. (1996). Hepatic venoocclusive disease as a complication of whole abdominopelvic irradiation and treatment with the transjugular intrahepatic portosystemic shunt: case report and literature review. *Gynecologic oncology*, 61(2), 282-6. PMID: 8626148.
 226. Mannel, R. S., Manetta, A., Buller, R. E., Braly, P. S., **Walker, J. L.**, Archer, J. S. (1995). Use of ileocecal continent urinary reservoir in patients with previous pelvic irradiation. *Gynecologic oncology*, 59(3), 376-8. PMID: 8522258. DOI: 10.1006/gyno.1995.9959
 227. Flanagan, C. W., Mannel, R. S., **Walker, J. L.**, Johnson, G. A. (1995). Incidence and location of para-aortic lymph node metastases in gynecologic malignancies. *Journal of the American College of Surgeons*, 181(1), 72-4. PMID: 7599775.
 228. Mannel, R. S., Manetta, A., Hickman, Jr, R. L., **Walker, J. L.**, Berman, M. L., DiSaia, P. J. (1994). Cost analysis of Hickman catheter insertion at bedside in gynecologic oncology patients. *Journal of the American College of Surgeons*, 179(5), 558-60. PMID: 7952458.
 229. Monk, B. J., Cha, D. S., **Walker, J. L.**, Burger, R. A., Ramsinghani, N. S., Manetta, A., DiSaia, P. J., Berman, M. L. (1994). Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma. *Gynecologic oncology*, 54(1), 4-9. PMID: 8020837. DOI:

10.1006/gyno.1994.1157

230. Khalifa, M. A., Mannel, R. S., Haraway, S. D., **Walker, J. L.**, Min, K. W. (1994). Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. *Gynecologic oncology*, 53(1), 84-92. PMID: 7909788. DOI: 10.1006/gyno.1994.1092
231. Monk, B. J., **Walker, J. L.**, Tewari, K., Ramsinghani, N. S., Nisar Syed, A. M., DiSaia, P. J. (1994). Open interstitial brachytherapy for the treatment of local-regional recurrences of uterine corpus and cervix cancer after primary surgery. *Gynecologic oncology*, 52(2), 222-8. PMID: 8314143.
232. Khalifa, M. A., Abdoh, A. A., Mannel, R. S., Haraway, S. D., **Walker, J. L.**, Min, K. W. (1994). Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. *Cancer*, 73(2), 370-6. PMID: 8293402.
233. Shanbour, K. A., Mannel, R. S., Morris, P. C., Yadack, A., **Walker, J. L.** (1992). Comparison of clinical versus surgical staging systems in vulvar cancer. *Obstetrics and gynecology*, 80(6), 927-30. PMID: 1448261.
234. **Walker, J. L.**, Manetta, A., Mannel, R. S. (1992). Hypogastric artery aneurysm masquerading as an ovarian neoplasm. *Gynecologic oncology*, 47(3), 382-4. PMID: 1473753.
235. Chapman, J. A., Mannel, R. S., DiSaia, P. J., **Walker, J. L.**, Berman, M. L. (1992). Surgical treatment of unexpected invasive cervical cancer found at total hysterectomy. *Obstetrics and gynecology*, 80(6), 931-4. PMID: 1448262.
236. Macri, C. I., Cook, N. S., **Walker, J. L.**, Berman, M. L., Patton, Jr, T. J., Wilczynski, S. P. (1992). Analysis of fine-needle aspirates for HPV by PCR may be useful in diagnosis of metastatic gynecologic malignancies. *Gynecologic oncology*, 46(3), 372-6. PMID: 1326475.
237. Fuchtnner, C., Manetta, A., **Walker, J. L.**, Emma, D., Berman, M., DiSaia, P. J. (1992). Radical hysterectomy in the elderly patient: analysis of morbidity. *American journal of obstetrics and gynecology*, 166(2), 593-7. PMID: 1536238.
238. Bloss, J. D., DiSaia, P. J., Mannel, R. S., Hyden, E. C., Manetta, A., **Walker, J. L.**, Berman, M. L. (1991). Radiation myelitis: a complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix. *Gynecologic oncology*, 43(3), 305-8. PMID: 1752503.
239. Bloss, J. D., Liao, S. Y., Wilczynski, S. P., Macri, C., **Walker, J. L.**, Peake, M., Berman, M. L. (1991). Clinical and histologic features of vulvar carcinomas analyzed for human papillomavirus status: evidence that squamous cell carcinoma of the vulva has more than one etiology. *Human pathology*, 22(7), 711-8. PMID: 1649118.
240. Bloss, J. D., Wilczynski, S. P., Liao, S. Y., **Walker, J. L.**, Manetta, A., Berman, M. L. (1990). The use of molecular probes to distinguish new primary tumors from recurrent tumors in gynecologic malignancies. *American journal of clinical pathology*, 94(4), 432-4. PMID: 2171321.
241. **Walker, J. L.**, Manetta, A., Mannel, R. S., Liao, S. Y. (1990). Cellular fibroma masquerading as ovarian carcinoma. *Obstetrics and gynecology*, 76(3 Pt 2), 530-1. PMID: 2381641.
242. Mannel, R. S., Berman, M. L., **Walker, J. L.**, Manetta, A., DiSaia, P. J. (1990). Management of endometrial cancer with suspected cervical involvement. *Obstetrics and gynecology*, 75(6), 1016-22. PMID: 2342727.

243. **Walker, J. L.**, Manetta, A., Mannel, R. S., Berman, M. L., DiSaia, P. J. (1990). The influence of endometriosis on the staging of cervical cancer. *Obstetrics and gynecology*, 75(3 Pt 2), 543-5. PMID: 2304733.
244. **Walker, J. L.**, Bloss, J. D., Liao, S. Y., Berman, M., Bergen, S., Wilczynski, S. P. (1989). Human papillomavirus genotype as a prognostic indicator in carcinoma of the uterine cervix. *Obstetrics and gynecology*, 74(5), 781-5. PMID: 2554228.
245. Wilczynski, S. P., **Walker, J. L.**, Liao, S. Y., Bergen, S., Berman, M. (1988). Adenocarcinoma of the cervix associated with human papillomavirus. *Cancer*, 62(7), 1331-6. PMID: 2843277.
246. Wilczynski, S. P., Pearlman, L., **Walker, J. L.** (1988). Identification of HPV 16 early genes retained in cervical carcinomas. *Virology*, 166(2), 624-7. PMID: 2845667.
247. Wilczynski, S. P., Bergen, S., **Walker, J. L.**, Liao, S. Y., Pearlman, L. F. (1988). Human papillomaviruses and cervical cancer: analysis of histopathologic features associated with different viral types. *Human pathology*, 19(6), 697-704. PMID: 2837431.

Book Chapters

1. **Walker, J. L.** (2010). Ancillary procedures. In Karlan, B. Y., Bristow, R. E., Li, A. J. (Eds.), *Gynecologic Oncology: Clinical Practice & Surgical Atlas* (8th ed., pp. Chapter 33). McGraw-Hill. DOI: 978-0323074193
2. **Walker, J. L.**, Zuna, R. E. (2010). Endometrial hyperplasia, estrogen therapy, and the prevention of endometrial cancer. In DiSaia, P. J., Creasman, W. (Eds.), *Clinical Gynecologic Oncology* (8th ed., pp. Chapter 4). Elsevier.
3. **Walker, J. L.** (2010). Selection and placement of intraperitoneal catheters for IP chemotherapy for ovarian cancer. In Alberts, D. S., Clouser, M. C., Hess, L. M. (Eds.), *Intraperitoneal Therapy for Ovarian Cancer* (pp. Chapter 6). Springer. DOI: 10.1007/978-3-642-12130-2
4. Landrum, L. M., **Walker, J. L.** (2010). Surgical issues for intraperitoneal chemotherapy. In Bristow, R. E., Karlan, B. Y. (Eds.), *Surgery for Ovarian Cancer: Principles and Practice* (pp. Chapter 10). Informa Healthcare.
5. **Walker, J. L.** (2009). Chemotherapy for ovarian cancer. *ASCO Educational Book*.
6. **Walker, J. L.** (2008). Cancer prevention and screening in women. *Precis: Oncology* (pp. Chapter 1). American College of Obstetricians and Gynecologists.
7. Gould, N. S., **Walker, J. L.**, Mannel, R. S. (2008). Vulvar and vaginal cancer. *Danforth's Obstetrics and Gynecology* (10th ed., pp. Chapter 51). Lippincott Williams & Wilkins.
8. **Walker, J. L.** (2007). Intraperitoneal chemotherapy: Technique and complications. In Helm, W. C., Edwards, R. (Eds.), *Current Clinical Oncology: Intraperitoneal Cancer Therapy* (pp. Chapter 5). Totowa, NJ: Humana Press, Inc..
9. **Walker, J. L.**, Zuna, R. E. (2006). Endometrial hyperplasia, estrogen therapy, and the prevention of endometrial cancer. In DiSaia, P. J., Creasman, W. (Eds.), *Clinical Gynecologic Oncology* (7th ed., pp. Chapter 4). Elsevier.
10. **Walker, J. L.**, Mannel, R. S. (2005). The role of laparoscopy in the management of endometrial cancer. In Coukos, G., Rubin, S. C. (Eds.), *Cancer of the Uterus*. Marcel Dekker, Inc..

11. Gould, N. S., **Walker, J. L.**, Mannel, R. S. (2003). Vulvar and Vaginal Cancer. *Danforth's Obstetrics and Gynecology* (9th ed., vol. Chapter 51, pp. 911-933). Lippincott Williams & Wilkins.
12. **Walker, J. L.**, Nunez, E. R. (1999). Endometrial Cancer. In Kramer, B. S., Gohagan, J. K., Prorok, P. C. (Eds.), *Cancer Screening: Theory and Practice* (Chapter 20 ed., vol. 18, pp. 531-556). New York: Marcel Dekker, Inc..
13. DiSaia, P. J., **Walker, J. L.**, Gold, M. A. (1999). Perioperative Care. In Scott, DiSaia, Hammond, Spellacy (Eds.), *Danforth's Obstetrics and Gynecology* (8th ed., pp. 699-712). Lippincott Williams & Wilkins.
14. Berman, M. L., **Walker, J. L.**, Berek, J. S. (1990). Carcinoma of the uterine cervix. In Haskell (Ed.), *Cancer Treatment, Third Edition*. Philadelphia, PA: W.B. Saunders.
15. DiSaia, P. J., **Walker, J. L.** (1990). Perioperative care of the surgical patient. In Danforth (Ed.), *Obstetrics & Gynecology* (6th ed.). Philadelphia, PA: J.B. Lippincott.
16. DiSaia, P. J., **Walker, J. L.** (1988). Cervix uteri. *Goldsmith's Practice of Surgery: Gynecology*. Philadelphia, PA: Harper and Row.

Published Abstracts

1. Randall, L. M., Java, J., Bookman, M., Fleming, G., Monk, B. J., **Walker, J. L.**, Homesley, H., Fowler, J., Greer, B., Burger, R. A. (2015). *Impact of thrombocytosis in women with ovarian cancer treated with and without bevacizumab on GOG 218* (Suppl 2 ed., vol. 25, pp. 521). *Int J Gynecol Cancer*.
2. Chan, J., Brady, W. E., Brown, J., Shahin, M. S., Rose, P. G., Kim, J. H., Secord, A. A., **Walker, J. L.**, Monk, B. J. (2015). *A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group study* (Suppl 1 ed., vol. 138, pp. 3). *Gynecologic Oncology*. DOI: 10.1016/j.ygyno.2015.04.021
3. **Walker, J. L.** (2014). *Complications and surgical staging of endometrial cancer with respect to obesity: A Gynecologic Oncology Group LAP2 ancillary data study* (31st ed., vol. 133). *Gynecologic Oncology*. DOI: 10.1016/j.ygyno.2014.03.096
4. Nickles Fader, A., Java, J., Tenney, M., Jackson, C. C., Kushnir, C. L., Spirtos, N. M., **Walker, J. L.** (2014). *Patterns of recurrence and survival after randomization to laparoscopy versus laparotomy in women with high-grade uterine cancer: A Gynecologic Oncology Group (GOG) study* (Suppl 1 ed., vol. 133, pp. 49). *Gynecologic Oncology*. DOI: 10.1016/j.ygyno.2014.03.138
5. Landrum, L. M., Java, J., Mathews, C. A., Lanneau, G. S., Copeland, L., Armstrong, D., **Walker, J. L.** (2013). *Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study* (1st ed., vol. 130, pp. 12-18). *JCO*. PMID: 23578540. DOI: 10.1016/j.ygyno.2013.04.001
6. Chase, D., Carter, J., Huang, H., Cella, D., **Walker, J. L.**, Wenzel, L. (2012). *Patient-reported sexual functioning in early stage endometrial cancer patients: An exploratory analysis of the Gynecologic Oncology Group (GOG) protocol LAP-2* (Suppl 1 ed., vol. 125, pp. S121). *Gynecologic Oncology*. DOI: 10.1016/j.ygyno.2011.12.293
7. **Walker, J. L.**, Piedmonte, M. R., Spirtos, N. M., Eisenkop, S. M., Schlaerth, J. B., Mannel, R. S., Barakat, R., Pearl, M. L., Sharma, S. K. (2012). *Recurrence and survival after randomization to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic*

Oncology Group LAP2 Study (7th ed., vol. 30, pp. 695-700). *Journal of Clinical Oncology*. PMID: 22291074. DOI: 10.1200/JCO.2011.38.8645

8. **Walker, J. L.** (2011). *Incidence of nodal metastasis in endometrioid endometrial cancer risk groups: A Gynecologic Oncology Group multicenter review* (Suppl 1 ed., vol. 120). *Gynecol Oncol*. DOI: 10.1016/j.ygyno.2010.12.012
9. Monk, B. J., Sill, M. W., Hanjani, P., Edwards, R., Rotmensch, J., DeGeest, K., Bonebrake, A., **Walker, J. L.** (2010). *Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group* (15S ed., vol. 28, pp. 401s). *Journal of Clinical Oncology*. DOI: 10.1200/jco.2010.28.15_suppl.5046
10. Burger, R. A., Liang, S. X., Brady, M. F., Bookman, M. A., Monk, B. J., **Walker, J. L.**, Homesley, H., Fowler, J., Greer, B. E., Boente, M. (2010). *Safety and subgroup efficacy analyses in GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): a Gynecologic Oncology Group study* (Suppl 8 ed., vol. 21, pp. 307). *Annals Oncol*.
11. Gould, N., Sill, M. W., Mannel, R. S., Fracasso, P., Thaker, P. H., DiSilvestro, P., Waggoner, S., Yamada, S. D., Armstrong, D. K., **Walker, J. L.** (2010). *A phase I trial of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study* (3 suppl ed., vol. 116). *Gynecologic Oncology*.
12. Farley, J. H., Sill, M., **Walker, J. L.**, Schilder, R. J., Thigpen, J. T., Coleman, R. L., Miller, B. E. (2009). *Phase II evaluation of cisplatin plus cetuximab in the treatment of recurrent and persistent cancers of the cervix: A limited access phase II study of the Gynecologic Oncology Group* (15_suppl ed., vol. 27). *Journal of Clinical Oncology*. DOI: 10.1200/jco.2009.27.15_suppl.5521
13. Carlson, J. W., Kauderer, J., **Walker, J. L.**, Gold, M. A., O'Malley, D., Tuller, E., Clarke-Pearson, D. L., G. O. G. (2008). *A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study* (1st ed., vol. 110, pp. 76-82). *Gynecologic Oncology*. PMID: 18482765. DOI: 10.1016/j.ygyno.2008.03.05
14. Wenzel, L., Huang, H., Armstrong, D., **Walker, J. L.**, Cella, D., Baergen, R., Lele, S., Copeland, L., Monk, B. (2007). *Health-related quality of life (HRQL) comparisons of intraperitoneal versus intravenous chemotherapy for ovarian cancer: A Gynecologic Oncology Group study* (vol. No. 1768:A-29). *Quality of Life Research*.
15. Carlson, J., Kauderer, J., **Walker, J. L.**, Gold, M. A., O'Malley, D., Tuller, E., Clarke-Pearson, D. (2007). *Phase III trial of Tisseel to reduce lymphedema after inguinal lymph node dissection: A Gynecologic Oncology Group study* (3rd ed., vol. 104, pp. S49). *Gynecologic Oncology*.
16. **Walker, J. L.** (2006). *Quality of life of patients in a randomized clinical trial of laparoscopy (scope) vs open laparotomy (open) for the surgical resection and staging of uterine cancer: A Gynecologic Oncology Group study* (22 suppl ed., vol. 101). *Gynecologic Oncology*.
17. **Walker, J. L.**, Piedmonte, M., Spirtos, N., Eisenkop, S., Schlaerth, J., Mannel, R. S., Spiegel, G. (2006). *Randomized trial of laparoscopy vs laparotomy for surgical staging of uterine cancer: A Gynecologic Oncology Group study* (3rd ed., vol. 16). *Int J Gynecol Cancer*.
18. **Walker, J. L.**, Piedmonte, M., Spirtos, N., Eisenkop, S., Schlaerth, J., Mannel, R. S., Spiegel, G. (2006). *Surgical staging of uterine cancer: Randomized phase III trial of laparoscopy vs laparotomy - Gynecologic Oncology Group (GOG) preliminary results* (18 suppl ed., vol. 24). *Journal of Clinical Oncology*. PMID: 27952161.

19. Spiegel, G., **Walker, J. L.**, Piedmonte, M. (2006). *The reliability of intraoperative consultations in assessing depth of invasion, subtypes and grades of endometrial carcinoma* (Suppl 3 ed., vol. 19, pp. 103). *Modern Pathol.*
20. **Walker, J. L.**, Armstrong, D., Bundy, B. N., Fowler, J., Webster, K., Burger, R. A., Clarke-Pearson, D. (2004). *Intraperitoneal catheter outcomes on GOG 172: Randomized trial of IV vs IP chemotherapy in optimal ovarian cancer* (1st ed., vol. 92, pp. 402). *Gynecologic Oncology*. DOI: 10.1056/NEJMoa052985
21. Wenzel, L., Huang, H., Armstrong, D., **Walker, J. L.**, Cella, D. (2004). *Quality of life (QOL) results of a randomized study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial* (pp. 19-20). *Proc ISOQOL*.

Other

1. Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., Kwok-Shing Ng, P., Jeong, K. J., Cao, S., Wang, Z., Gao, J., Gao, Q., Wang, F., Liu, E. M., Mularoni, L., Rubio-Perez, C., Nagarajan, N., Cortés-Ciriano, I., Zhou, D. C., Liang, W. W., Hess, J. M., Yellapantula, V. D., Tamborero, D., Gonzalez-Perez, A., Suphavitai, C., Ko, J. Y., Khurana, E., Park, P. J., Van Allen, E. M., Liang, H., **Cancer Genome Atlas Research Network**, Lawrence, M. S., Godzik, A., Lopez-Bigas, N., Stuart, J., Wheeler, D., Getz, G., Chen, K., Lazar, A. J., Mills, G. B., Karchin, R., Ding, L. (2018). *Comprehensive Characterization of Cancer Driver Genes and Mutations*. (4th ed., vol. 174, pp. 1034-1035). *Cell*. PMID: 30096302. DOI: 10.1016/j.cell.2018.07.034
2. **Walker, J. L.** (2016). *Intraperitoneal chemotherapy for ovarian cancer* (1st ed., vol. 142, pp. 1-2). *Gynecologic oncology*. PMID: 27328898. DOI: 10.1016/j.ygyno.2016.06.011
3. Cohn, D. E., Sill, M., **Walker, J. L.**, O'Malley, D. M., Nagel, C. I., Rutledge, T., Bradley, W. G., Richardson, D. L., Moxley, K. M., Aghajanian, C. (2016). *GOG 186H: A randomized phase II evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin) in the treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer* (Suppl 1 ed., vol. 141, pp. 6-7). *Gynecologic Oncology*. DOI: 10.1016/j.ygyno.2016.04.042
4. Modesitt, S., **Walker, J. L.** (2014). *Obesity crisis in cancer care: gynecologic cancer prevention, treatment, and survivorship in obese women in the United States*. (1st ed., vol. 133, pp. 1-3). *Gynecologic oncology*. PMID: 24680583. DOI: 10.1016/j.ygyno.2014.01.050
5. **Walker, J. L.** (2012). *Re: Clinical practice guidelines for the management of patients with endometrial cancer in France* (2nd ed., vol. 22, pp. 179-81). *International journal of gynecological cancer: official journal of the International Gynecological Cancer Society*. PMID: 22237380. DOI: 10.1097/IGC.0b013e318231ad4a
6. **Walker, J. L.** (2009). *Intraperitoneal chemotherapy for ovarian cancer: 2009 goals* (3rd ed., vol. 112, pp. 439-40). *Gynecologic oncology*. PMID: 19245944. DOI: 10.1016/j.ygyno.2009.01.007
7. **Walker, J. L.** (2000). *Preventing perineal trauma during childbirth: a systematic review*. (1st ed., vol. 96, pp. 154). *Obstetrics and gynecology*. PMID: 10928906.

Publications - Non Peer-Reviewed/Refereed

* indicates Mentee

+ indicates Co-First Author

indicates Contributing Author/Corresponding Author

Commentary

1. **Walker, J. L.**, Wang, S. S., Schiffman, M., Soloman, D., A. L. T. S. G. (2008). *Letter to the Editor: Reply*. Am J Obst Gynec.

Newsletters

1. **Walker, J. L.** (1989). *FIGO classification of endometrial cancer*. Gynecologic Oncology Newsletter.
2. **Walker, J. L.** (1987). *Advances in gestational trophoblastic disease*. Gynecologic Oncology Newsletter.
3. **Walker, J. L.** (1987). *The new FIGO staging classification for cervical and ovarian carcinoma*. Gynecologic Oncology Newsletter.
4. **Walker, J. L.** (1986). *Update on condylomata infections*. Gynecologic Oncology Newsletter.

Other

1. **Walker, J. L.** (1995). *Should we be screening for ovarian cancer?*. Oklahoma County Medical Society Bulletin.
2. **Walker, J. L.**, DiSaia, P. J. (1988). *Prevention of cervical cancer* (2nd ed., vol. 1, pp. 201-202). OB/GYN Report.

Non-Authored Publications

1. Khan, M. J., Partridge, E. E., Wang, S., Schiffman, M., **Walker, J. L.** (2005). Socioeconomic status and the risk of cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. *Cancer*, 104(1), 61-70. PMID: 15889450. DOI: 10.1002/cncr.21129
2. McIntyre-Seltman, K., Castle, P. E., Guido, R., Schiffman, M., Wheeler, C. M., **Walker, J. L.** (2005). Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 14(5), 1165-70. PMID: 15894667. DOI: 10.1158/1055-9965.EPI-04-0918
3. **Walker, J. L.** (2003). Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. *American journal of obstetrics and gynecology*, 188(6), 1383-92. PMID: 12824967.
4. Wright, Jr, T. C., Cox, J. T., Massad, L. S., Twiggs, L. B., Wilkinson, E. J., **Walker, J. L.** (2002). 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. *JAMA*, 287(16), 2120-9. PMID: 11966387.
5. Solomon, D., Davey, D., Kurman, R., Moriarty, A., O'Connor, D., Prey, M., Raab, S., Sherman, M., Wilbur, D., Wright, Jr, T., Young, N., **Walker, J. L.** (2002). The 2001 Bethesda System: terminology for reporting results of cervical cytology. *JAMA*, 287(16), 2114-9. PMID: 11966386.

PRESENTATIONS

Abstracts

* indicates mentee

National/International

1. **Walker, J. L.**, "Efficacy of MAPS in facilitating smoking abstinence among cervical cancer survivors: RCT outcomes", 28th Annual Meeting of the Society for Research on Nicotine and Tobacco, Society for Research on Nicotine and Tobacco, Baltimore, MD, Accepted, Oral Presentation. March 17, 2022.
2. Jackson, C. C., Cantrell, L., Erickson, B. K., Moore, K., Duska, L. R., Richardson, D. L., Landrum, L. M., Holman, L. L., **Walker, J. L.**, Mannel, R. S., Moxley, K. M., Queimado, L., Ding, K., Cohoon, A., Vesely, S. K., Dockery, L. E., "A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium", 2021 ASCO Annual Meeting, American Society of Clinical Oncology, Virtual Platform, Accepted, Abstract. June 2021.
3. Lee, T., Gatsonis, C., Ng, C., Coleman, R., Bookman, M., Zhang, Z., Marques, H., Burgers, K., Su, F., Bauza, J., Mannel, R. S., **Walker, J. L.**, Huh, W., Rubin, S., DiSilvestro, P., Martin, L., Chan, J., "Reproducibility of CT perfusion in ovarian cancer - A substudy of ACRIN 6695/GOG-0262", 103rd Scientific Assembly and Annual Meeting of the Radiological Society of North America, RSNA, Chicago, IL, Accepted, Poster. November 2017.
4. Wenzel, L. B., Mukamel, D. B., Osann, K., Sparks, L., Havrilesky, L. J., Wright, A. A., **Walker, J. L.**, Robison, K., Alvarez, R. D., Le, L. V., Wakabayashi, M. T., Randall, L. M., Wahi, A., Hsieh, S., Lipscomb, J., Cohn, D. E., "Shared decision-making in ovarian cancer", American Society of Clinical Oncologists Annual Meeting, ASCO, Chicago, IL, Accepted, Lecture. June 2017.
5. **Walker, J. L.**, "Intraperitoneal chemotherapy for ovarian cancer: Trials and tribulations", American Society of Clinical Oncology Annual Meeting, ASCO, Chicago, IL, Invited, Oral Presentation. June 3, 2016.
6. **Walker, J. L.**, "Emerging strategies for cancer prevention", American College of Obstetricians and Gynecologists Annual Meeting, ACOG, Washington, DC, Invited, Oral Presentation. May 14, 2016.
7. **Walker, J. L.**, Tsunoda, A. T., "Preventing cancer: Impact of screening and prevention", SGO Annual Meeting, Society of Gynecologic Oncology, Scientific Plenary VIII. March 2016.
8. Felix, A. S., McMeekin, S., Mutch, D., **Walker, J. L.**, Creasman, W. T., Cohn, D. E., Ali, S., Moore, R. G., Downs, L. S., Ioffe, O. B., Park, K. J., Sherman, M. E., Brinton, L. A., "Endometrial carcinoma stage and mortality in relation to fallopian tube ligation: a Gynecologic Oncology Group study", 47th Annual SER Meeting, Society for Epidemiologic Research, Seattle, WA, Oral Presentation. June 2014.
9. Ferris, J. S., Java, J. J., Burger, R. A., Bookman, M. A., Fleming, G. F., Monk, B. J., **Walker, J. L.**, Homesley, H. D., Fowler, J., Greer, B. E., "Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial, ovarian, fallopian tube and peritoneal cancers: A Gynecologic Oncology Group study", 45th Annual Meeting on Women's Cancer, SGO, Tampa, FL, Accepted, Oral Presentation. March 2014.
10. Milam, M. R., Java, J., Parker, L., Metzinger, D., **Walker, J. L.**, Coleman, R., "Survival in early stage endometrioid endometrial cancer risk groups: A Gynecologic Oncology Group multicenter review", SGO Annual Meeting, Accepted, Paper. 2013.

11. Richard, S., Miller, A., Markman, M., Armstrong, D., **Walker, J. L.**, Kirvak, T., "Nadir CA125 and second look surgery in patients with advanced stage epithelial ovarian cancer treated with intravenous compared to intraperitoneal chemotherapy: a study of Gynecologic Oncology Group protocols 114 and 172", Society of Gynecologic Oncologists Annual Meeting, SGO, Los Angeles, CA, Accepted, Oral Presentation. March 9, 2013.
12. Nugent, E. K., Wild, R. S., Moxley, K. M., Bishop, E. A., Mathews, C. A., Landrum, L. M., Mannel, R. S., **Walker, J. L.**, Moore, K., McMeekin, S., "Prospective lifestyle modification in patients with good prognosis endometrioid adenocarcinoma (EC) of the uterus", Society of Gynecologic Oncologists Annual Meeting, SGO, Los Angeles, CA, Accepted, Oral Presentation. March 9, 2013.
13. Thomas, E. D., Nugent, E. K., Bishop, E. A., Moxley, K. M., Landrum, L. M., Mannel, R. S., **Walker, J. L.**, Moore, K., McMeekin, S., "Reduction of post operative wound complications in patients undergoing open gynecologic procedures with the use of cyanoacrylate microbial sealant", Society of Gynecologic Oncologists Annual Meeting, SGO, Los Angeles, CA, Accepted, Oral Presentation. March 9, 2013.
14. Monk, B. J., Brady, W. E., Lankes, H. A., Facciabene, A., Manjarrez, K., Hershbert, R. M., Fracasso, P. M., Bell-McGuinn, K. M., **Walker, J. L.**, McCourt, C. K., Aghajanian, C., Coukos, G., "VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: Preclinical and phase I data by the Gynecologic Oncology Group", Society of Gynecologic Oncologists Annual Meeting, SGO, Los Angeles, CA, Accepted, Oral Presentation. March 9, 2013.
15. Zhao, L., Wentzensen, N., Zhang, R. R., Dunn, S. T., Gold, M. A., Wang, S. S., Schiffman, M., **Walker, J. L.**, Zuna, R. E., "Accuracy-reducing factors in Pap test for patients with invasive cervical cancer", American Society of Cytopathology, ASC, Las Vegas, NV, Accepted, Oral Presentation. November 2, 2012.
16. Dellinger, T., Eskander, R. N., Ali, S., Lankes, H., Randall, L. M., Ramirez, N., Monk, B. J., **Walker, J. L.**, Eisenhauer, E., Hoang, B., "Expression patterns of the Wnt pathway inhibitors dickkopf3 (Kdd3) and secreted frizzled-related proteins (SFRP) 1 and 4 in endometrial endometrioid adenocarcinoma: a Gynecologic Oncology Group study", Society of Gynecologic Oncologists Annual Meeting, SGO, Austin, TX, Accepted, Oral Presentation. March 24, 2012.
17. Chase, D., Carter, J., Huang, H., **Walker, J. L.**, Wenzel, L., "Patient-reported sexual functioning in early stage endometrial cancer patients: an exploratory analysis of the Gynecologic Oncology Group (GOG) Protocol LAP-2", Society of Gynecologic Oncologists Annual Meeting, SGO, Austin, TX, Accepted, Oral Presentation. March 24, 2012.
18. Burger, R., Brady, M., Bookman, M., Monk, B., **Walker, J. L.**, Homesley, H., Fowler, J., Greer, B., Boente, M., Liang, S., "Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: a Gynecologic Oncology Group Study", Society of Gynecologic Oncologists Annual Meeting, SGO, Austin, TX, Accepted, Oral Presentation. March 24, 2012.
19. Moore, D. H., Ali, S., Koh, W. J., Michael, H., Barnes, M. N., McCourt, C. K., Homesley, H. D., **Walker, J. L.**, "A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study", Society of Gynecologic Oncologists Annual Meeting, SGO, Orlando, FL, Accepted, Oral Presentation. March 5, 2011.
20. Burger, R. A., Brady, M. F., Bookman, M. A., Monk, B. J., **Walker, J. L.**, Homesley, H. D., Fowler, J. M., Greer, B. E., Boente, M. P., Liang, S. X., "Prospective investigation of risk factors for

gastrointestinal adverse events in phase III randomized trial of bevacizumab (BEV) in first-line therapy of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): a Gynecologic Oncology Group Study", Society of Gynecologic Oncologists Annual Meeting, SGO, Orlando, FL, Accepted, Oral Presentation. March 5, 2011.

21. Burger, R. A., Liang, S. X., Brady, M. F., Bookman, M. A., Monk, B. J., **Walker, J. L.**, Homesley, H., Fowler, J., Greer, B. E., Boente, M., "Safety and subgroup efficacy analyses in GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or Fallopian tube cancer (FTC): a Gynecologic Oncology Group study", 35th Annual Meeting of the European Society of Medical Oncology, ESMO, Milan, Italy, Accepted, Poster. October 2010.
22. **Walker, J. L.**, "GOG 218", 2010 Annual American Society of Clinical Oncology, ASCO, Chicago, IL, Oral Presentation. June 2010.
23. Burger, R. A., Brady, M. F., Bookman, M. A., **Walker, J. L.**, Homesley, H. D., Fowler, J., Monk, B. J., Greer, B. E., Boente, M., Liang, S. X., "Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group Study", American Society of Clinical Oncologists Annual Meeting, ASCO, Chicago, IL, Accepted, Oral Presentation. June 6, 2010.
24. Mathews, C. A., Stoner, J. A., Wentzensen, N., Moxley, K. M., Tenney, M. E., Tuller, E. R., Myers, T. K., Landrum, L. M., Lanneau, G. S., Zuna, R. E., Gold, M. A., Wang, S. S., **Walker, J. L.**, "Tubal ligation frequency in Oklahoma women with cervical cancer", Society of Gynecologic Oncologists Annual Meeting, SGO, San Francisco, CA, Accepted, Oral Presentation. March 2010.
25. **Walker, J. L.**, "Phase III trial of laparoscopy vs laparotomy for surgical resection and staging of endometrial cancer: a Gynecologic Oncology Group study", Gynecologic Oncology Group Semi-Annual Business Meeting, GOG, Washington, DC, Accepted, Oral Presentation. July 19, 2006.
26. **Walker, J. L.**, McMeekin, S., Johnson, R. L., Vesely, S., Crichley, C., Moore, K., Goff, B., "Prevalence of symptoms of ovarian cancer", UICC World Cancer Congress, Union for International Cancer Control, Washington, DC, Accepted, Oral Presentation. July 8, 2006.
27. Gage, J. C., Hanson, V., Abbey, K., Dippery, S., Gardner, S., Kubota, J., Schiffman, M. H., Solomon, D., Jeronimo, J., **ASCUS LSIL Triage Study (ALTS) Group**, "Evidence that taking more cervical biopsies substantially improves the sensitivity of colposcopically-guided biopsies", Biennial Meeting of American Society for Colposcopy and Cervical Pathology, Las Vegas, NV, Oral Presentation. March 2006.
28. Landrum, L. M., Gould, N. S., Gold, M. A., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., McMeekin, S., "Comparison of two distinct populations with advanced vulvar cancer", Society of Gynecologic Oncology Annual Meeting, SGO, Palm Springs, CA, Accepted, Oral Presentation. March 23, 2006.
29. Moore, K., McMeekin, S., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., Gold, M. A., Zorn, K. K., "Identification of positive paraaortic lymph nodes in extraperitoneal lymph node dissection for cervical cancer: A single-institution experience", Society of Gynecologic Oncologists Annual Meeting, SGO, Palm Springs, CA, Accepted, Oral Presentation. March 23, 2006.
30. **Walker, J. L.**, "Phase III trial of laparoscopy versus laparotomy for surgical resection and comprehensive surgical staging of uterine cancer: A Gynecologic Oncology Group Study funded by the National Cancer Institute", Society of Gynecologic Oncology Annual Meeting, SGO, Palm Springs, CA, Accepted, Oral Presentation. March 23, 2006.

31. Kornblith, A., **Walker, J. L.**, Huang, H., Cella, D., "Quality of life of patients in a randomized clinical trial of laparoscopy versus open laparotomy for the surgical resection and staging of uterine cancer: A Gynecologic Oncology Group study", Society of Gynecologic Oncology Annual Meeting, SGO, Palm Springs, CA, Accepted, Oral Presentation. March 23, 2006.
32. Moore, K., McMeekin, S., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., Gold, M. A., Zorn, K. K., "Survival in patients with cervical cancer metastatic to the paraaortic lymph nodes", Society of Gynecologic Oncology Annual Meeting, SGO, Palm Springs, CA, Accepted, Oral Presentation. March 23, 2006.
33. Moore, K., Cofer, A. M., Elliott, L., Lanneau, G. S., Downing, K. A., **Walker, J. L.**, Gold, M. A., "High prevalence of cervical intraepithelial neoplasia grade 2 & 3 among adolescents discovered with biopsy at time of incident colposcopic evaluation", American Society for Colposcopy and Cervical Pathology Biennial Meeting, ASCCP, Las Vegas, NV, Accepted, Oral Presentation. March 13, 2006.
34. Wenzel, L. B., Huang, H. Q., Armstrong, D., **Walker, J. L.**, Cella, D., "Validation of a FACT-GOG-Abdominal Discomfort (AD) subscale: A Gynecologic Oncology Group (GOG) trial", American Society of Clinical Oncologists, ASCO, Chicago, IL, Paper. 2005.
35. Gold, M. A., McMeekin, S., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Effects of tubal occlusion on dissemination of uterine cancer", Society of Gynecologic Oncologists Annual Meeting, SGO, Miami Beach, FL, Accepted, Oral Presentation. March 19, 2005.
36. Engle, D. B., Tillmanns, T. D., Falkner, C. A., Gold, M. A., Schultz, C., McMeekin, S., **Walker, J. L.**, Mannel, R. S., Johnson, G. A., Wan, J., Zuna, R. E., "Preoperative predictors of positive margins after loop electrosurgical excisional procedure-cone", Society of Gynecologic Oncologists Annual Meeting, SGO, Miami Beach, FL, Accepted, Oral Presentation. March 19, 2005.
37. **Walker, J. L.**, DiSilvestro, P. A., Morrison, A., "GOG Protocol 9803: Phase I evaluation of the treatment of invasive cervical cancer confined to the pelvis with combination of radiation and weekly cisplatin and paclitaxel", 10th Biennial International Gynecologic Cancer Society Meeting, IGCS, Edinburgh, Scotland, Oral Presentation. October 4, 2004.
38. Gold, M. A., McMeekin, S., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Effects of tubal occlusion on dissemination of uterine cancer", 10th Biennial International Gynecologic Cancer Society Meeting, IGCS, Edinburgh, Scotland, Accepted, Oral Presentation. October 3, 2004.
39. Faulkner, C. A., Gold, M. A., Alward, E. K., McMeekin, S., Johnson, G. A., **Walker, J. L.***, Mannel, R. S., "Excisional conization and morbidity of subsequent radical hysterectomy: does time make a difference?", 10th Biennial International Gynecologic Cancer Society Meeting, IGCS, Edinburgh, Scotland, Accepted, Oral Presentation. October 3, 2004.
40. **Walker, J. L.**, Morrison, A., DiSilvestro, P. A., Brady, M., "GOG protocol 9803: Phase I evaluation of the treatment of invasive cervical cancer confined to the pelvis with combination of radiation and weekly cisplatin and paclitaxel", 10th Biennial International Gynecologic Cancer Society Meeting, IGCS, Edinburgh, Scotland, Accepted, Oral Presentation. October 3, 2004.
41. **Walker, J. L.**, Armstrong, D., Huang, H., Fowler, J., Webster, K., Burger, R., Clarke-Pearson, D., "Intraperitoneal catheter outcomes on GOG 172: A Gynecologic Oncology Group study in women with optimally debulked stage III ovarian cancer", 10th Biennial International Gynecologic Cancer Society Meeting, IGCS, Edinburgh, Scotland, Accepted, Oral Presentation. October 3, 2004.
42. Huh, W. K., Gold, M. A., **Walker, J. L.**, Garcia, F. A., Cestero, R. M., Harper, D. M., Guido, R. M.,

- McIntyre-Seltman, K., Sundborg, M., Holschneider, C., Blank, S., Edwards, R., De Santis, T., Ferris, D. G., Felix, J. C., Alvarez, R. D., "Optical detection of cervical neoplasia: final results from a randomized dual-arm, multi-center clinical trial", 10th Biennial International Gynecologic Cancer Society Meeting, IGCS, Edinburgh, Scotland, Accepted, Oral Presentation. October 3, 2004.
43. Rutledge, T. L., Gold, M. A., McMeekin, S., Huh, W., Powell, M., Lewin, S., Mutch, D., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Carcinosarcoma of the ovary", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 7, 2004.
44. Hyde, Jr., J., Gold, M. A., Tillmanns, T. D., McMeekin, S., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Invasive cervical cancer identified at the time of extrafascial hysterectomy", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 7, 2004.
45. Gold, M. A., Tillmanns, T. D., Morrison, A. E., McMeekin, S., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Phase I trial of topotecan and cisplatin in combination with whole pelvic radiation for patients with high risk factors following radical hysterectomy", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 7, 2004.
46. McMeekin, S., Tillmanns, T. D., Chaudry, T., Gold, M. A., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 7, 2004.
47. Rutledge, T. L., Gold, M. A., McMeekin, S., Hyde, Jr., J., Huh, W., Cohn, D., Rothrock, R., Fowler, J., Powell, M., Lewin, S., Mutch, D., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Uterine carcinosarcoma – evaluation of surgical treatment and adjuvant therapy", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 7, 2004.
48. Bell, J., Brady, M., Lage, J., Look, K. Y., Spirtos, N., **Walker, J. L.**, Rose, G. S., Young, R. C., "A randomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a Gynecologic Oncology Group study", Society of Gynecologic Oncology Annual Meeting, SGO, New Orleans, LA, Accepted, Oral Presentation. February 1, 2003.
49. Lhomme, C., Joly, F., Mangioni, C., Nicoletto, M., Manikhas, G. M., **Walker, J. L.**, Mietlowski, W., Jones, G., Wysowskyj, H., Dugan, M., "A Phase III study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum", American Society of Clinical Oncologists Annual Meeting, ASCO, Orlando, FL, Accepted, Oral Presentation. May 18, 2002.
50. Mietlowski, W., Lhomme, C., Joly, F., Mangioni, C., Nicoletto, M., Manikhas, G. M., **Walker, J. L.**, Rae, P. E., Scott, J. W., Dugan, M., "CA-125 at the end of cycle 3 as a measure of anti-tumor activity in advanced ovarian cancer: potential utility in phase I/II trials", American Society of Clinical Oncologists Annual Meeting, ASCO, Orlando, FL, Accepted, Oral Presentation. May 18, 2002.
51. Johnson, G. A., Gould, N. S., McMeekin, S., Kamelle, S. A., Gold, M. A., **Walker, J. L.**, Mannel, R. S., "Frequency and distribution of extra-ovarian disease in borderline tumors of the ovary", American Society of Clinical Oncologists Annual Meeting, ASCO, Orlando, FL, Accepted, Oral Presentation. May 18, 2002.
52. Kamelle, S. A., Rutledge, T. L., Tillmanns, T. D., Cohn, D. E., Wright, J., Herzog, T. J., Rader, J. S., **Walker, J. L.**, Mannel, R. S., McMeekin, S., "Predictors of recurrence in patients with IB2 cervical cancer treated by primary radical hysterectomy", American Society of Clinical Oncologists

Annual Meeting, ASCO, Orlando, FL, Accepted, Oral Presentation. May 18, 2002.

53. Armstrong, D. K., Bundy, B. N., Baergen, R., Lele, S. B., Copeland, L. J., **Walker, J. L.**, Burger, R., "Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172)", American Society of Clinical Oncologists Annual Meeting, ASCO, Orlando, FL, Accepted, Oral Presentation. May 18, 2002.
54. Rutledge, T. L., Kamelle, S. A., Tillmanns, T. D., Cohn, D. E., Wright, J. D., Rader, J. S., Herzog, T. J., Gold, M. A., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., McMeekin, S., "A comparison of stage IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?", Society of Gynecologic Oncology Annual Meeting, SGO, Miami Beach, FL, Accepted, Oral Presentation. March 16, 2002.
55. Tillmanns, T. D., Gold, M. A., Kamelle, S. A., McMeekin, S., **Walker, J. L.**, Mannel, R. S., "Phase II clinical trials in cervical cancer through the Gynecologic Oncology Group: an evaluation of response, recurrence and toxicity", Society of Gynecologic Oncology Annual Meeting, SGO, Miami Beach, FL, Accepted, Oral Presentation. March 16, 2002.
56. **Walker, J. L.**, "ALTS: ASCUS/LSIL Triage Study; Management of Women with LSIL", Society of Gynecologic Oncology Annual Meeting, SGO, Miami Beach, FL, Accepted, Poster. March 16, 2002.
57. McMeekin, S., Garcia, M., Gold, M., Johnson, G., **Walker, J. L.**, Mannel, R. S., "Stage IV Endometrial Cancer: Survival, Recurrence, and Role of Surgery", American Society of Clinical Oncology Annual Meeting, ASCO, San Francisco, CA, Accepted, Oral Presentation. May 2001.
58. Kamelle, S., Tillmanns, T. D., Gold, M. A., Gould, N. S., **Walker, J. L.**, "Adenoca of the Uterus with Cervical Extension and Adenoca of the Cervix: Are the Clinical Presentations Truly Different?", American College of Obstetrics and Gynecology Annual Meeting, ACOG, Chicago, IL, Accepted, Oral Presentation. April 2001.
59. Tillmanns, T. D., Gold, M. A., Gould, N. S., Kamelle, S. A., McMeekin, S., **Walker, J. L.**, "Hormone Replacement Practice Patterns Among Oklahoma Physicians", American College of Obstetricians and Gynecologists Annual Meeting, ACOG, Chicago, IL, Accepted, Oral Presentation. April 2001.
60. Rose, P. G., Rodriguez, M., **Walker, J. L.**, Greer, B. E., Fusco, N., McGuire, W. P., "A phase I study of oral etoposide and liposomal doxorubicin in ovarian, peritoneal and tubal carcinoma: a Gynecologic Oncology Group study", Society of Gynecologic Oncology Annual Meeting, SGO, Nashville, TN, Accepted, Oral Presentation. March 3, 2001.
61. Scribner, Jr., D. R., **Walker, J. L.**, Gould, N. S., Johnson, G. A., McMeekin, S., Gold, M. A., Mannel, R. S., "Laparoscopic pelvic and paraaortic lymph node dissection in the obese", Society of Gynecologic Oncology Annual Meeting, SGO, Nashville, TN, Accepted, Oral Presentation. March 3, 2001.
62. Scribner, Jr., D. R., **Walker, J. L.**, Johnson, G. A., McMeekin, S., Gold, M. A., Mannel, R. L., "Laparoscopic pelvic and paraaortic lymph node dissection. Analysis of the first 100 cases", Society of Gynecologic Oncology Annual Meeting, SGO, Nashville, TN, Accepted, Oral Presentation. March 3, 2001.
63. **Walker, J. L.**, "Laparoscopic versus laparotomy in the staging of endometrial cancer in the elderly", Society of Gynecologic Oncology Annual Meeting, SGO, Nashville, TN, Accepted, Oral Presentation. March 3, 2001.

64. Scribner, Jr., D. R., Bishop, L. J., **Walker, J. L.**, Johnson, G. A., McMeekin, S., Gold, M. A., Mannel, R. S., Minor, P., "Percutaneous endoscopic gastrostomy tubes for decompression of intestinal obstruction in gynecologic oncology patients", Society of Gynecologic Oncology Annual Meeting, SGO, Nashville, TN, Accepted, Oral Presentation. March 3, 2001.
65. Gould, N. S., McMeekin, S., Gold, M. A., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Modified versus Radical Vulvectomy: Does Size Really Matter?", Gynecologic Oncology Fellows' Forum, GlaxoSmithKline, Tucson, AZ, Oral Presentation. February 2001.
66. Gould, N. S., Kamelle, S. A., Gold, M. A., **Walker, J. L.**, Johnson, G. A., "Predictors of Complications After Inguinal Lymphadenectomy", American Society of Clinical Oncology Annual Meeting, ASCO, New Orleans, LA, Accepted, Oral Presentation. May 2000.
67. Gould, N. S., Kamelle, S. A., Gold, M. A., **Walker, J. L.**, "Predictors of Complications after Inguinal Lymphadenectomy", Gynecologic Oncology Fellows' Forum, Smith Kline Beecham, San Diego, CA, Oral Presentation. February 2000.
68. Gold, M. A., Alberts, D. S., **Walker, J. L.**, Berek, J. S., Hallum, A. V., Garcia, D. J., "Amifostine Pretreatment for Protection Against Topotecan-Induced Hematologic Toxicity: Results of a Multi-Center Phase II Trial in Patients with Advanced Gynecologic Malignancies", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 5, 2000.
69. McMeekin, S., Lashbrook, D., Gold, M. A., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Analysis of FIGO Stage IIIc Endometrial Cancer Patients", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 5, 2000.
70. **Walker, J. L.**, Schiffman, M., The ALTS Group, "ASCUS/LSIL Triage Study (ALTS) Enrollment Analysis of Prevalent CIN 3", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 5, 2000.
71. Scribner, D. R., Mannel, R. S., **Walker, J. L.**, Johnson, G. A., "Cost Analysis of Laparoscopy Versus Laparotomy for Early Endometrial Cancer", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 5, 2000.
72. Gold, M. A., Gould, N. S., McMeekin, S., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Oral Etoposide as a Single Agent in the Palliative Treatment of Ovarian and Primary Peritoneal Malignancies", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 5, 2000.
73. Gold, M. A., Gould, N. S., McMeekin, S., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Oral Hexamethylmelamine as a Single Agent in the Palliative Treatment of Ovarian and Primary Peritoneal Malignancies", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 5, 2000.
74. Gold, M. A., Gould, N. S., McMeekin, S., **Walker, J. L.**, "Patterns of Pap Smear Screening and the Management of Abnormal Pap Smears and Cervical Dysplasia Among Oklahoma Physicians", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 5, 2000.
75. Mannel, R. S., **Walker, J. L.**, Gould, N. S., "Successful Enrollment of Women into Cancer Clinical Trials", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 5, 2000.

76. Mannel, R. S., **Walker, J. L.**, Gould, N. S., "Successful Enrollment of Women into Cancer Clinical Trials", Society of Gynecologic Oncology Annual Meeting, SGO, San Diego, CA, Accepted, Oral Presentation. February 5, 2000.
77. Gold, M. A., Lashbrook, D. L., DiSilvestro, P. A., Gould, N. S., Scribner, D. R., McMeekin, S., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Malignant Transformation of Endometriosis", American College of Obstetrics and Gynecology Annual Meeting, ACOG, Philadelphia, PA, Accepted, Oral Presentation. June 1999.
78. Rose, P. G., Brunetto, G., VanLe, L., Bell, J., **Walker, J. L.**, Lee, R. B., "A Phase II Study of Anastrozole in Recurrent or Persistent Endometrial Carcinoma", Society of Gynecologic Oncology Annual Meeting, SGO, San Francisco, CA, Accepted, Oral Presentation. March 1999.
79. Keys, H. M., Bundy, B. N., Stehman, F. B., Muderspach, L. I., Chafe, W. E., Suggs III, C. L., **Walker, J. L.**, Gersell, D., "Weekly cisplatin chemotherapy during irradiation improves survival and reduces relapses for patients with bulky stage IB cervical cancer treated with irradiation and adjuvant hysterectomy: Results of a randomized GOG trial", 29th Annual Meeting of the Society of Gynecologic Oncologists, SGO, Oral Presentation. March 1998.
80. Shen-Gunther, J., Mannel, R. S., **Walker, J. L.**, Johnson, G. A., "Construction of the ileocolonic continent urinary reservoir: Operative technique at University of Oklahoma", Oral Presentation. 1997.
81. Khalifa, M., Chase, G. A., Lage, J. M., Sheikh, S. S., Mannel, R. S., **Walker, J. L.**, Angros, L. H., Min, K. W., "Ki-67 and proliferating cell nuclear antigen (PCNA) immunopositivity in ovarian adenocarcinoma", US and Canadian Academy of Pathology Annual Meeting, USCAP, Washington, DC, Accepted, Oral Presentation. 1996.
82. Khalifa, M., Chase, G. A., Lage, J. M., Sheikh, S. S., Mannel, R. S., **Walker, J. L.**, Angros, L. H., Min, K. W., "The assessment of the proliferative activity of ovarian adenocarcinoma by Ki-67 and proliferating cell nuclear antigen (PCNA) immunopositivity", American Society of Clinical Pathologists/College of American Pathologists, ASCP/CAP, New Orleans, LA, Accepted, Oral Presentation. October 1995.
83. Hall, M. A., **Walker, J. L.**, North American Menopause Society Meeting, San Francisco, CA, Poster. September 27, 1995.
84. Khalifa, M., Mannel, R. S., Wren, M. R., **Walker, J. L.**, Min, K. W., "Evaluation of the Gynecologic Oncology Group grading system for invasive squamous cell carcinoma of the vulva", US and Canadian Academy of Pathology Annual Meeting, USCAP, Accepted, Oral Presentation. 1994.
85. Flanagan, C. W., Mannel, R. S., **Walker, J. L.**, Johnson, G. A., "Incidence and location of para-aortic lymph node metastases in gynecologic malignancies", American College of Obstetrics and Gynecology District I & VII Meeting, ACOG, Accepted, Oral Presentation. 1994.
86. Khalifa, M., Abdoh, A., Mannel, R. S., **Walker, J. L.**, Angros, K., Min, K. W., "P-Glycoprotein as a prognostic marker in recurrent ovarian adenocarcinoma", US and Canadian Academy of Pathology Annual Meeting, USCAP, Accepted, Oral Presentation. 1994.
87. Khalifa, M., Haraway, S., Mannel, R. S., Abdoh, A., **Walker, J. L.**, Min, K. W., "Prognostic utility of EGF-R oncoprotein in papillary serous, clear cell and endometrioid-type endometrial adenocarcinomas", US and Canadian Academy of Pathology Annual Meeting, USCAP, Accepted, Oral Presentation. 1994.

88. Mannel, R. S., Wren, M., **Walker, J. L.**, "Prognostic utility of EGF-R in vulvar malignancies", 25th Annual Society of Gynecologic Oncologists Meeting, SGO, San Francisco, CA, Accepted, Oral Presentation. February 1994.
89. Mannel, R. S., Khalifa, M., Wren, M., **Walker, J. L.**, Min, K. W., Benbrook, D. M., "Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival", 26th Annual Society of Gynecologic Oncologists Meeting, ASCO, San Francisco, CA, Accepted, Oral Presentation. February 19, 1994.
90. Benbrook, D. M., Medlin, M., Rogers, R., Dunn, T., Lord, B., **Walker, J. L.**, American Association for Cancer Research, Banff, Canada, Poster. March 16, 1993.
91. Khalifa, M., Haraway, S., Mannel, R. S., Min, K. W., **Walker, J. L.**, "Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas", Society of Gynecologic Oncology Annual Meeting, SGO, Accepted, Oral Presentation. February 1993.
92. Rogers, R. S., Benbrook, D. M., **Walker, J. L.**, Lord, B. J., Haas, G. G., 48th Annual American Fertility Society Meeting, American Fertility Society, New Orleans, LA, Poster. November 2, 1992.
93. Mannel, R. S., Manetta, A., Buller, R., Braley, P., **Walker, J. L.**, Archer, S., "Use of ileocecal continent urinary reservoir in patients with previous pelvic irradiation", Society of Gynecologic Oncology Annual Meeting, SGO, Accepted, Oral Presentation. March 1992.
94. Fuchtnner, C., Manetta, A., **Walker, J. L.**, "Radical hysterectomy in the elderly patient: Analysis of morbidity", Society of Gynecologic Oncology Annual Meeting, SGO, Accepted, Oral Presentation. February 1991.
95. Mannel, R. S., Berman, M. L., **Walker, J. L.**, DiSaia, P. J., "Initial surgical therapy in the management of clinical stage II endometrial cancer", Society of Gynecologic Oncology Annual Meeting, SGO, Accepted, Oral Presentation. 1989.
96. Mannel, R. S., Berman, M. L., **Walker, J. L.**, DiSaia, P. J., "Stage II endometrial cancer: A multivariate analysis of prognostic variables in patients treated with primary surgical therapy", American College of Obstetrics and Gynecology District IX Proceedings, ACOG, Accepted, Oral Presentation. 1988.
97. Wilczynski, S., Pearlman, L., **Walker, J. L.**, "Genetic analysis of cervical carcinomas containing HPV 16 DNA", International Papillomavirus Workshop, Nice, France, Accepted, Oral Presentation. May 1988.
98. **Walker, J. L.**, Wilczynski, S. P., Liao, S., Berman, M. L., DiSaia, P. J., "Comparison of clinical and histologic features of carcinoma of the uterine cervix and the associated human papillomavirus", International Papillomavirus Workshop, Nice, France, Accepted, Oral Presentation. May 1987.

Local/Regional

1. Bishop, E. A., Nugent, E. K., Mathews, C. A., Moxley, K. M., Tenney, M. E., **Walker, J. L.**, Landrum, L. M., Moore, K., Mannel, R. S., McMeekin, S., "Body mass index (BMI) and outcomes in completely staged endometrioid adenocarcinoma of the uterus", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Park City, UT, Accepted, Oral Presentation. June 16, 2011.
2. Farrell, R., Mathews, C. A., **Walker, J. L.**, Landrum, L. M., "Cervical adenocarcinoma in the

- elderly", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Park City, UT, Accepted, Oral Presentation. June 16, 2011.
3. Nugent, E. K., Park, A. L., Barr, C. D., Bishop, E. A., Moxley, K. M., Mathews, C. A., Zuna, R. E., Wentzensen, N., Tenney, M. E., **Walker, J. L.**, Smith, K. M., "Leep results increasingly correlate with histology at colposcopy as additional cervical biopsies and ECC are performed in two step discrepancy", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Park City, UT, Accepted, Oral Presentation. June 16, 2011.
 4. Moxley, K. M., Nugent, E. K., Mathews, C. A., Tenney, M. E., **Walker, J. L.**, Landrum, L. M., Moore, K., Mannel, R. S., McMeekin, S., Bishop, E. A., "Prevalence of the metabolic syndrome in Native American patients diagnosed with adenocarcinoma of the endometrium: a retrospective case review", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Park City, UT, Accepted, Oral Presentation. June 16, 2011.
 5. Tenney, M. E., Nugent, E. K., Kimmer, J., Mathews, C. A., McMeekin, S., Mannel, R. S., Landrum, L. M., Moore, K., **Walker, J. L.**, "Robotic versus open radical hysterectomy for invasive cervical cancer: A single institution review of the first three years of practice", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Park City, UT, Accepted, Oral Presentation. June 16, 2011.
 6. Khan, S., Nugent, E. K., Mathews, C. A., Saya, S., Rathbun, S., Gold, M. A., **Walker, J. L.**, "The use of retrievable inferior vena cava filters in gynecologic oncology patients", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Park City, UT, Accepted, Oral Presentation. June 16, 2011.
 7. Landrum, L. M., Gold, M. A., Moore, K., Zorn, K. K., McMeekin, S., **Walker, J. L.**, Zuna, R. E., "Adenocarcinoma of the cervix: evaluation of HPV genotyping and outcome measures at a single institution", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Sonoma, CA, Accepted, Oral Presentation. June 11, 2008.
 8. Elfrink, S. H., Myers, T. K., Gold, M. A., **Walker, J. L.**, McMeekin, S., Moore, K., "Chemotherapy in recurrent ovarian cancer: what clinical benefit should be expected?", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Sonoma, CA, Accepted, Oral Presentation. June 11, 2008.
 9. Tuller, E. R., Tillmanns, T. D., Estep, R. E., **Walker, J. L.**, Gold, M. A., McMeekin, S., Moore, K., "Neoadjuvant chemotherapy: patterns of utilization and predictors of surgical resectability", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Sonoma, CA, Accepted, Oral Presentation. June 11, 2008.
 10. Alward, E. K., Moore, K., Frank, S. G., Landrum, L. M., Myers, T. K., **Walker, J. L.**, Gold, M. A., McMeekin, S., "Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: self-reported and objective toxicities", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Sunriver, OR, Accepted, Oral Presentation. June 6, 2007.
 11. Myers, T. K., Moore, K., Cofer, A., Landrum, L. M., Gold, M. A., **Walker, J. L.**, McMeekin, S., "Advanced ovarian cancer: is cure a reasonable expectation?", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Sunriver, OR, Accepted, Oral Presentation. June 6, 2007.
 12. Landrum, L. M., Gold, M. A., McMeekin, S., **Walker, J. L.**, "Catheter-related complications of intraperitoneal chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Sunriver, OR, Accepted, Oral Presentation. June 6, 2007.

13. Landrum, L. M., Moore, K., Myers, K. T., Lanneau, G. S., **Walker, J. L.**, Gold, M. A., "Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes?", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Sunriver, OR, Accepted, Oral Presentation. June 6, 2007.
14. Saunders, B. A., Tillmanns, T. D., Faulkner, C. A., Schultz, C., McMeekin, S., **Walker, J. L.**, Mannel, R. S., Johnson, G. A., Wan, Y. J., Zuna, R. E., Gold, M. A., "A retrospective analysis of leep specimens to determine the optimal depth to maximize negative margin rate", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Santa Fe, NM, Accepted, Oral Presentation. June 2005.
15. Moore, K., Zorn, K. K., McMeekin, S., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Extraperitoneal lymphadenectomy via pfannenstiel incision in advanced cervical cancer", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Santa Fe, NM, Accepted, Oral Presentation. June 2005.
16. **Walker, J. L.**, "Fistula formation in patients with stage IVA cervical carcinoma", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Santa Fe, NM, Accepted, Oral Presentation. June 2005.
17. Moore, K., Zorn, K. K., McMeekin, S., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., Gold, M. A., "Identification of positive paraaortic lymph nodes in extraperitoneal lymph node dissection for cervical cancer: a comparison of para-median and pfannenstiel approach", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Santa Fe, NM, Accepted, Oral Presentation. June 2005.
18. Falkner, C. A., Zorn, K. K., Hyde, Jr., J., Dearnley, D. D., Moore, K., Rutledge, T. L., Gold, M. A., **Walker, J. L.**, Mannel, R. S., McMeekin, S., "Integrating peer review of medical literature into gynecologic oncology training", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Santa Fe, NM, Accepted, Oral Presentation. June 2005.
19. Zorn, K. K., Moore, K., McMeekin, S., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., Gold, M. A., "Survival in patients with cervical cancer metastasis to the para-aortic lymph nodes", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Santa Fe, NM, Accepted, Oral Presentation. June 2005.
20. Moore, K., McMeekin, S., Gold, M. A., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "The role of sequential salvage chemotherapy regimens in patients with advanced and recurrent endometrial cancer", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Santa Fe, NM, Accepted, Oral Presentation. June 2005.
21. Rutledge, T. L., Gold, M. A., Johnson, G. A., McMeekin, S., **Walker, J. L.**, Mannel, R. S., "Carcinosarcoma of the ovary", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Steamboat Springs, CO, Accepted, Oral Presentation. June 25, 2003.
22. Tillmanns, T. D., Chaudry, T., Gold, M. A., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., McMeekin, S., "Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Steamboat Springs, CO, Accepted, Oral Presentation. June 25, 2003.
23. Falkner, C. A., Tillmanns, T. D., McMeekin, S., **Walker, J. L.**, Gold, M. A., "Two-step discrepancy as an indication for LEEP", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Steamboat Springs, CO, Accepted, Oral Presentation. June 25, 2003.

24. Rutledge, T. L., Kamelle, S. A., Tillmanns, T. D., Gould, N. S., Gold, M. A., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., McMeekin, S., "Number of nodal metastasis in IB cervical cancer: a predictor of distance recurrence", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Newport Beach, CA, Accepted, Oral Presentation. June 2002.
25. Tillmanns, T. D., Nazareth, S., Kemelle, S. A., McMeekin, S., **Walker, J. L.**, Gold, M. A., "Age is a Predictor of Deep Endocervical Involvement on LEEP", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Sun Valley, ID, Accepted, Oral Presentation. June 2001.
26. Tillmanns, T. D., Kamelle, S. A., McMeekin, S., **Walker, J. L.**, Gold, M. A., "Clinical Trials in Cervical Cancer: A Report Card for the GOG", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Sun Valley, ID, Accepted, Oral Presentation. June 2001.
27. Gould, N. S., McMeekin, S., Gold, M. A., Johnson, G. A., **Walker, J. L.**, Mannel, R. S., "Modified versus Radical Vulvectomy: Does Size Really Matter?", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Sun Valley, ID, Accepted, Oral Presentation. June 2001.
28. Kamelle, S. A., Gould, N., **Walker, J. L.**, "Stage II adenocarcinoma of the uterus and adenocarcinoma of the cervix: Are there clinical presentations truly different?", Annual Gyn Oncology Fellows Forum, Oklahoma City, OK, Oral Presentation. 2000.
29. Gould, N. S., Kamelle, S. A., Gold, M. A., **Walker, J. L.**, Johnson, G. A., "Predictors of Complications After Inguinal Lymphadenectomy", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Monterey, CA, Accepted, Oral Presentation. May 2000.
30. Scribner, Jr., D. R., Mannel, R. S., **Walker, J. L.**, Johnson, G. A., "Cost analysis of laparoscopy versus laparotomy for early endometrial cancer", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Victoria, British Columbia, Accepted, Oral Presentation. June 1999.
31. DiSilvestro, P. A., Gold, M. A., Biscopink, R. J., Mannel, R. S., Johnson, G. A., **Walker, J. L.**, "Significance of estrogen and progesterone receptor status in patients with malignancies arising in endometriosis, a case series", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Napa, CA, Accepted, Oral Presentation. May 1998.
32. Scribner, D. S., **Walker, J. L.**, Johnson, G. A., Mannel, R. S., Gold, M. A., "Neurotoxicity associated with IV and IP Paclitaxel combined with IP Cisplatin in patients with stage III ovarian carcinoma or primary peritoneal carcinoma", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Napa, CA, Accepted, Oral Presentation. May 20, 1998.
33. Gold, M. A., Sienko, A. N., **Walker, J. L.**, "Uterine malignancies in women previously treated for breast cancer", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Napa, CA, Accepted, Oral Presentation. May 20, 1998.
34. Shen-Gunther, J., Mannel, R. S., **Walker, J. L.**, Johnson, G. A., "Outpatient implantation of the Port-a-Cath II fluoro-free venous access system in gynecologic oncology patients", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Alberta, Canada, Accepted, Oral Presentation. June 11, 1997.
35. Parker, L. P., **Walker, J. L.**, "Cervical conization: A comparison of large loop excision of the transformation zone (LLETZ) and cold knife cone", Tiger Day, University of Oklahoma Department of Obstetrics & Gynecology, Oklahoma City, OK, Accepted, Oral Presentation. 1995.
36. Hall, M. A., **Walker, J. L.**, "Treatment of endometrial hyperplasia", Tiger Day, University of Oklahoma Department of Obstetrics & Gynecology, Oklahoma City, OK, Accepted, Oral

Presentation. 1995.

37. Stone, D. G., Mannel, R. S., **Walker, J. L.**, "Typing and incidence of human papillomavirus in cervical cancer", Tiger Day, University of Oklahoma Department of Obstetrics & Gynecology, Oklahoma City, OK, Accepted, Oral Presentation. 1994.
38. Flanagan, C. W., **Walker, J. L.**, "Characteristics of para-aortic lymphatic metastasis in gynecologic malignancies", Tiger Day, University of Oklahoma Department of Obstetrics & Gynecology, Oklahoma City, OK, Accepted, Oral Presentation. 1993.
39. Engelbrecht, V., **Walker, J. L.**, "To drain or not to drain: A study of closed-suction drainage following lymphadenectomy in gynecologic malignancies", Tiger Day, University of Oklahoma Department of Obstetrics & Gynecology, Oklahoma City, OK, Accepted, Oral Presentation. 1993.
40. Cobb, J., **Walker, J. L.**, "Second look laparotomy outcomes as predicted by CA-125 levels", Tiger Day, University of Oklahoma Department of Obstetrics & Gynecology, Oklahoma City, OK, Accepted, Oral Presentation. 1991.
41. Mannel, R. S., DiSaia, P. J., Chapman, J. A., **Walker, J. L.**, Berman, M. L., "Management of unexpected cervical cancer found at the time of simple hysterectomy", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, San Francisco, CA, Accepted, Oral Presentation. May 1989.
42. Cha, D., Berman, M. L., **Walker, J. L.**, Mannel, R. S., DiSaia, P. J., "The influence of various factors on survival of cervical cancer patients treated by radical hysterectomy and adjuvant postoperative radiotherapy", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, San Francisco, CA, Accepted, Oral Presentation. May 1989.
43. **Walker, J. L.**, Wilczynski, S. P., Bergen, S., Sheets, E., Berman, M. L., DiSaia, P. J., "Association of human papillomavirus with adenocarcinoma of the uterine cervix", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Jackson Hole, WY, Accepted, Oral Presentation. June 1988.
44. Mannel, R. S., Berman, M. L., Rettenmaier, M. A., **Walker, J. L.**, Sheets, E. E., DiSaia, P. J., "Evaluation of clinical stage II endometrial cancer treated with primary surgical therapy", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Tucson, AZ, Accepted, Oral Presentation. May 1987.
45. **Walker, J. L.**, Wilczynski, S. P., Bergen, S., Sheets, E., Rettenmaier, M. A., Berman, M. L., DiSaia, P. J., "Is cervical cancer in young women a different disease?", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Tucson, AZ, Accepted, Oral Presentation. May 1987.
46. Mannel, R. S., Berman, M. L., **Walker, J. L.**, Sheets, E. E., Rettenmaier, M. A., DiSaia, P. J., "Surgical management of stage II endometrial carcinoma", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Tucson, AZ, Accepted, Oral Presentation. May 1987.

Other Presentations

* indicates mentee

National/International

1. **Walker, J. L.**, "The impact of body mass index on survival outcomes in early stage endometrial cancer: an individual participant data meta-analysis of trial data (OCTOPUS).", RCOG OCTOPUS, Virtual Platform, Accepted, Abstract. October 13, 2021.

2. **Walker, J. L.**, "Cancer Prevention and Control Committee Report", NRG Oncology Summer 2021 Virtual Meeting, NRG Oncology, Virtual Platform, Accepted, Oral Presentation. July 24, 2021.
3. **Walker, J. L.**, "Phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube and primary peritoneal carcinoma", NRG Oncology Summer 2021 Virtual Meeting, NRG Oncology, Virtual Platform, Accepted, Oral Presentation. July 23, 2021.
4. **Walker, J. L.**, "NRG Plenary Session", NRG Oncology Summer 2021 Virtual Meeting, NRG Oncology, Virtual Platform, Accepted, Panel. July 22, 2021.
5. **Walker, J. L.**, Huh, W., "Salpingectomy Recruitment Strategies", NRG Oncology Summer 2021 Virtual Meeting, NRG Oncology, Virtual Platform, Accepted, Panel. July 22, 2021.
6. **Walker, J. L.**, "Welcome and Objectives", NCORP 2019 Retreat, NRG Oncology, Philadelphia, PA, Invited, Keynote/Plenary Address. November 4, 2019.
7. **Walker, J. L.**, "TBD", SGO 50th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Honolulu, HI, Accepted, Oral Presentation. March 15, 2019.
8. Slomovitz, B., Filiaci, V. L., Coleman, R. L., **Walker, J. L.**, Fleury, A. C., Holman, L. L., Miller, D. S., "GOG 3007: A randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent, or recurrent endometrial carcinoma (EC): A GOG Foundation study [Abstract 1]", SGO 49th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, New Orleans, LA, Oral Presentation. March 27, 2018.
9. **Walker, J. L.**, "HPV vaccination", Montana and Idaho Section of ACOG Annual Meeting, American Congress of Gynecologists, Big Sky, MT, Oral Presentation. January 28, 2017.
10. **Walker, J. L.**, "Prevention of ovarian cancer", Montana and Idaho Section of ACOG Annual Meeting, American Congress of Gynecologists, Big Sky, MT, Oral Presentation. January 28, 2017.
11. **Walker, J. L.**, "Prevention of endometrial cancer", Montana and Idaho Section of ACOG Annual Meeting, American Congress of Gynecologists, Big Sky, MT, Oral Presentation. January 27, 2017.
12. Armstrong, D., MacKay, H., **Walker, J. L.**, "Preliminary Results of GOG 252", Society of Gynecologic Oncologists Annual Meeting, SGO Connect Ed, Chicago, IL, Invited, Video Panel Discussion. June 5, 2016.
13. **Walker, J. L.**, "Surgical Approaches to Cervical Cancer", NRG Oncology Semiannual Meeting, NRG Oncology, Chicago, IL, Invited, Oral Presentation. July 14, 2014.
14. **Walker, J. L.**, "Clinical trials and drug repurposing", 45th Annual Meeting on Women's Cancer, SGO, Tampa, FL, Discussant for featured poster session IV and Abstracts 94-105. March 2014.
15. Bishop, E. A., Java, J., Moore, K., **Walker, J. L.**, "Operative outcomes among a geriatric population of endometrial cancer patients: An ancillary data analysis of Gynecologic Oncology Group study LAP2", Society of Gynecologic Oncologists Annual Meeting, SGO, Tampa, FL, Accepted, Focused Plenary. March 2014.
16. **Walker, J. L.**, Society of Gynecologic Oncology Annual Meeting, SGO, Los Angeles, CA, Poster. March 2013.
17. **Walker, J. L.**, "Current situations and new developments in IP chemotherapy", 9th International

- Symposium Advanced Ovarian Cancer: Optimal Therapy - Update, Valencia, Spain, Oral Presentation. March 1, 2013.
18. **Walker, J. L.**, "Ovarian cancer management - On the front line", Gynecologic Oncology Group Semi-Annual Business Meeting, GOG, San Diego, CA, Oral Presentation. January 2013.
 19. **Walker, J. L.**, "Disease management - Ovarian cancer", 8th International World Congress on Peritoneal Surface Malignancies, International World Congress, Berlin, Germany, Oral Presentation. October 2012.
 20. **Walker, J. L.**, Rader, J., "Chemoprevention for cervical, endometrial and ovarian cancer: Fact or fantasy? (cervical portion)", Gynecologic Oncology Group Symposium at the 78th Semi-Annual Meeting of the Gynecologic Oncology Group, GOG, Garden Grove, CA, Oral Presentation. January 22, 2009.
 21. **Walker, J. L.**, "U.S. cancer prevention in the era of HPV vaccine: Will we tolerate failure", Board of Scientific Advisors, National Cancer Institute, Bethesda, MD, Oral Presentation. November 15, 2007.
 22. **Walker, J. L.**, "Endometrial cancer: To scope or not to scope", Society of Gynecologic Oncologists Summer Meeting, SGO, Rohnert Park, CA, Oral Presentation. August 2007.
 23. **Walker, J. L.**, Gold, M. A., "Gynecologic oncology for the generalist", American College of Obstetricians and Gynecologists Annual Clinical Meeting, ACOG, San Diego, CA, Oral Presentation. May 2007.
 24. **Walker, J. L.**, "Surgical aspects", 38th Annual Society of Gynecologic Oncologists, SGO, San Diego, CA, Discussant at Focused Plenary Session II. March 2007.
 25. **Walker, J. L.**, "Gyn cancer care of the obese: Surgery and beyond", 38th Annual Society of Gynecologic Oncologists, SGO, San Diego, CA, Oral Presentation. March 2007.
 26. **Walker, J. L.**, 38th Annual Society of Gynecologic Oncologists, SGO, San Diego, CA, Session Moderator. March 2007.
 27. **Walker, J. L.**, "Update on IP therapy for epithelial ovarian cancer: Update on GOG trials in IP therapy", Controversies in Gynecology XII, SGO, Beaver Creek, CO, Oral Presentation. February 2007.
 28. **Walker, J. L.**, "Upcoming clinical trials: GOG and others", SGO Intraperitoneal Chemotherapy: A State of the Art Conference, SGO, Chicago, IL, Oral Presentation. December 9, 2006.
 29. **Walker, J. L.**, "Placement of ports: Video presentation", SGO Intraperitoneal Chemotherapy: A State of the Art Conference, SGO, Chicago, IL, Video Presentation. December 9, 2006.
 30. **Walker, J. L.**, "Lap II", Biennial International Gynecologic Cancer Society Meeting, IGCS, Santa Monica, CA, Oral Presentation. October 2006.
 31. **Walker, J. L.**, "Ovarian cancer and intraperitoneal cisplatin therapy", Gynecologic Oncology Group Semi-Annual Meeting, GOG, Washington, DC, Roundtable. July 21, 2006.
 32. **Walker, J. L.**, "Prevalence of symptoms of ovarian cancer", UICC World Cancer Congress, Centers for Disease Control and Prevention and National Cancer Institute, Washington, DC, Oral Presentation. July 9, 2006.

33. **Walker, J. L.**, 2006 Annual Meeting of the American Society of Clinical Oncology, ASCO, Atlanta, GA, Poster Discussion. June 4, 2006.
34. **Walker, J. L.**, "Intraperitoneal therapy", National Ovarian Cancer Association Symposium, National Ovarian Cancer Association, Windsor, Canada, Oral Presentation. May 6, 2006.
35. **Walker, J. L.**, "Impact of HPV on current screening programs", Society of Gynecologic Oncologists Annual Meeting, SGO, Palm Springs, CA, Oral Presentation. March 2006.
36. **Walker, J. L.**, "Laparoscopy debate (Ethicon-Endo)", Society of Gynecologic Oncologists Annual Meeting, SGO, Palm Springs, CA, Oral Presentation. March 2006.
37. **Walker, J. L.**, "IP chemotherapy", Austrian Association of Gynecologic Oncologists, Innsbruck, Austria, Oral Presentation. February 2006.
38. **Walker, J. L.**, "IP chemotherapy symposium", Gynecologic Oncology Semi-Annual Meeting, SGO, San Diego, CA, Oral Presentation. January 2006.
39. **Walker, J. L.**, "Peritoneal delivery systems & complications of IP therapy", First International Symposium on Regional Cancer Therapies, International Society for Regional Cancer Therapy, Snowmass Village, CO, Oral Presentation. January 2006.
40. **Walker, J. L.**, "Intraperitoneal catheter outcomes on GOG 172: A Gynecologic Oncology Group study in women with optimally debulked stage III ovarian cancer", 10th Biennial International Gynecologic Cancer Society Meeting, IGCS, Edinburgh, Scotland, Oral Presentation. October 7, 2004.
41. **Walker, J. L.**, GOG LAP II Protocol Chart Review, GOG, Buffalo, NY, Chart Reviewer. April 2003.
42. **Walker, J. L.**, "ASCUS/LSIL triage study - The main results", American College of Obstetricians and Gynecologists 52st Annual Clinical Meeting, ACOG, New Orleans, LA, Oral Presentation. April 2003.
43. **Walker, J. L.**, Gynecologic Oncology Group Interim Protocol Meeting, GOG, Buffalo, NY, Participant. April 2003.
44. **Walker, J. L.**, "Meet the professor sessions and abstract evaluation", 2003 National Gynecologic Oncology Fellows' Forum, Phoenix, AZ, Participant. February 2003.
45. **Walker, J. L.**, "ASCCP guidelines and the American Cancer Society cervical cancer Screening guidelines", 34th Annual Meeting of the Society of Gynecologic Oncologists, SGO, New Orleans, LA, Oral Presentation. January 2003.
46. **Walker, J. L.**, "Changing paradigms in cervical cancer screening - The Bethesda system", 34th Annual Meeting of the Society of Gynecologic Oncologists, SGO, New Orleans, LA, Oral Presentation. January 2003.
47. **Walker, J. L.**, Gynecologic Oncology Group Site Visit Rehearsal, Semi-Annual Meeting, Savannah, GA, Participant. January 2003.
48. **Walker, J. L.**, "Surgical Forum Program", American College of Surgeons Clinical Congress, ACS, San Francisco, CA, Discussant. October 2002.
49. **Walker, J. L.**, "GOG Site Visit Rehearsal", Interim Protocol Committee, Philadelphia, PA,

Participant. October 2002.

50. **Walker, J. L., A. G.**, "ALTS data update", Current Trends in Obstetrics and Gynecology, 41st Annual OB/GYN Update 2002 Fall Symposium, Department of Obstetrics and Gynecology, University of Oklahoma College of Medicine; Maternal and Child Health Services at the Oklahoma State Department of Health; and the Oklahoma Chapter of the American College of Obstetricians and Gynecologists, Oklahoma City, OK, Oral Presentation. September 2002.
51. **Walker, J. L.**, "Mini pearls of wisdom", Cancer Pilot Collaborative Learning Session 2, Institute of Healthcare Improvement, Reston, VA, Oral Presentation. September 2002.
52. **Walker, J. L.**, "Topics in gynecologic oncology", Current Trends in Obstetrics and Gynecology, 41st Annual OB/GYN Update 2002 Fall Symposium, Department of Obstetrics and Gynecology, University of Oklahoma College of Medicine; Maternal and Child Health Services at the Oklahoma State Department of Health; and the Oklahoma Chapter of the American College of Obstetricians and Gynecologists, Oklahoma City, OK, Oral Presentation. September 2002.
53. **Walker, J. L.**, "Luncheon Roundtable Discussions", Current Trends in Obstetrics and Gynecology, 41st Annual OB/GYN Update 2002 Fall Symposium, Department of Obstetrics and Gynecology, University of Oklahoma College of Medicine; Maternal and Child Health Services at the Oklahoma State Department of Health; and the Oklahoma Chapter of the American College of Obstetricians and Gynecologists, Oklahoma City, OK, Roundtable. September 2002.
54. **Walker, J. L.**, "Data safety monitoring committee should only review toxicity - Pro and con debate", Vancouver Symposium: Controversies in Clinical Trials Design, GOG Annual Meeting, Vancouver, BC, Oral Presentation. July 25, 2002.
55. Hoskins, W., **H.**, "Interim analysis of randomized trials should only be done to monitor for significant differences in toxicity", Pro and con debate - Controversies in clinical trials design, Vancouver Symposium and GOG Meeting, Vancouver, BC, Oral Presentation. July 25, 2002.
56. **Walker, J. L.**, "Abnormal Pap smears", Society of Canadian Colposcopists and Society of Gynecologic Oncologists of Canada Meetings, SCO and SGO, Winnipeg, Manitoba, Canada, Oral Presentation. June 2002.
57. **Walker, J. L.**, "Access and barriers to novel therapies in the treatment of recurrent epithelial cancer", Society of Canadian Colposcopists and Society of Gynecologic Oncologists of Canada Meetings, SCO and SGO, Winnipeg, Manitoba, Canada, Oral Presentation. June 2002.
58. **Walker, J. L., A. G.**, "ALTS Trial - Perspective on the diagnosis of LSIL", Society of Canadian Colposcopists and Society of Gynecologic Oncologists of Canada Meetings, SCO and SGO, Winnipeg, Manitoba, Canada, Oral Presentation. June 2002.
59. Taplin, S., Brooks, D., **Walker, J. L.**, "Opening plenary: What is the gap in cancer screening in follow-up and where do we fit in?", Bureau of Primary Health Care Cancer Pilot Learning Session, Bureau of Primary Health Care Cancer, Denver, CO, Oral Presentation. June 2002.
60. **Walker, J. L.**, "Presentation of new LSIL guidelines", Society of Canadian Colposcopists and Society of Gynecologic Oncologists of Canada Meetings, SCO and SGO, Winnipeg, Manitoba, Canada, Oral Presentation. June 2002.
61. Taplin, S., Brooks, D., **Walker, J. L.**, "Screening techniques and recommended follow-up", Bureau of Primary Health Care Cancer Pilot Learning Session - Changing Practices/Changing Lives, Bureau of Primary Health Care Cancer, Denver, CO, Oral Presentation. June 2002.

62. **Walker, J. L.**, Cox, T. J., A. G., "ALTS ASCUS/LSIL triage study: The main results", 50th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, ACOG, Los Angeles, CA, Oral Presentation. May 2002.
63. **Walker, J. L.**, "Gestational trophoblastic disease", 50th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, ACOG, Los Angeles, CA, Oral Presentation. May 2002.
64. **Walker, J. L.**, "Chemoprevention", 2nd International Conference on Cervical Cancer, M.D. Anderson Cancer Center, the National Cancer Institute and Johns Hopkins University, Houston, TX, Oral Presentation. April 2002.
65. **Walker, J. L.**, American College of Obstetricians and Gynecologists Legislative Workshop, ACOG, Washington, DC, Participant. April 2002.
66. **Walker, J. L.**, "HPV vaccine", 33rd Annual Society of Gynecologic Oncologists Meeting, SGO, Miami Beach, FL, Meet the Professor Session. March 2002.
67. **Walker, J. L.**, "Adenocarcinoma in-situ of the cervix - minimalistic vs aggressive approaches", 33rd Annual Society of Gynecologic Oncologists Meeting, SGO, Miami Beach, FL, Poster. March 2002.
68. **Walker, J. L.**, Gynecologic Oncology Group Semi Annual Meeting, GOG, New Orleans, LA, Participant. January 2002.
69. **Walker, J. L.**, "Reducing health disparities in high cervical cancer mortality regions", Center to Reduce Cancer Health Disparities and Division of Cancer Control and Population Sciences at the National Cancer Institute, Corpus Christi, TX, Roundtable. November 2001.
70. **Walker, J. L.**, "Management of LSIL Pap smears", ASCCP/NCI Consensus Conference, ASACCP/NCI, Bethesda, MD, Oral Presentation. September 2001.
71. **Walker, J. L.**, "HPV/cervical cancer update", 2001 Alabama Section ACOG Annual Meeting, ACOG, Sandestin Beach, FL, Oral Presentation. May 2001.
72. **Walker, J. L.**, "Laparoscopic management of the adnexal mass", 2001 Alabama Section ACOG Annual Meeting, ACOG, Sandestin Beach, FL, Oral Presentation. May 2001.
73. **Walker, J. L.**, "Gynecologic oncology for the generalist", ACOG's 50th Anniversary Meeting, ACOG, Chicago, IL, Workshop. April 2001.
74. **Walker, J. L.**, Society of Gynecologic Oncologists 32nd Annual Meeting, SGO, Nashville, TN, Oral Presentation. March 2001.
75. **Walker, J. L.**, "The effects of tamoxifen", Society of Radiologists in Ultrasound Consensus Conference on Post-Menopausal Bleeding, Washington, DC, Oral Presentation. October 2000.
76. **Walker, J. L.**, "Debate - Surgical staging improves survival in patients with advanced cervical cancer", Society of Gynecologic Oncologists 2000 Winter Meeting, SGO, Park City, UT, Oral Presentation. March 2000.
77. **Walker, J. L.**, "New techniques in cervical cancer screening and update on ASCUS trial", Society of Gynecologic Oncologists 2000 Winter Meeting, SGO, Park City, UT, Oral Presentation. March 2000.

78. **Walker, J. L.**, Schiffman, M., A. G., "ASCUS/LSIL triage study (ALTS) enrollment analysis of prevalent CIN 3", 31st Annual Meeting of the SGO, Society of Gynecologic Oncology, San Diego, CA, Poster. February 2000.
79. **Walker, J. L.**, "Grant writing course", National Cancer Institute, Washington, DC, Oral Presentation. November 1999.
80. **Walker, J. L.**, "Abnormal Pap smears", 12th Annual Winter Symposium, University of Oklahoma Health Sciences Center, Maricopa Medical Center of Phoenix, Texas Tech University Health Sciences Center and Pennsylvania State University, Aspen, CO, Oral Presentation. January 1999.
81. **Walker, J. L.**, "Adnexal masses workup", 12th Annual Winter Symposium, University of Oklahoma Health Sciences Center, Maricopa Medical Center of Phoenix, Texas Tech University Health Sciences Center and Pennsylvania State University, Aspen, CO, Oral Presentation. January 1999.
82. **Walker, J. L.**, "Clinical management of abnormal Pap smears - the ALTS trial and the role of HPV testing", 17th Annual International Papillomavirus Conference, Charleston, SC, Oral Presentation. January 1999.
83. **Walker, J. L.**, "Human papilloma virus", ACOG District VIII and IX and Pacific Northwest Review of Obstetrics and Gynecology Annual Meeting, ACOG District VIII and IX, Portland, OR, Oral Presentation. October 1998.
84. **Walker, J. L.**, "Management of ASCUS", ACOG District VIII and IX and Pacific Northwest Review of Obstetrics and Gynecology Annual Meeting, ACOG District VIII and IX, Portland, OR, Oral Presentation. October 1998.
85. **Walker, J. L.**, ACOG District VIII and IX and Pacific Northwest Review of Obstetrics and Gynecology Annual Meeting, ACOG District VIII and IX, Portland, OR, Panel. October 1998.
86. **Walker, J. L.**, "Controversies in endometrial pathology", Society of Gynecologic Oncologists Winter Meeting, SGO, Snowbird, UT, Oral Presentation. March 22, 1996.
87. **Walker, J. L.**, "Controversies in endometrial pathology", Society of Gynecologic Oncologists Winter Meeting, SGO, New Orleans, LA, Oral Presentation. February 1996.
88. **Walker, J. L.**, "Early detection and prevention of cervix cancer, high risk patients and 'one-stop' management", Gynecologic Oncology Group Cancer Prevention Committee Meeting, GOG, Atlanta, GA, Oral Presentation. October 1995.
89. **Walker, J. L.**, "Endometrial hyperplasia management", Gynecologic Oncology Group Cancer Prevention Committee Meeting, GOG, Atlanta, GA, Oral Presentation. October 1995.
90. **Walker, J. L.**, "Vulvar disease", Obstetrics and Gynecology Review Course, Osler Institute, Dallas, TX, Oral Presentation. September 15, 1995.
91. Khalifa, M., Haraway, S., Mannel, R. S., Min, K. W., **Walker, J. L.**, "P-glycoprotein as a prognostic marker in recurrent ovarian adenocarcinoma", U.S.-Canadian Academy of Pathology, San Francisco, CA, Oral Presentation. 1994.
92. **Walker, J. L.**, "Vulvar & vaginal in situ neoplasia and vulvar carcinoma", Obstetrics and gynecology board review course, The Osler Institute, Board Review Course. August 1994.
93. **Walker, J. L.**, 8th Annual Winter Symposium, Family Medicine and Obstetrics and Gynecology

Specialties: Collaboration in the 90's, Aspen, CO, Moderator. January 29, 1994.

94. **Walker, J. L.**, "HPV and dysplasia", 8th Annual Winter Symposium, Family Medicine and Obstetrics and Gynecology Specialties: Collaboration in the 90's, Aspen, CO, Oral Presentation. January 29, 1994.
95. **Walker, J. L.**, "Preventing GYN malignancies", 7th Annual Winter Symposium, Family Medicine and Obstetrics and Gynecology Specialties: Collaboration in the 90's, Oral Presentation. February 1993.
96. Khalifa, M. A., Mannel, R. S., Haraway, S. D., **Walker, J. L.**, Min, K. Y., "Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas", Society of Gynecologic Oncologists Annual Meeting, SGO, Palm Desert, CA, Accepted, Poster. February 1993.
97. **Walker, J. L.**, "HPV and cervical dysplasia: When is treatment necessary?", Annual Scientific Assembly, National Medical Association, OB/GYN Section, San Francisco, CA, Oral Presentation. August 1992.
98. **Walker, J. L.**, "Abnormal Pap smears and colposcopy", 5th Annual Winter Symposium, Family Medicine and Obstetrics and Gynecology Specialties: Collaboration in the 90's, Aspen, CO, Oral Presentation. February 1991.
99. **Walker, J. L.**, "Experience with HPV and genital cancer", IV International Symposium on Gynecologic Oncology, Surgery and Urology, Newport Beach, CA, Oral Presentation. April 1989.
100. **Walker, J. L.**, Wilczynski, S. P., Liao, S., Berman, M. L., DiSaia, P. J., "Comparison of clinical and histologic features of carcinoma of the uterine cervix and the associated human papillomavirus", International Papillomavirus Workshop, Nice, France, Accepted, Oral Presentation. May 1988.
101. Wilczynski, S., Pearlman, L., **Walker, J. L.**, "Genetic analysis of cervical carcinomas containing HPV 16 DNA", International Papillomavirus Workshop, Nice, France, Oral Presentation. May 1988.

Local/Regional

1. **Walker, J. L.**, "Developing Translational Research Projects using GOG/NRG Biospecimens", Gynecologic Cancers Program Think Tank, NRG, Oklahoma City, OK, Accepted, Oral Presentation. September 28, 2018.
2. **Walker, J. L.**, "Molecular Evidence for Cancer Prevention", 2018 Frontiers in Translational Cancer Research, OUHSC Office of Cancer Research, Accepted, Oral Presentation. May 11, 2018.
3. Rowland, M. R., Ruskin, R., Moore, K., **Walker, J. L.**, Landrum, L. M., Matzo, M., "Identifying gynecologic oncology patients with high symptom burden", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Santa Rosa, CA, Accepted, Poster. June 2015.
4. Rowland, M. R., Ruskin, R., Prammanasudh, C., Walter, A. C., Slaughter, K. N., Moore, K., Landrum, L. M., **Walker, J. L.**, Matzo, M., "Older versus younger gynecologic cancer patients: Differences in symptom experience", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Santa Rosa, CA, Accepted, Poster. June 2015.
5. Rowland, M. R., Ruskin, R., Prammanasudh, C., Walter, A. C., Slaughter, K. N., Moore, K., Landrum, L. M., **Walker, J. L.**, Matzo, M., "Symptom burden in elderly gynecologic cancer patients", Western Association of Gynecologic Oncologists Annual Meeting, WAGO, Santa Rosa, CA, Accepted, Poster. June 2015.

6. **Walker, J. L.**, "Patient centered conversation with the HOPE Group", Peggy and Charles Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, Conversation. September 21, 2013.
7. **Walker, J. L.**, "Women's Health Issues - Presented to MS I-II", Academic Afternoon, University of Oklahoma, Oklahoma City, OK, Oral Presentation and Q&A Panel. March 2, 2012.
8. **Walker, J. L.**, "Cervical & ovarian cancer", 13th Annual Primary Care Update 2010, University of Oklahoma College of Medicine, Oklahoma City, OK, Oral Presentation. May 13, 2010.
9. **Walker, J. L.**, "Cervical cancer prevention in the era of prophylactic vaccines", Oklahoma Section Conference, Association of Women's Health, Obstetric and Neonatal Nurses, Norman, OK, Oral Presentation. April 5, 2010.
10. **Walker, J. L.**, "Ovarian cancer screening and prevention", Ovarian Cancer Research Fund Super Luncheon, Ovarian Cancer Research Fund, Oklahoma City, OK, Keynote/Plenary Address. September 2, 2009.
11. **Walker, J. L.**, "Cervical cancer: What is new?", 40th Annual OB/GYN Spring Symposium, Medical University of South Carolina, Charleston, SC, Oral Presentation. March 2009.
12. **Walker, J. L.**, "Ovarian cancer: Screening, symptoms and risk reducing strategies", 40th Annual OB/GYN Spring Symposium, Medical University of South Carolina, Charleston, SC, Oral Presentation. March 2009.
13. **Walker, J. L.**, "Prevention of cervical cancer: Screening guidelines", 40th Annual OB/GYN Spring Symposium, Medical University of South Carolina, Charleston, SC, Oral Presentation. March 2009.
14. **Walker, J. L.**, "Ovarian cancer prevention", Ovarian Cancer Research Fund Luncheon, Tulsa, OK, Guest Lecturer. October 18, 2007.
15. **Walker, J. L.**, "HPV vaccine", University of Kansas School of Medicine - Wichita Campus, Wichita, KS, Visiting Professor. October 10, 2007.
16. **Walker, J. L.**, "Use of laparoscopy in gynecologic oncology", University of Kansas School of Medicine - Wichita Campus, Wichita, KS, Visiting Professor. October 10, 2007.
17. **Walker, J. L.**, "HPV vaccine", Southwestern Medical Center, Lawton, OK, Lecture. May 22, 2007.
18. **Walker, J. L.**, "HPV vaccine and recommendations", Oklahoma City Area Indian Health Summit "Health Challenges in Indian Country", Tulsa, OK, Oral Presentation. September 13, 2006.
19. **Walker, J. L.**, "Cervical cancer and other human papillomavirus related diseases", Oklahoma Association of Family Physicians Annual Meeting, OAFP, Oklahoma City, OK, Oral Presentation. June 17, 2006.
20. **Walker, J. L.**, "Ovarian cancer", Oklahoma Association of Family Physicians Annual Meeting, OAFP, Oklahoma City, OK, Oral Presentation. June 17, 2006.
21. **Walker, J. L.**, "Abnormal Paps and ASCCP guidelines", 9th Annual Primary Care Update, University of Oklahoma College of Medicine, Department of Family & Preventive Medicine and the Irwin H. Brown Office of Continuing Medical Education, Oklahoma City, OK, Oral Presentation. May 20, 2006.

22. **Walker, J. L.**, "Ovarian cancer update", 9th Annual Primary Care Update, University of Oklahoma College of Medicine, Department of Family & Preventive Medicine and the Irwin H. Brown Office of Continuing Medical Education, Oklahoma City, OK, Oral Presentation. May 20, 2006.
23. **Walker, J. L.**, "Ovarian cancer awareness", 8th Annual OU Women's Health Conference - Women's Health for Life, University of Oklahoma, Tulsa, OK, Keynote/Plenary Address. May 17, 2006.
24. **Walker, J. L.**, The Group Room (radio broadcast show), Participant. April 23, 2006.
25. **Walker, J. L.**, "HPV vaccine", Oklahoma State Department of Health "Take Charge" Nurses, Oklahoma City, OK, Lecture. April 13, 2006.
26. **Walker, J. L.**, "IP chemotherapy", HOPE Support Group, Helping Ovarian Cancer Patients Everywhere (HOPE), Oklahoma City, OK, Oral Presentation. March 4, 2006.
27. **Walker, J. L.**, "Prevention of cervical cancer, vaccines and recent advances", Oklahoma Society of Clinical Oncology, Tulsa, OK, Oral Presentation. February 2006.
28. **Walker, J. L.**, "Pap smear update", Hillcrest Medical Center Fall Medical Update, Hillcrest Medical Center, Kansas City, KS, Oral Presentation. October 15, 2005.
29. **Walker, J. L.**, "Early screening and detection of ovarian cancer", OSMA Women in Medicine, Oklahoma State Medical Association, Oklahoma City, OK, Oral Presentation. September 29, 2005.
30. **Walker, J. L.**, "Predicting absolute risk of CIN 3 after the first colposcopic diagnosis of CIN 1 or less: Follow-up results from the ASCUS-LSIL Triage (ALTS) study", 2005 Annual Meeting of Western Association of Gynecologic Oncologists, WAGO, Santa Fe, NM, Oral Presentation. June 2005.
31. **Walker, J. L.**, "Intraperitoneal chemotherapy: Practical techniques and complications", International Symposium on Peritoneal Therapy for Ovarian Cancer, University of Louisville Health Sciences Center, Louisville, KY, Oral Presentation. May 2005.
32. **Walker, J. L.**, "Techniques of intraperitoneal catheter insertion and care", International Symposium on Peritoneal Therapy for Ovarian Cancer, University of Louisville Health Sciences Center, Louisville, KY, Oral Presentation. May 2005.
33. **Walker, J. L.**, "Cervical cancer: From infectious to oncology", Annual OB/GYN Seminar, University of Miami School of Medicine, Miami Beach, FL, Oral Presentation. March 2005.
34. **Walker, J. L.**, "VIN, VAIN: Risks, diagnosis, management", Annual OB/GYN Seminar, University of Miami School of Medicine, Miami Beach, FL, Oral Presentation. March 2005.
35. **Walker, J. L.**, "Abnormal Paps and ASCCP guidelines", 7th Annual Primary Care Update 2004, University of Oklahoma College of Medicine and Department of Family Medicine, Oklahoma City, OK, Oral Presentation. May 15, 2004.
36. **Walker, J. L.**, "Ovarian cancer awareness", 7th Annual Primary Care Update 2004, University of Oklahoma College of Medicine and Department of Family Medicine, Oklahoma City, OK, Oral Presentation. May 15, 2004.
37. **Walker, J. L.**, "Updates on ovarian cancer treatment", Second Annual HOPE in Oklahoma Group Retreat, Helping Ovarian Cancer Patients Everywhere (HOPE), Norman, OK, Oral Presentation.

May 15, 2004.

38. **Walker, J. L.**, "Abnormal Paps and ASCCP guidelines", 6th Annual Primary Care Update 2003, University of Oklahoma College of Medicine and Department of Family Medicine, Oklahoma City, OK, Oral Presentation. May 3, 2003.
39. **Walker, J. L.**, "Ovarian cancer awareness", 6th Annual Primary Care Update 2003, University of Oklahoma College of Medicine and Department of Family Medicine, Oklahoma City, OK, Oral Presentation. May 3, 2003.
40. **Walker, J. L.**, "Cervical cancer and HPV", Obstetric and Neonatal Nurses - Oklahoma Section Conference, Association of Women's Health, Oklahoma City, OK, Oral Presentation. April 25, 2003.
41. **Walker, J. L.**, "Ovarian cancer awareness", Carol Arnold Show on KOMA, Oklahoma City, OK, Radio Interview. April 14, 2003.
42. **Walker, J. L.**, "Challenges to good clinical research", Current Controversies in Obstetrics and Gynecology - in celebration of the Philip J. DiSaia, M.D. Endowed Chair in Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California - Irvine, Newport Beach, CA, Lecture. November 2002.
43. **Walker, J. L.**, Shirley Nissen Lecturer, University of California - Irvine, Orange, CA, Lecture. October 2002.
44. **Walker, J. L.**, Orange County Obstetrical and Gynecological Society, Orange, CA, Visiting Lecturer. October 17, 2002.
45. **Walker, J. L.**, "Ovarian cancer: Signs and symptoms", Candlelight vigil sponsored by HOPE, OU Medical Center and OU Physicians, Oklahoma City, OK, Oral Presentation. September 7, 2002.
46. **Walker, J. L.**, "New classification on Pap smear", Obstetrics and Gynecology Section, Mercy Health Center, Oklahoma City, OK, Oral Presentation. August 1, 2002.
47. **Walker, J. L.**, "Gynecology and related cancers", Health huddle presented at time out! For women's health, OU Physicians, Oklahoma City, OK, Oral Presentation. June 8, 2002.
48. **Walker, J. L.**, "Using HPV DNA testing to triage the equivocal Pap smear", The John L. McKelvey Lecture in Gynecologic Oncology Patients, 32nd Annual Obstetrics and Gynecology Autumn Seminar, Minneapolis, MN, Oral Presentation. October 2001.
49. **Walker, J. L.**, "Update on the ALTS trial", Women's Health Coordinators, Oklahoma State Health Department Region IV, Oklahoma City, OK, Oral Presentation. October 17, 2001.
50. **Walker, J. L.**, "Roundtable Discussion", 40th Annual OB/GYN Update 2001 Fall Symposium; Current Trends in Obstetrics and Gynecology, Oklahoma City, OK, Roundtable. September 2001.
51. **Walker, J. L.**, "Update on the ALTS trial: Whither goest the Pap smear?", 40th Annual OB, Oklahoma City, OK, Oral Presentation. September 20, 2001.
52. **Walker, J. L.**, "Topics in gynecologic oncology", 40th Annual OB/GYN Update 2001 Fall Symposium; Current Trends in Obstetrics and Gynecology, Oklahoma City, OK, Oral Presentation. September 19, 2001.
53. **Walker, J. L.**, "Estrogen replacement therapy", HOPE in Oklahoma Group, Helping Ovarian

- Cancer Patients Everywhere (HOPE), Oklahoma City, OK, Oral Presentation. June 30, 2001.
54. **Walker, J. L.**, "The clinical research team", Clinical Research and GCP Investigator Training, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Oral Presentation. June 26, 2001.
 55. **Walker, J. L.**, "The clinical research team", Clinical Research and GCP Investigator Training, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Oral Presentation. May 22, 2001.
 56. **Walker, J. L.**, Bethesda 2001 Workshop, Minneapolis, MN, Workshop. April 2001.
 57. **Walker, J. L.**, Bethesda 2001 Workshop, Minneapolis, MN, Workshop. April 2001.
 58. **Walker, J. L.**, "ASCUS/LGSIL Pap smears", ACOG 2000 District VII Annual District Meeting, ACOG District VII, St. Louis, MO, Oral Presentation. September 2000.
 59. **Walker, J. L.**, "Endometrial cancer", Breast Cancer Survivors Group, OUHSC Breast Health Institute, Oklahoma City, OK, Oral Presentation. June 8, 2000.
 60. Schwartz, P. E., Hatcher, K. D., **Walker, J. L.**, "Gynecologic oncology for the generalist", 48th Annual Clinical Meeting and 060 Postgraduate Course, San Francisco, CA, Oral Presentation. May 2000.
 61. **Walker, J. L.**, "Prevention of breast cancer - Star trial", Columbia Presbyterian Hospital, Oklahoma City, OK, Oral Presentation. February 23, 2000.
 62. **Walker, J. L.**, "Current research into management of abnormal Pap smears: Results of the ALTS and STAR trials", New Horizons in Women's Health Winter Symposium, University of Oklahoma College of Continuing Education, Aspen, CO, Oral Presentation. January 2000.
 63. **Walker, J. L.**, "The ABC's of IRB's: What do we need to know?", Healthcare Ethics: Dilemmas in Practice, Oklahoma Association for Healthcare Ethics and the Oklahoma Alliance for Better Care of the Dying, Oklahoma City, OK, Oral Presentation. December 3, 1999.
 64. **Walker, J. L.**, "Atypical Pap smear", 2nd Annual Primary Care Update '99, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Oral Presentation. June 1999.
 65. **Walker, J. L.**, "Vulvovaginal lesions", Women's Health Care Nurse Practitioner Conference, Oklahoma State Department of Health, Edmond, OK, Oral Presentation. May 13, 1999.
 66. **Walker, J. L.**, "The use of intraperitoneal therapy in ovarian cancer", SmithKline Beecham Workshop, Santa Fe, NM, Oral Presentation. May 2, 1999.
 67. **Walker, J. L.**, "Cancer's effects on women", Women's Cancer Support Group, Troy and Dollie Smith Cancer Center - Baptist Medical Center, Oklahoma City, OK, Oral Presentation. April 26, 1999.
 68. **Walker, J. L.**, "Choices", Women's Cancer Support Group, Troy and Dollie Smith Cancer Center - Baptist Medical Center, Oklahoma City, OK, Oral Presentation. April 26, 1999.
 69. **Walker, J. L.**, "Cervical and uterine carcinoma", Women's Cancer - Issues and Answers, 31st Annual Southeastern Wisconsin Cancer Conference, Milwaukee, WI, Oral Presentation. April 10, 1999.

70. **Walker, J. L.**, "Prevention of cancer in women", 26th Annual Irwin Brown Memorial Oklahoma Physicians' Winter Retreat, University of Oklahoma Health Sciences Center, Copper Mountain, CO, Oral Presentation. December 1998.
71. **Walker, J. L.**, "Cervix cancer prevention - What is the future?", Oklahoma Society of Cytopathology Annual Fall Meeting, Oklahoma Society of Cytopathology, Oklahoma City, OK, Oral Presentation. October 10, 1998.
72. **Walker, J. L.**, "Cervical cancer", Johnston/Marshall County Women's Health Network, Oral Presentation. May 30, 1998.
73. **Walker, J. L.**, "Hats off to health", Johnston/Marshall County Women's Health Network, Oral Presentation. May 30, 1998.
74. **Walker, J. L.**, "Causation and management of low grade cervical lesions", 13th Annual Public Health Nursing Conference, Oklahoma City, OK, Oral Presentation. October 10, 1997.
75. **Walker, J. L.**, "Cervical conization by LEEP vs. cold knife conization", Oklahoma City OB/GYN Society Meeting, Oklahoma City, OK, Oral Presentation. November 11, 1996.
76. **Walker, J. L.**, "Cost effective cervical cancer screening", Fall Symposium, University of Oklahoma College of Medicine Department of Obstetrics and Gynecology, Oklahoma City, OK, Oral Presentation. October 1996.
77. **Walker, J. L.**, "Prevention of cervix cancer in a cost effective manner", Fall Symposium, University of Oklahoma College of Medicine Department of Obstetrics and Gynecology, Oklahoma City, OK, Oral Presentation. October 1996.
78. **Walker, J. L.**, "Tamoxifen", Joint Meeting of Breast Cancer Support Groups, American Cancer Society, Oklahoma City, OK, Oral Presentation. October 28, 1996.
79. **Walker, J. L.**, "Cancer screening", Osler Society, Oklahoma City, OK, Oral Presentation. September 23, 1996.
80. **Walker, J. L.**, "Bone marrow transplant with cancer", University Hospital/Department of Transplant, Oklahoma City, OK, Oral Presentation. August 13, 1996.
81. **Walker, J. L.**, "Cervical cytology interpretation", Women's Health Care Nurse Practitioner Spring Conference, Oklahoma State Department of Health, Oklahoma City, OK, Oral Presentation. May 17, 1996.
82. **Walker, J. L.**, "Doctor of the day", Program at state capital for legislators, Oklahoma State County Medical Association, Oklahoma City, OK, Oral Presentation. May 6, 1996.
83. **Walker, J. L.**, "HIV and cervical cancer in Oklahoma", Oklahoma City, OK, Oral Presentation. April 30, 1996.
84. **Walker, J. L.**, "Corpus cancer", Texas and Oklahoma Prevention and Detection of Gynecologic Cancers for the Primary Care Provider, Southwestern Medical Center, Dallas, TX, Oral Presentation. October 13, 1995.
85. **Walker, J. L.**, "Vulvar abnormalities", Texas and Oklahoma Prevention and Detection of Gynecologic Cancers for the Primary Care Provider, Southwestern Medical Center, Dallas, TX, Oral Presentation. October 13, 1995.

86. **Walker, J. L.**, "Diagnostic and treatment of carcinoma of the corpus uteri", HCA Presbyterian Hospital, Oklahoma Cancer Registrars' Association, Oklahoma City, OK, Oral Presentation. October 12, 1995.
87. **Walker, J. L.**, "Staging of Carcinoma of the Corpus uteri", HCA Presbyterian Hospital, Oklahoma Cancer Registrars' Association, Oklahoma City, OK, Oral Presentation. October 12, 1995.
88. **Walker, J. L.**, "Management of ASCUS and low-grade SIL Pap smears", Oklahoma City Obstetrical and Gynecological Society, Oklahoma City, OK, Oral Presentation. October 9, 1995.
89. **Walker, J. L.**, "Pap smear screening", Tenth Annual Public Health Nursing Conference, Oklahoma City, OK, Oral Presentation. October 6, 1995.
90. **Walker, J. L.**, Fall Symposium, University of Oklahoma College of Medicine Department of Obstetrics and Gynecology, Moderator. September 21, 1995.
91. **Walker, J. L.**, "Prevention of endometrial cancer", Fall Symposium, University of Oklahoma College of Medicine Department of Obstetrics and Gynecology, Oklahoma City, OK, Oral Presentation. September 21, 1995.
92. **Walker, J. L.**, "Tamoxifen and the prevention of endometrial cancer", Medical Oncology Conference, University of Oklahoma College of Medicine, Oklahoma City, OK, Oral Presentation. August 2, 1995.
93. **Walker, J. L.**, "Utilization of mammography as a screening procedure in the Medicare population", Oklahoma City, OK, Oral Presentation. June 1, 1995.
94. **Walker, J. L.**, "Uterine tumor", Hematology/Oncology Conference, Presbyterian Hospital, Oklahoma City, OK, Oral Presentation. May 19, 1995.
95. **Walker, J. L.**, "Cancers and Women", Health Matters, OETA-TV, Oklahoma City, OK, Television Presentation. March 1995.
96. **Walker, J. L.**, "Oncology: Prevention and screening", New Horizons in Women's Health Care, University of Oklahoma Health Sciences Center Spring Symposium, Palm Springs, CA, Oral Presentation. March 29, 1995.
97. **Walker, J. L.**, "Women's Health Issues", New Horizons in Women's Health Care, University of Oklahoma Health Sciences Center Spring Symposium, Palm Springs, CA, Moderator. March 28, 1995.
98. **Walker, J. L.**, "Cancer prevention and early detection for the primary care provider", University of Oklahoma College of Medicine Department of Obstetrics and Gynecology, and the American Cancer Society, Oklahoma City, OK, Director/Moderator. March 11, 1995.
99. **Walker, J. L.**, "Human papillomavirus infection", Grand Rounds, Mercy Hospital, Oklahoma City, OK, Oral Presentation. March 9, 1995.
100. **Walker, J. L.**, "Reproductive oncology, cervical dysplasia, and cancer screening", New Horizons in Women's Health Care, University of Oklahoma Health Sciences Center Winter Symposium, Aspen, CO, Oral Presentation. February 1, 1995.
101. **Walker, J. L.**, Shen-Gunther, J., "Endocervical dysplasia", Hematology/Oncology Tumor Conference, Presbyterian Hospital, Oklahoma City, OK, Oral Presentation. December 16, 1994.

102. **Walker, J. L.**, Shen-Gunther, J., "Paget's Disease", Hematology/Oncology Tumor Conference, Presbyterian Hospital, Oklahoma City, OK, Oral Presentation. December 16, 1994.
103. **Walker, J. L.**, Shen-Gunther, J., "Retroperitoneal tumor", Hematology/Oncology Tumor Conference, Presbyterian Hospital, Oklahoma City, OK, Oral Presentation. November 18, 1994.
104. **Walker, J. L.**, Tumor Conference, St. Mary's Hospital, Enid, OK, Oral Presentation. November 7, 1994.
105. **Walker, J. L.**, "Cancers and women", Health Matters, OETA-TV, Television Presentation. October 1994.
106. **Walker, J. L.**, "Vulvar abnormalities", Texas and Oklahoma Prevention and Detection of Gynecologic Cancers for the Primary Care Provider, Southwestern Medical Center, Dallas, TX, Oral Presentation. October 7, 1994.
107. **Walker, J. L.**, "Sertoli Leydig", Tumor Conference, Presbyterian Hospital, Oklahoma City, OK, Oral Presentation. September 2, 1994.
108. **Walker, J. L.**, "Prevention of cancer", 33rd Annual OB/Gyn Spring Symposium, University of Oklahoma, Oklahoma City, OK, Oral Presentation. May 1994.
109. **Walker, J. L.**, "Carcinoma of the cervix", Tumor Board Case Presentation, St. Anthony Hospital, Oklahoma City, OK, Oral Presentation. May 2, 1994.
110. **Walker, J. L.**, "Oncology for the gynecologist", University of California, Irvine Department of Obstetrics and Gynecology, Division of Gynecologic Oncology in conjunction with University of Texas Southwestern Medical Center Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Lake Tahoe, CA, Oral Presentation. March 1994.
111. **Walker, J. L.**, "Ovarian cancer", Tumor Board Case Presentation, Mercy Hospital, Oklahoma City, OK, Oral Presentation. March 30, 1994.
112. **Walker, J. L.**, "Paget's Disease", Hematology-Oncology Tumor Conference, Presbyterian Hospital, Oklahoma City, OK, Oral Presentation. January 7, 1994.
113. **Walker, J. L.**, "Preventative health care for women", Women in Medicine Seminar, Oklahoma City, OK, Oral Presentation. October 20, 1993.
114. **Walker, J. L.**, "Ovarian cancer", Ninth Annual Public Health Nursing: The first 100 years, Oklahoma City, OK, Oral Presentation. September 16, 1993.
115. **Walker, J. L.**, "Prevention of GYN malignancies", Planned Parenthood, Oklahoma City, OK, Oral Presentation. September 7, 1993.
116. **Walker, J. L.**, "Presentation of private patient's pathology on cervical carcinoma - its histology and behavior", Tumor Conference, St. Anthony Hospital, Oklahoma City, OK, Oral Presentation. July 12, 1993.
117. **Walker, J. L.**, "Reproductive oncology: Prevention of GYN malignancies - Laparoscopic approach to pelvic masses", OBGYN Palm Springs Conference, New Horizons in Women's Health Care, Rancho Mirage, CA, Oral Presentation. April 1993.
118. **Walker, J. L.**, "Ovarian cancer", Tumor Board, St. Mary's Hospital, Enid, OK, Oral Presentation.

March 17, 1993.

119. **Walker, J. L.**, "Ovarian cancer", Health Matters - KOCO-TV Channel 5, Presbyterian Health Foundation, Oklahoma City, OK, Television Presentation. March 3, 1993.
120. **Walker, J. L.**, "The significance of HPV: How it relates to abnormal Pap smears and how to talk to patients about it", Oklahoma's Price in Changing Times, Eighth Annual Public Health Nursing, Tulsa, OK, Oral Presentation. September 1992.
121. **Walker, J. L.**, "Detecting cervical cancer", Health Matters, OETA-TV, Oklahoma City, OK, Television Presentation. September 1992.
122. **Walker, J. L.**, "Cervical cancer and sexually transmitted disease", Health Matters, OETA-TV, Oklahoma City, OK, Television Presentation. June 1992.
123. **Walker, J. L.**, "Current therapies for reproductive cancers: Urologic and reproductive cancers", ACS: Current issues in the treatment of urologic and reproductive cancers, Southwest Medical Center of Oklahoma, Oklahoma City, OK, Oral Presentation. April 1992.
124. **Walker, J. L.**, "Cervical cancer", Comanche County Memorial Hospital Cancer Committee, Lawton, OK, Oral Presentation. February 1992.
125. **Walker, J. L.**, OB/GYN Educational Day, Carl Albert Indian Health Facility, Ada, OK, Oral Presentation. January 1992.
126. Miles, P., Reilly, K., **Walker, J. L.**, "Management of difficult HPV cases and "hands on" colposcopy", 6th Annual Winter Symposium, Family Medicine and Obstetrics and Gynecology Specialties: Collaboration in the 90's, Aspen, CO, Oral Presentation. January 1992.
127. **Walker, J. L.**, "Management of pelvic mass", 6th Annual Winter Symposium, Family Medicine and Obstetrics and Gynecology Specialties: Collaboration in the 90's, Aspen, CO, Oral Presentation. January 1992.
128. **Walker, J. L.**, "Cervical and ovarian cancer", Holiday Health Fair for Women, Oklahoma City, OK, Oral Presentation. November 1991.
129. **Walker, J. L.**, "Evaluation of pelvic mass", Grand Rounds, South Community Hospital, Oklahoma City, OK, Oral Presentation. October 1991.
130. **Walker, J. L.**, "Prevention of cervical cancer: Dealing with perinatal and women's health issues in the 90's", Baptist Medical Center, Oklahoma City, OK, Oral Presentation. October 1991.
131. **Walker, J. L.**, "Prevention of endometrial cancer", St. Mary's Hospital, Enid, OK, Oral Presentation. October 1991.
132. **Walker, J. L.**, "Treatment of ovarian cancer", County Medical Association, Enid, OK, Oral Presentation. October 1991.
133. **Walker, J. L.**, "Cancers and women", Health Matters, OETA-TV, Oklahoma City, OK, Televised Presentation. October 1991.
134. **Walker, J. L.**, "Prevention of cervical cancer", Cancer Conference, Baptist Medical Center/Cancer Center of the Southwest, Oklahoma City, OK, Oral Presentation. May 1991.
135. **Walker, J. L.**, "Surgical therapy of ovarian cancer", Tumor Registry Conference, Oklahoma City,

OK, Oral Presentation. April 1991.

136. **Walker, J. L.**, "Evaluation of abnormal Pap smears", Goddard Health Center, University of Oklahoma, Oklahoma City, OK, Oral Presentation. March 1991.
137. **Walker, J. L.**, "Treatment of ovarian cancer", Combined Tumor Board, OU Health Sciences Center and Presbyterian Hospital, Oklahoma City, OK, Oral Presentation. March 1991.
138. **Walker, J. L.**, "Vulvar lesions", Oklahoma State Nurse Practitioners Symposium, Oklahoma Association of Nurse Practitioners, Oklahoma City, OK, Oral Presentation. December 1990.
139. **Walker, J. L.**, "Cancer screening for women", Benefit for Emerson Teen Parent Program, All Souls Episcopal Church, Oklahoma City, OK, Oral Presentation. 1990.
140. **Walker, J. L.**, "Gestational trophoblastic diseases", Grand Rounds, University of California Medical Center, Oral Presentation. April 1989.

TEACHING AND INSTRUCTION

Teaching and Course Instruction – OUHSC/SCM

Year(s) of Instruction	Course ID	Course/Lecture Title	Role	Avg. Contact Hrs/Year	Primary Learner Audience
Fall 2017		Gyn-Onc Fellows' Didactic Session: Chemotherapy Unit: Alkylating Agents	Instructor		Fellows
Summer 2017		Cervical/Gynecological Cancer: For the Cancer Epidemiology Class - Department of Biostatistics and Epidemiology	Attending Physician	1.5	Graduate
Summer 2017		Gyn-Onc Fellows' Didactic Session: Quality Metrics	Instructor		Fellows
Spring 2017		Gyn-Onc Fellows' Didactic Session: Anatomy Bootcamp: Upper Abdominal Anatomy	Instructor		Fellows
Spring 2017		Gyn-Onc Fellows' Didactic Session: Vulva Trials: Hea;s/Chan for Margins, GOG 36, GOG 37, GOG 74, GOG 88, GOG 101, GOG 173, GROINS	Instructor		Fellows
Winter 2017		Gyn-Onc Fellows' Didactic Session: Endometrial Cancer: Management of Advanced Disease Part II	Instructor		Fellows
Winter 2006		Learning on patients/clinical trials: For the Professional Ethics and Professionalism Course for Graduate Students	Instructor		Graduate
Winter 2000		Learning on patients/clinical trials: Presented to first year medical students and the Professional Ethics and Professionalism Course	Attending Physician		MSI
Winter 1999		Series of lectures to first year PA students	Attending Physician		Physician Assistant

Year(s) of Instruction	Course ID	Course/Lecture Title	Role	Avg. Contact Hrs/Year	Primary Learner Audience
Winter 1996		Gynecologic neoplasms: Obstetrics and gynecology section of physician assistant student clinical medicine course; University of Oklahoma Health Sciences Center	Attending Physician		Physician Assistant
Fall 1995		Pelvic anatomy	Instructor		Medical Students (Mixed Level)
Spring 1995		Gynecologic neoplasms: Obstetrics and Gynecology Section of Physician Assistant Student Clinical Medicine Course	Attending Physician		Graduate
Fall 1994		Diagnosis and management of cervical dysplasias and persistent abnormal Pap smears	Attending Physician		Cytotechnology students
Spring 1994		Gynecologic neoplasms: Obstetrics and Gynecology Section of Physician Assistant Student Clinical Medicine Course	Attending Physician		Graduate
Fall 1993		Gynecologic cancer: Hematology-Oncology Resident/Student Conference	Attending Physician		Hematology-Oncology residents and students
Spring 1993		Diagnosis and management of cervical dysplasias and persistent abnormal Pap smears: Medical Correlations in Cytotechnology I - Spring session for junior cytotechnology students	Attending Physician		Cytotechnology students
Spring 1993		Prevention of gynecologic malignancies: Obstetrics and Gynecology Section of Physician Assistant Student Clinical Medicine Course	Attending Physician		Graduate

Teaching and Course Instruction – Institutions Outside of OUHSC/SCM

Year(s) of Instruction	Institution / Location	Course ID	Course/Lecture Title	Role	Avg. Contact Hrs/Year	Primary Learner Audience
Spring 2019 - Present	Society of Gynecologic Oncology		Review of Gynecologic Oncology for Fellows: Chemotherapy for Ovarian Cancer	Lecturer		Fellows and New Faculty
Summer 2017	American Cancer Society		HPV Epidemic Film Screening and Discussion Panel	Panel Member		MDs, Nurses and Pharmacists

Graduate Medical Education (GME) Instruction Delivered

Date	Course Name or Session Topic	Role	Number of Instruction Hours	Primary Learner Audience	Sponsoring Department or Organization
October 22, 2021	Didactic Session: Front line chemotherapy: IP chemo, is it dead or still have a role?	Co-Instructor	1 hr(s)	Fellows	Department of Gynecologic Oncology

Date	Course Name or Session Topic	Role	Number of Instruction Hours	Primary Learner Audience	Sponsoring Department or Organization
October 12, 2021	Gyn Onc Fellows' Didactic Session: Front Line Chemotherapy - How did we get to the SOC and where are we going?	Lecturer	1 hr(s)	Fellows	Department of Gynecologic Oncology
September 10, 2021	Gyn Onc Fellows' Didactic Session: Anti-angiogenics - Indications, Use and Side Effect Management	Lecturer	1 hr(s)	Fellows	Department of Gynecologic Oncology
August 3, 2021	Gyn Onc Resident Teaching: Session 3 - Pre-Invasive/Invasive Vulva/Vagina	Lecturer	1 hr(s)	Residents	Department of Gynecologic Oncology
August 3, 2021	Problem-Based Learning Discussion (PBLD): Pre-Invasive/Invasive Vulva/Vagina	Lecturer	1 hr(s)	Residents	Department of Obstetrics & Gynecology
May 28, 2021	Gyn Onc Fellows' Didactic Session: Overview of Vulvar Melanoma - Surgical and Systemic Management + Other Rare Vulvar Ailments	Lecturer	1 hr(s)	Fellows	Department of Gynecologic Oncology
May 7, 2021	Journal Club: Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial	Lecturer	1 hr(s)	Residents	Department of Obstetrics and Gynecology
February 12, 2021	Gyn Onc Fellows' Didactic Session: Radiation for Endometrial Cancer	Instructor	1 hr(s)	Fellows	Department of Gynecology Oncology
September 11, 2019	Gyn Onc Fellows' Didactic Session: Chemotherapy Unit: Neutropenic Fever: Management and Evaluation	Lecturer	1 hr(s)	Fellows	Department of Gynecologic Oncology
April 26, 2019	Gyn Onc Fellows' Didactic Session: Rare Ovarian Tumors (Germ Cell, Stromal Cell)	Lecturer	1 hr(s)	Fellows	Department of Gynecologic Oncology
March 8, 2019	Gyn Onc Fellows' Didactic Session: Ovarian Cancer (Genetics/Histopath/Molecular Characterization)	Lecturer	1 hr(s)	Fellows	Department of Gynecologic Oncology
January 18, 2019	Gyn Onc Fellows' Didactic Session: Treatment Options for Early Stage Cervical Cancer	Lecturer	1 hr(s)	Fellows	Department of Gynecologic Oncology
September 28, 2018	M&M Conference: OB/GYN	Instructor	2 hr(s)	Residents	Department of Obstetrics and Gynecology
September 11, 2018	Lecture: Gyn Onc Resident Teaching Session	Instructor	1 hr(s)	Residents	Department of Gynecologic Oncology
July 17, 2018	Lecture: Gyn Onc Resident Teaching Session	Instructor	1 hr(s)	Residents	Department of Gynecologic Oncology
May 8, 2018	Lecture: Gyn Onc Resident Teaching Session	Instructor	1 hr(s)	Residents	Department of Gynecologic Oncology
March 13, 2018	Lecture: Gyn Onc Resident Teaching Session	Instructor	1 hr(s)	Residents	Department of Gynecologic Oncology

Date	Course Name or Session Topic	Role	Number of Instruction Hours	Primary Learner Audience	Sponsoring Department or Organization
March 2, 2018	Gyn Onc Fellows' Didactic Session: Endometrial Cancer: Staging and Treatment of Early Stage Disease	Lecturer	1 hr(s)	Fellows	Department of Gynecologic Oncology
January 12, 2018	Gyn Onc Fellows' Didactic Session: Platinum Resistant Disease (Gordon PLD vs topo), Gem vs PLD, AURELIA - Mechanisms of Resistance, Outcomes	Lecturer	1 hr(s)	Fellows	Department of Gynecologic Oncology
January 9, 2018	Gyn Onc Resident Teaching Session: Carcinoma of the Breast	Instructor	1 hr(s)	Residents	Department of Gynecologic Oncology
July 21, 2017	Gyn-Onc Fellows' Didactic Session: Anatomy Bootcamp: Upper Abdominal Anatomy with Dr. Kate Morris	Instructor			Department of Obstetrics and Gynecology
December 16, 2016	Lecture: Carcinoma of the breast	Instructor		Residents	Department of Gynecologic Oncology
September 13, 2016	Lecture: Carcinoma of the breast	Instructor		Residents	Department of Gynecologic Oncology
July 12, 2016	Lecture: Carcinoma of the breast	Instructor		Residents	Department of Gynecologic Oncology
June 17, 2016	Gyn-Onc Fellows' Didactic Session: IP Chemotherapy for Ovarian Cancer	Instructor		Fellows	Department of Gynecologic Oncology
January 19, 2016	Lecture: Vulva/Vagina Dysplasia and Carcinoma	Instructor		Residents	Gynecologic Oncology
January 5, 2007	Grand Rounds: Cancer in pregnancy	Attending Physician		Physicians, Fellows, Residents and Students	Department of Obstetrics and Gynecology
September 20, 2006	Grand Rounds: HPV vaccine and recommendations	Lecturer			Department of Obstetrics and Gynecology
April 21, 2006	Grand Rounds: HPV vaccine and cervix screening for cancer prevention	Attending Physician		Physicians, Fellows, Residents and Students	Department of Obstetrics and Gynecology
April 14, 2003	Grand Rounds: Ovarian Cancer	Attending Physician		Physicians, Fellows, Residents and Students	Department of Medicine
May 21, 2002	Grand Rounds: ALTS ASCUS/LSIL Triage Study	Lecturer		Physicians, Fellows, Residents and Students	Department of Obstetrics and Gynecology
June 4, 1998	Lecture: Ethics in research	Attending Physician		Graduate students	
February 12, 1997	Grand Rounds: Pap smears	Attending Physician		Physicians, Fellows, Residents and Students	Family Medicine
September 27, 1995	Grand Rounds: Cervix and vulvar cancer	Lecturer		Physicians, Fellows, Residents and Students	Department of Medicine
August 30, 1995	Grand Rounds: Tamoxifen and endometrial cancer	Lecturer			Hematology Oncology

Date	Course Name or Session Topic	Role	Number of Instruction Hours	Primary Learner Audience	Sponsoring Department or Organization
August 8, 1995	Grand Rounds: Tamoxifen and endometrial cancer	Lecturer			Department of Obstetrics and Gynecology
September 6, 1994	Grand Rounds: Evaluation of pelvic masses	Lecturer		Faculty, fellows, residents, students	Department of Obstetrics and Gynecology
May 1992	Grand Rounds: Cervical cancer	Lecturer	1 hr(s)		
1990	Grand Rounds: Gestational trophoblastic neoplasia	Lecturer	1 hr(s)	Medical students, residents, fellows and faculty	Obstetrics and Gynecology
1990	Grand Rounds: Human papillomavirus and cervical cancer	Lecturer	1 hr(s)	Medical students, residents, fellows and faculty	Obstetrics and Gynecology

Professional and Continuing Education Instruction

Date	Course Name or Session Topic	Role	Number of Instruction Hours	Primary Learner Audience	Sponsoring Department or Organization
March 10, 2021	Gyn Onc Journal Club: Hormonal Therapy for Endometrial Cancer	Presenter	1 hr(s)	Physicians	Gynecologic Oncology, Stephenson Cancer Center, Virtual Platform
October 31, 2017	Continuing Education: Cervical Cancer	Presenter	1 hr(s)	Physicians and nurses	MercyHospital - Ada, Ada, OK
June 23, 2005	Guest Lecture: Gynecologic cancer update	Presenter		Physicians and nurses	Mercy Health Center Continuing Medical Education Series, Oklahoma City, OK

Mentoring and Advising

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentee Outcomes
2021 - Present	Brooke Meelheim, DO	Fellow, Stephenson Cancer Center, Gynecologic Oncology Fellowship Program	Research Mentor	
2021 - Present	Danielle Krause, MD	Fellow, Stephenson Cancer Center, Gynecologic Oncology Fellowship Program	Research Mentor	
2020 - Present	Anna Kuan-Celarier, MD	Fellow, Stephenson Cancer Center, Gynecologic Oncology Fellowship Program	Research Mentor	
2020 - Present	Lindsay Borden, MD	Fellow, Stephenson Cancer Center, Gynecologic Oncology Fellowship Program	Research Mentor	
2017 - Present	Leah Underwood	Medical Student, University of Oklahoma College of Medicine	Mentor	

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentee Outcomes
2015 - 2017	Rachel Ruskin, MD	Fellow, OBGYN/Gynecologic Oncology/COM	Mentor	Ongoing research
2014 - 2017	Michelle Rowland, MD,PhD	Fellow, OBGYN/Gynecologic Oncology/COM	Mentor	Ongoing research

CLINICAL SERVICE

Clinical Committee Service

Member, Patient Care Committee, University Hospital, Oklahoma City, OK, 1999 - 2016

ORGANIZATIONAL SERVICE

Organizational Administration and Leadership

Campus/University

Medical Director, Medical Director of Gynecologic Oncology Clinic, OU Physicians, 2016 - Present

Organizational Committee Service

Campus/University

Member, Ethics in Research Inquiry Committee, University of Oklahoma, July 5, 2017 - Present

Chair, Cancer Committee, OU Medical Center, 1999 - 2000

Vice-Chairman, Institutional Review Board, University of Oklahoma Health Sciences Center, April 1996 - January 1997

College

Member, Oncology Patient Experience Council, Stephenson Cancer Center, February 2021 - Present

Member, College of Medicine Dean's Search Committee, College of Medicine, 2016 - Present

Member, Cancer Committee, OU Medical Center, 1994 - Present

Member, College of Medicine Admissions Board Committee, The University of Oklahoma College of Medicine, 1994 - 1995

Department

Chair, NCORP, Stephenson Cancer Center, September 2021

PROFESSIONAL SERVICE

National/International

Co-PI, NCI NCORP Research Base, NRG Oncology, 2014 - Present

Member, NRG Oncology Protocol Committee for Gynecologic Cancers, NRG Oncology, 2014 - Present

Member, Research Strategy Committee, NRG Oncology, 2014 - Present

Member, Reproductive Scientist Development Evaluation Committee, Society for Gyn Investigation, 2012 - Present

Member, SGO/ACOG Liaison Task Force Committee, Society of Gynecologic Oncologists, March 1, 2004 - Present

Member, Reproductive Scientist Development Program Evaluation Committee, Society for Gynecologic Investigation, September 2002 - Present

Member, Board of Directors HOPE, Helping Ovarian Cancer Patients Everywhere, 2001 - Present

Co-Chair, Cancer Prevention and Early Detection Committee, Gynecologic Oncology Group-NIH Contract, July 1998 - Present

Member, Focus Group Member, Society of Gynecologic Oncologists, July 18, 1996 - Present

Member, Executive Committee-National Institute of Health, National Institute of Health/Gynecologic Oncology Group, July 1996 - Present

Member, Steering Committee, National Cancer Institute, 1996 - Present

Member, Cancer Prevention and Early Detection Committee, Gynecologic Oncology Group-NIH Contract, September 1995 - Present

Session Chair, 2019 ASCO Annual Meeting Session Chair, ASCO, Chicago, IL, 2019

Co-Chair, New Paradigms in the Pathogenesis of High-grade Serous Carcinoma: Translating Biological Advances into Prevention, NRG Oncology, Chicago, IL, July 10, 2014

Oral Examiner, Gynecologic Oncology Oral Boards, American Board of Obstetrics and Gynecology, 2007 - 2013

Attendee, Gynecologic Oncology Group Interim Protocol Meeting in conjunction with the NRG Oncology Retreat, GOG/NRG, Philadelphia, PA, September 26, 2012 - September 29, 2012

Attendee, MC Anderson Board Review Course for the Hospice and Palliative Care Sub-Specialty Board Exams, MD Anderson, Houston, September 3, 2012 - September 6, 2012

Attendee, Gynecologic Oncology Group Semi-Annual Business Meeting, GOG, Boston, July 26, 2012 - July 29, 2012

Participant, Ovarian Cancer National Advisory Board, Dallas, July 13, 2012

Representative, Represented the Gynecologic Oncology Group Cancer Prevention and Control Committee, Radiation Therapy Oncology Group's Semi-Annual Business Meeting, Philadelphia, PA, June 14, 2012 - June 16, 2012

Oral Examiner, Gynecologic Oncology Oral Boards, American Board of Obstetrics and Gynecology, Dallas, TX, April 15, 2012 - April 18, 2012

Member, Society of Gynecologic Oncologists Council, January 2008 - January 2011

Oral Examiner, Gynecologic Oncology Oral Boards, American Board of Obstetrics and Gynecology, Dallas, TX, April 11, 2010 - April 14, 2010

Question writer for ABOG, ABOG Written Examination in Gynecology Oncology Preparation, American Board of Obstetrics and Gynecology, Dallas, August 27, 2009 - August 29, 2009

Scientific Session Chair, Scientific Session Chair for gynecologic cancer oral abstract session, American Society of Clinical Oncology, Orlando, FL, May 29, 2009 - June 2, 2009

Course Director, Annual American College of Obstetricians and Gynecologists Meeting, Chicago, IL, May 2, 2009

Member, Gynecologic Oncology Group Interim Protocol Development Meeting and Site Visit Rehearsal, Buffalo, NY, April 23, 2009 - April 25, 2009

Oral Examiner, Gynecologic Oncology Oral Boards, American Board of Obstetrics and Gynecology, Dallas, April 19, 2009 - April 22, 2009

Council Member, Society of Gynecologic Oncology, 2008

Member, Council and Education Committee, Society of Gynecologic Oncology, 2008

Attendee, Society of Gynecologic Oncologists Cervical Cancer Forum, SGO, Chicago, September 11, 2008 - September 13, 2008

Attendee, Gynecologic Oncology Group Semi-Annual Business Meeting, GOG, Chicago, IL, July 16, 2008 - July 20, 2008

Postgraduate Course Director, American College of Obstetricians and Gynecologists ACM Courses, New Orleans, LA, May 3, 2008

Attendee, Gynecologic Oncology Group Interim Protocol Meeting, GOG, Buffalo, April 23, 2008 - April 25, 2008

Attendee, Gynecologic Oncology Group Interim Protocol Meeting, GOG, Buffalo, NY, April 23, 2008 - April 25, 2008

Oral Examiner, Gynecologic Oncology Oral Boards, American Board of Obstetrics and Gynecology, April 7, 2007 - April 9, 2008

Member, ACOG/SGO Liaison Task Force, Society of Gynecologic Oncologists, 2006 - 2007

Member, Program Committee, Society of Gynecologic Oncologists Program Committee, 2006 - 2007

Attendee, Gynecologic Oncology Group, Buffalo, NY, April 25, 2007 - April 26, 2007

Oral Examiner, Gynecologic Oncology Oral Boards, American Board of Obstetrics and Gynecology, Dallas, TX, April 15, 2007 - April 18, 2007

Chair, Oklahoma Section District VII, American College of Obstetricians and Gynecologists, 2002 - 2005

Member, Cancer Liaison for the University Hospital Commission on Cancer, American College of Surgeons, January 1, 2002 - 2004

Oral Examiner, Subspecialty Gynecologic Oncology, American Board of Obstetrics and Gynecology, 1997 - 2004

Vice-Chairman, Oklahoma Section District VII, American College of Obstetricians and Gynecologists, 2001 - 2002

Examiner, American Board of Obstetrics and Gynecology Oral Board, American Board of Obstetrics and Gynecology, Dallas, TX, January 17, 2002 - January 20, 2002

Secretary, Oklahoma Section District VII, American College of Obstetricians and Gynecologists, 2000 - 2001

Member, Committee on Human Research, American College of Obstetricians and Gynecologists, 1997 - 2000

Cancer Liaison for the University Hospital Commission on Cancer, American College of Surgeons, January 1, 1994 - January 1, 2000

Chair, NCI Steering Committee, National Cancer Institute, 1998

Member, Program Committee 1998 Meeting, Society of Gynecologic Oncology, Phoenix, AZ, 1998

Member, Program Committee 1997 Meeting, Society of Gynecologic Oncology, Phoenix, AZ, 1997

Member, Strategic Planning Focus Group, Society of Gynecologic Oncologists, 1996

Clinical Oncology Fellow, American Cancer Society, 1989 - 1990

Local/Regional

Attendee, Gyn Onc Patient Safety Conference Quarter 1, Stephenson Cancer Center, 2021 - Present

Member, Community Health Committee, Oklahoma County Medical Society, Oklahoma City, OK, 2001 - Present

Member, Oklahoma Breast Cancer Prevention and Treatment Advisory Committee, State Department of Health, 1999 - Present

Member, Oklahoma Genetics Advisory Committee, 1999 - Present

Member, Professional Education Committee, American Cancer Society--Oklahoma Division, Inc., February 1994 - Present

Advisor, Oklahoma Breast and Cervical Cancer Task Force, Oklahoma State Department of Health, Oklahoma City, OK, January 1, 1994 - Present

Panel Member, HPV Film Screening and Discussion Panel, American Cancer Society, Oklahoma City, OK, June 15, 2017

Representative, Gynecologic Oncology Site Visit Rehearsal, Cancer Prevention and Control Committee, Grapevine, TX, September 17, 2009 - September 19, 2009

Board of Directors, Planned Parenthood of Central Oklahoma, Planned Parenthood of Central Oklahoma, Oklahoma City, OK, 2008

Chair, Oklahoma Section District VII, American College of Obstetricians and Gynecologists, 2002 - 2005

President, Western Association of Gynecologic Oncologists, 2003

Program Chair/President, Western Association of Gynecologic Oncologists, WAGO, 2002 - 2003

Sponsor, Annual Ladies Golf Classic, American Cancer Society, Oklahoma City, OK, 1999 - 2003

Chair, Program Committee for Annual Meeting, Western Association of Gynecologic Oncologists, 2002

Panel Member, Ad Hoc Panel, Department of Veterans Affairs, Oklahoma City, OK, June 1, 1995 - August 30, 2002

Member, Data Safety Monitoring Board, StressGen, 1998 - 2000

Member, Oklahoma Genetics Advisory Council, Oklahoma Genetics Advisory Council, Oklahoma City, OK, 1998

Member, Medical Committee, Planned Parenthood of Central Oklahoma, Oklahoma City, OK, 1992 - 1998

Member, Oklahoma Breast Cancer Advisory Committee, Oklahoma City, OK, 1997

Alternate Delegate, Oklahoma State Medical Society, Oklahoma County Medical Society, Oklahoma City, OK, 1996

Member, Program Committee, Western Association of Gynecologic Oncologists, 1995 - 1996

Member, Council on State Legislation and Regulation Committee, Oklahoma State Medical Association, Oklahoma City, OK, 1994 - 1996

President, Oklahoma City Obstetrics and Gynecology Society, Oklahoma City, OK, 1995

Vice-President, Oklahoma City Obstetrics and Gynecology Society, Oklahoma City, OK, 1994

Chair, Planned Parenthood of Central Oklahoma, Oklahoma City, OK, 1994

Secretary, Oklahoma City Obstetrics and Gynecology Society, Oklahoma City, OK, 1993

Editor, Editorial Board, Journal Reviewer

Editorial Board Member, Cancer Investigation, 2006 - Present

Ad-Hoc Reviewer:

Completeness of Salpingectomy Intended for Ovarian Cancer Risk	2019 - Present
New England Journal of Medicine	2005 - Present

Previous Service to Other Academic Institutions

Member, Medical Records Committee, University of California, Irvine, Medical Center, Orange, CA, 1989 - 1990

Chair, Cancer Research Committee Member Memorial Cancer Center, Memorial Medical Center, Long Beach, CA, 1988 - 1990

Member, Medical Student Selection Committee, University of California, Irvine; California College of Medicine, Irvine, CA, 1986 - 1990

PERSONAL COMMUNITY SERVICE

Attendee, Tour of Regional Food Bank, Regional Food Bank, Oklahoma City, OK, November 9, 2021

MEDIA CONTRIBUTIONS

Interviewed Expert, Daily Oklahoman, Covid effects on cancer prevention early detection and HPV vaccination, Covid effects on cancer prevention early detection and HPV vaccination, This interview was requested by the daily oklahoman, June 2, 2021

Interviewed Expert, KOCO, Cervical Cancer, Cervical Cancer, Questions:

- 1) Explain to us what cervical cancer is.
- 2) Do we know what causes it?
- 3) Are there things women can do to prevent it?
- 4) Is it important to be diagnosed early and if so, then when should women be seeing a doctor – i.e., is there an annual screening? Are there symptoms to look for?
- 5) Did the fear of COVID keep some women from being checked for cervical cancer earlier?
- 6) How is the HPV vaccine helping change the future of cervical cancer in women?
- 7) Who should receive this vaccine and when?, May 25, 2021

PROFESSIONAL MEMBERSHIPS

American Association for the Advancement of Science
American College of Obstetrics and Gynecology
American College of Surgeons
American Medical Association (AMA)
American Society for Colposcopy and Cervical Pathology
American Society of Clinical Oncology
Association of Professors of Gynecology and Obstetrics
California Medical Association
Oklahoma City Obstetrics and Gynecology Society
Oklahoma County Medical Society
Oklahoma State Medical Association
Western Association of Gynecologic Oncologists
American Gynecological and Obstetrical Society (AGOS) September 2017 - Present

PROFESSIONAL GROWTH AND DEVELOPMENT

Certification

Good Clinical Practice, Collaborative Institutional Training Initiative (CITI), November 24, 2020 - November 24, 2023

Forte eReg Lite 1200: Principal Investigator (Document Signer) Curriculum, FORTE, November 16, 2020

University of Oklahoma COVID-19 Compliance Training, OU Emergency Operations Committees, Oklahoma City, OK, October 29, 2020

Coding and Practice Management Part 1, American Academy of Professional Coders™, 1.5 Credit Hours, October 1, 2020

Seminars, Workshops, and Other Training

ATS Evidence Based Teaching Boot Camp 2020, Academy of Teaching Scholars, Virtual Platform, September 11, 2020

Employee Hazard Communication/General Safety Training, University of Oklahoma Medical Center, Oklahoma City, OK, September 11, 2020

The 17th Annual Nixon Lectureship, Norton Cancer Institute, Louisville, KY, September 24, 2018

NRG Semi- Annual Meeting, Gynecologic Oncology Group, Philadelphia, PA, US, 10.5 Credit Hours, July 13, 2018 - July 15, 2018

Training Institute in Dissemination Research in Cancer (TIDIRC), National Institutes of Health/National Cancer Institute, Bethesda, MD, March 7, 2018 - July 10, 2018

Robotic Surgery Certification Training, Houston, TX, May 8, 2009

Meetings and Conferences

Gyn Oncology Patient Safety Conference, Stephenson Cancer Center, Oklahoma City, October 21, 2021

NCORP Annual Meeting, NRG Foundation, Virtual Platform, August 26, 2021 - August 27, 2021

2021 Oklahoma GeroOncology Symposium-A Deeper Dive into the Inner Workings of Aging in Cancer, Stephenson Cancer Center and the Oklahoma Nathan Shock Aging Center, Virtual Platform, August 18, 2021 - August 19, 2021

NRG Oncology Summer 2021 Virtual Meeting, NRG Oncology, Virtual Platform, July 19, 2021 - July 28, 2021

WAGO 2021 Virtual Annual Meeting, Western Association of Gynecologic Oncologists, Virtual Platform, June 16, 2021 - June 18, 2021

Gyn Oncology Fellowship Spring 2021 CCC Meeting, Stephenson Cancer Center, Oklahoma City, OK, 2 Credit Hours, June 4, 2021

Gyn Onc Patient Safety Conference, Stephenson Cancer Center, Oklahoma City, OK, June 2, 2021

SGO 2021 Virtual Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Virtual Platform, March 19, 2021 - March 25, 2021

CCDR Symposium, NRG Oncology, Virtual Platform, March 15, 2021

Gyn Onc Fellows' Endometrial Symposium, Stephenson Cancer Center, Virtual Platform, March 12, 2021

Survivorship-Surviving and Thriving in the Shadow of Cancer, NRG Oncology, Virtual Platform, February 25, 2021

2021 Annual Cancer Research Symposium, OU Health Stephenson Cancer Center, Virtual Platform, February 5, 2021

NRG Oncology Winter 2021 Virtual Meeting, NRG, Virtual Platform, January 27, 2021 - January 30, 2021

AGOS 2019 Annual Meeting, American Gynecological & Obstetrical Society (AGOS), Washington, DC, September 12, 2019 - September 14, 2019

NCORP 2019 Annual Meeting, National Cancer Institute and National Cancer Institute, Bethesda, MD, August 22, 2019 - August 23, 2019

NRG Oncology Semiannual Meeting, NRG Oncology, Philadelphia, PA, July 18, 2019 - July 20, 2019

PSC CTN/CRA Workshop and Educational Session, NRG Oncology, Philadelphia, PA, July 18, 2019

2019 WAGO Annual Meeting, Western Association Of Gynecologic Oncologists, Huntington Beach, CA, June 13, 2019 - June 15, 2019

2019 ASCO, American Society of Clinical Oncology, Chicago, IL, May 31, 2019 - June 4, 2019

SGO 50th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Honolulu, HI, March 15, 2019 - March 19, 2019

NRG Oncology Semiannual Meeting, NRG Oncology, Phoenix, AZ, February 7, 2019 - February 9, 2019

Introduction to Clinical Trials: Principles of Clinical Trial Management, NRG Oncology, Phoenix, AZ, February 7, 2019

11th Annual Conference on the Science of Dissemination and Implementation in Health, National Institutes of Health, Washington, DC, December 3, 2018 - December 5, 2018

NCORP Annual Meeting, National Cancer Institute, Bethesda, MD, September 20, 2018 - September 21, 2018

ATS/ORL Breakfast of Champions: "People Learn Differently: Adapting to Help Learners Succeed", Academy of Teaching Scholars University of Oklahoma, Oklahoma City, OK, United States, March 8, 2017

NCI Community Oncology Research Program (NCORP) Investigators Meeting 2015, NCORP, Bethesda, MD, August 27, 2015 - August 28, 2015

ASCO Leadership Skills Seminar, American Society of Clinical Oncology, Alexandria, VA, March 2014

Western Association of Gynecologic Oncologists Annual Meeting, Western Association of Gynecologic Oncologists, Huntington Beach, CA, June 27, 2012 - July 1, 2012

Gynecologic Oncology Group Interim Protocol Meeting, GOG, Buffalo, NY, April 25, 2012 - April 26, 2012

Gynecologic Oncology Group Semi-Annual Business Meeting, GOG, San Diego, CA, January 26, 2012 - January 30, 2012

Gynecologic Oncology Group Semi-Annual Business Meeting, GOG, San Diego, CA, January 28, 2010 - January 31, 2010

Gynecologic Oncology Group Semi-Annual Business Meeting, GOG, Baltimore, MD, July 16, 2009 - July 18, 2009

Summer Society of Gynecologic Oncologists Council Meeting at the Gynecologic Oncology Group Meeting, GOG, Baltimore, MD, July 16, 2009

Western Association of Gynecologic Oncologists Annual Meeting, Western Association of Gynecologic Oncologists, Vancouver, BC, Canada, June 24, 2009 - June 28, 2009

Western Association of Gynecologic Oncologists Annual Meeting, Western Association of Gynecologic Oncologists, Sonoma, June 11, 2008 - June 14, 2008

Society of Gynecologic Oncologists Annual Meeting, Society of Gynecologic Oncology, Tampa, FL, March 9, 2008 - March 13, 2008

Gynecologic Oncology Group Semi-Annual Business Meeting, GOG, San Diego, CA, January 24, 2008 - January 26, 2008

State of the Art Conference, Society of Gynecologic Oncologists, Chicago, IL, December 1, 2007

Gynecologic Oncology Group Meeting, GOG, San Diego, CA, July 19, 1996 - July 20, 1996

Anthra Pharmaceuticals, Chicago, IL, June 8, 1996

Western Association of Gynecologic Oncologists Annual Meeting, Western Association of Gynecologic Oncologists, San Diego, CA, May 26, 1996 - June 2, 1996

Tiger Day, University of Oklahoma Health Sciences Center Department of Obstetrics and Gynecology, Oklahoma City, OK, May 25, 1996

Hispanic Health Fair, Oklahoma City, OK, May 18, 1996

Other Professional Development

Findings From GOG 233, Stephenson Cancer Center, Oklahoma City, OK, October 6, 2021

GY023 Training, Stephenson Cancer Center, Oklahoma City, OK, 1 Credit Hours, June 15, 2021

HIPEC, Stephenson Cancer Center, Oklahoma City, OK, June 14, 2021

Overview of Vulvar Cancer - Surgical and Systemic Management, Stephenson Cancer Center, Virtual Platform, May 21, 2021

NCORP 2019 Retreat, NRG Oncology, Philadelphia, PA, November 4, 2019

Kay Yow Cancer Fund Golf Classic, Kay Yow Cancer Fund, Pinehurst, NC, August 24, 2019 - August 25, 2019

Procedures BootCamp, Stephenson Cancer Center, Oklahoma City, OK, August 9, 2019

2018 Kay Yow Cancer Fundraiser Golf Classic, Kay Yow Cancer Fund, Pinehurst, NC, August 24, 2018 - August 26, 2018

Burnout in Physicians: Scope of the Problem, Implications in Surgeons, Potential Solutions, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 1 Hours Per Year, May 4, 2018

Enhanced Recovery After Surgery - A Segway to Continuous Improvement, OUHSC, Oklahoma City, OK, US, 1 Hours Per Year, April 20, 2018

Addressing Conflict and Professionalism, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States, December 15, 2017

Chemotherapy Unit: Alkylating Agents, Stephenson Cancer Center, Oklahoma City, OK, September 1, 2017

Evaluation & Feedback: The gifts that keep on giving, Academy of Teaching Scholars University of Oklahoma, Oklahoma City, OK, United States, March 31, 2017

We wear suits and lie to each other, OUHSC, Oklahoma City, OK, United States, September 30, 2016

2016 Kay Golf Classic, Kay Yow Cancer Fund, Pinehurst, NC, September 3, 2016 - September 5, 2016

Ovarian Cancer: Therapeutic Targets, 2nd Annual Meeting of the International Ovarian Cancer Consortium in conjunction with the International Symposium on Tumor Microenvironment and Therapy Resistance, Oklahoma City, OK, August 16, 2015 - August 17, 2015

Changing lifestyle with mind body medicine: How to build resiliency in patients, Harvard Medical School, Boston, MA, December 13, 2012 - December 16, 2012

Cervical Cancer Awareness Month and HPV vaccination, Oklahoma City, OK, January 14, 2008